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The crucial role of CADD in the drug design process is now indisputable and has proven over the 
years that it can accelerate the discovery potential drug candidates while reducing the associated 
cost. Using knowledge and information about biological target or knowledge about a ligand with 
proven bioactivity, CADD, and its techniques can influence various drug discovery pipeline stages. 
The ability CADD approaches to elucidate drug-target interactions at the atomistic level allows 
for investigations of the mechanism of drugs' actions, revealing atomistic insights that influence 
drug design and improvement. CADD approaches also seek to augment traditional in vitro and in 
vivo experimental techniques and not replace them since CADD approaches can also allow 
modeling complex biological processes that hitherto seemed impossible to explore using 
experimental methods. 
According to the World Health Organization (WHO), featuring prominently in the top ten causes 
of death are cancer, lower respiratory tract infection, tuberculosis (TB), and viral infections such 
as HIV/AIDS.  Collectively, these diseases are of global health concerns, considering a large 
number of associated deaths yearly. Over the years, several therapeutic interventions have been 
employed to treat, manage, or cure these diseases, including chemotherapy, surgery, and 
radiotherapy. Of these options, small molecule inhibitors have constituted an integral component 
in chemotherapy, thereby undoubtedly playing an essential role in patient management.  
Although significant success has been achieved using existing therapeutic approaches, the 
emergence of drug resistance and the challenges of associated adverse side effects has prompted 
the need for the drug design processes against these diseases to remain innovative, including 
combining existing drugs and establishing improved therapeutic options that could overcome 
resistance while maintaining minimal side effects to patients. Therefore, an exploration of drug-
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target interactions towards unraveling mechanisms of actions as performed in the reports in this 
thesis are relevant since the molecular mechanism provided could form the basis for the design 
and identification of new therapeutic agents, improvement of the therapeutic activity of existing 
drugs, and also aid in the development of novel therapeutic strategies against these diseases of 
global health concern. 
Therefore the studies in this thesis employed CADD approaches to investigates molecular 
mechanisms of actions of novel therapeutic strategies directed towards some crucial therapeutics 
implicated in viral infections, tuberculosis, and cancer. Therapeutic targets studied included; 
SARS-CoV-2 RNA dependent RNA polymerase (SARS-CoV-2 RdRp), Human Rhinovirus B14 
(HRV-B14) and  human N-myristoyltransferases in viral infections, Dihydrofolate reductase 
(DHFR) and Flavin-dependent thymidylate synthase (FDTS) in TB, human variants of  TCR-
CD1d, and Protein Tyrosine Phosphatase Receptor Zeta (PTPRZ) in cancer.  
The studies in this thesis is divided into three domains and begins with a thorough review of the 
concept of druggability and drug-likeness since the crux of the subsequent reports revolved around 
therapeutic targets and their inhibitions by small molecule inhibitors. This review highlights the 
principles of druggability and drug-likeness while detailing the recent advancements in drug 
discovery. The review concludes by presenting the different computational, highlighting their 
reliability for predictive analysis. 
In the first domain of the research, we sought to unravel the inhibitory mechanism of some small 
molecule inhibitors against some therapeutic targets in viral infections by explicitly focusing on 
the therapeutic targets; SARS-CoV-2 RdRp, HRV-B14, and N-myristoyltransferase.  
Therapeutic targeting of SARS-CoV-2 RdRp has been extensively explored as a viable approach 
in the treatment of COVID-19. By examining the binding mechanism of Remdesivir, which 
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hitherto was unclear, this study sought to unravel the structural and conformational implications 
on SARS-CoV-2 RdRp and subsequently identify crucial pharmacophoric moieties of Remdesivir 
required for its inhibitory potency. Computational analysis showed that the modulatory activity of 
Remdesivir is characterized by an extensive array of high-affinity and consistent molecular 
interactions with specific active site residues that anchor Remdemsivir within the binding pocket 
for efficient binding. Results also showed that Remdesivir binding induces minimal individual 
amino acid perturbations, subtly interferes with deviations of C-α atoms, and restricts the 
systematic transition of SARS-CoV-2 RdRp from the “buried” hydrophobic region to the “surface-
exposed” hydrophilic region. Based on observed high-affinity interactions with SARS-CoV-2 
RdRp, a pharmacophore model was generated, which showcased the crucial functional moieties 
of Remdesivir. The pharmacophore was subsequently employed for virtual screening to identify 
potential inhibitors of SARS-CoV-2 RdRp. The structural insights and the optimized 
pharmacophoric model provided would augment the design of improved analogs of Remdesivir 
that could expand treatment options for COVID-19. 
The next study sought to explore the therapeutic targeting of human rhinoviruses (HRV) amidst 
challenges associated with the existence of a wide variety of HRV serotypes. By employing 
advanced computational techniques, the molecular mechanism of inhibition of a novel 
benzothiophene derivative that reportedly binds HRV-B14 was investigated. An analysis of the 
residue-residue interaction profile revealed of HRV upon the benzothiophene derivative binding 
revealed a distortion of the hitherto compacted and extensively networked HRV structure. This 
was evidenced by the fewer inter-residue hydrogen bonds, reduced van der Waals interactions, and 
increased residue flexibility. However, a decrease in the north-south wall's flexibility around the 
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canyon region also suggested that the benzothiophene derivative's binding impedes the “breathing 
motion” of HRV-B14; hence its inhibition. 
The next study in the first domain of the research investigated the structural and molecular 
mechanisms of action associated with the dual inhibitory activity of IMP-1088. This novel 
compound reportedly inhibits human N-myristoyltransferase subtypes 1 and 2 towards common 
cold therapy. This is because it has emerged that the pharmacological inhibition of N-
myristoyltransferase is an efficient non-cytotoxic strategy to completely thwart the replication 
process of rhinovirus toward common cold treatment. Using augmentative computational and 
nanosecond-based analyses, findings of the study revealed that the steady and consistent 
interactions of IMP-1088 with specific residues; Tyr296, Phe190, Tyr420, Leu453, Gln496, 
Val181, Leu474, Glu182, and Asn246, shared within the binding pockets of both HNMT subtypes, 
in addition to peculiar structural changes account for its dual inhibitory potency. Findings thus 
unveiled atomistic and structural perspectives that could form the basis for designing novel dual-
acting inhibitors of N-myristoyltransferase towards common cold therapy. 
In the second domain of the research, the mechanism of action of some small molecule inhibitors 
against DHFR, FDTS, and Mtb ATP synthase in treating tuberculosis is extensively investigated 
and reportedly subsequently. 
To begin with, the dual therapeutic targeting of crucial enzymes in the folate biosynthetic pathway 
was explored towards developing novel treatment methods for TB. Therefore, the study 
investigated the molecular mechanisms and structural dynamics associated with dual inhibitory 
activity of PAS-M against both DHFR and FDTS, which hitherto was unclear. MD simulations 
revealed that PAS-M binding towards DHFR and FDTS is characterized by a recurrence of strong 
conventional hydrogen bond interactions between a peculiar site residue the 2-amino-
v 
 
decahydropteridin-4-ol group of PAS-M. Structural dynamics of the bound complexes of both 
enzymes revealed that, upon binding, PAS-M is anchored at the entrance of hydrophobic pockets 
by a strong hydrogen bond interaction while the rest of the structure gains access to deeper 
hydrophobic residues to engage in favorable interactions. Further analysis of atomistic changes of 
both enzymes showed increased C-α atom deviations and an increase C-α atoms radius of gyration 
consistent with structural disorientations. These conformational changes possibly interfered with 
the enzymes' biological functions and hence their inhibition as experimentally reported. 
Additionally, in this domain, the therapeutic targeting of the ATP machinery of Mtb by 
Bedaquiline (BDQ) was explored towards unravelling the structures and atomistic perspectives 
that account for the ability of BDQ to selectively inhibits mycobacterial F1Fo-ATP synthase via its 
rotor c-ring. BDQ is shown to form strong interaction with Glu65B and Asp32B and, consequently, 
block these residues' role in proton binding and ion. BDQ binding was also revealed to impede the 
rotatory motion of the rotor c-ring by inducing a compact conformation on the ring with its bulky 
structure. Complementary binding of two molecules of BDQ to the rotor c-ring, proving that 
increasing the number of BDQ molecule enhances inhibitory potency. 
The last study in this research domain investigated the impact of triple mutations (L59V, E61D, 
and I66M) on the binding of BDQ to Mtb F1F0 ATP-synthase. The study showed that the 
mutations significantly impacted the binding affinity of BDQ, evidenced by a decrease in the 
estimated binding free energy (ΔG). Likewise, the structural integrity and conformational 
architecture of F1F0 ATP-synthase was distorted due to the mutation, which could have interfered 
with the binding of BDQ. 
The third domain of the research in this thesis investigated some small molecule inhibitors' 
inhibitory mechanism against some therapeutic targets in cancer, specifically PTPRZ and hTCR-
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CD1d. Studies in the third domain of the research in the thesis began with the investigation of the 
investigation of the inhibitory mechanism of NAZ2329, an allosteric inhibitor of PTPRZ, by 
specifical investigating its binding effect on the atomic flexibility of the WPD-loop. Having been 
established as crucial determinant of the catalytic activity of PTPRZ an implicated protein in 
glioblastoma cells, its successfully therapeutic modulation could present a viable treatment option 
in glioblastoma. Structural insights from an MD simulation revealed that NAZ2329 binding 
induces an open conformation of the WPD-loop which subsequently prevents the participation of 
the catalytic aspartate of PTPRZ from participating in catalysis hence inhibiting the activity of 
PTPRZ. A pharmacophore was also created based of high energy contributing residues which 
highlighted essential moieties of NAZ2329 and could be used in screening compound libraries for 
potential inhibitors of PTPRZ. 
A second study in this domain sought to explore how structural modification could improve a 
therapeutic agent's potency from an atomistic perspective. This study was based on an earlier report 
in which the incorporation of a hydrocinnamoyl ester on C6’’ and C4-OH truncation of the 
sphingoid base of KRN7000 generated a novel compound AH10-7 high therapeutic potency and 
selectivity in human TCR-CD1d and subsequently results in the activation of invariant natural 
killer T cells (iNKT). The hydrocinnamoyl ester moiety was shown to engage in high-affinity 
interactions, possibly accounting for the selectivity and higher potency of AH10-7. Molecular and 
structural perspectives provided could aid in the design of novel α-GalCer derivatives for cancer 
immunotherapeutics. 
Chapter 3 provides theoretical insights into the various molecular modeling tools and techniques 
employed to investigate the various conformational changes, structural conformations, and the 
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associated mechanism of inhibitions of the studied inhibitors towards viral, tuberculosis, and 
cancer therapy. 
Chapter 4 provided sufficient details on druggability and drug-likeness principles and their recent 
advancements in the drug discovery field. The study also presents the different computational tools 
and their reliability of predictive analysis in the drug discovery domain. It thus provides a 
comprehensive guide for computational-oriented drug discovery research.  
Chapter 5 provides an understanding of the binding mechanism of Remdesivir, providing structural 
and conformational implications on SARS-CoV-2 RdRp upon its binding and identifying its 
crucial pharmacophoric moieties.  
Chapter 6 explains the mechanism of inhibition of a novel benzothiophene derivative, revealing 
its distortion of the native extensively networked and compact residue profile. 
Chapter 7 unravels molecular and structural bases behind this dual inhibitory potential of the novel 
inhibitor IMP-1088 toward common cold therapy using augmentative computational and 
cheminformatics methods. The study also highlights the pharmacological propensities of IMP-
1088.  
Chapter 8 unravels the molecular mechanisms and structural dynamics of the dual inhibitory 
activity of PAS-M towards DHFR and FDTS.  
Chapter 9 reports the structural dynamics and atomistic perspectives that account for the reported 
ability of BDQ to halt the ion shuttling ability of mycobacterial c-ring. 
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Chapter 10 presents the structural dynamics and conformational changes that occur on Mtb F1F0 
ATP-synthase binding as a result of the triple mutations using molecular dynamics simulations, 
free energy binding, and residue interaction network (RIN) analyses.  
Chapter 11 explored the impact of NAZ2329, a recently identified allosteric inhibitor of Protein 
Tyrosine Phosphatase Receptor Zeta (PTPRZ), on the atomic flexibility of the WPD-loop, an 
essential loop in the inhibition of PTPRZ. The study also presents the drug-likeness of NAZ2329 
using in silico techniques and its general inhibitory mechanism.   
Chapter 12 provides atomistic insights into the structural dynamics and selective mechanisms of 
AH10-7 for human TCR-CD1d towards activating iNKT cells. 
The studies in this thesis collectively present a thorough and comprehensive in silico perspective 
that characterizes the pharmacological inhibition of some known therapeutic targets in viral 
infections, tuberculosis, and cancer. The augmentative integration of computational methods to 
provide structural insights could help design highly selective inhibitors of these therapeutic targets. 
Therefore, the findings presented are fundamental to the design and development of next-
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1.1 Background and rational of study 
 
The studies presented in this thesis are geared towards exploring drug-target interactions in 
antiviral, antitubercular, and anticancer therapeutic interventions using Computer-Aided Drug 
Design (CADD) approaches revealing structural and mechanistic events that could inform the drug 
design of novel and improved small molecule inhibitors. Drug discovery is multifaceted, 
comprising a diverse and multidisciplinary approach towards designing a therapeutically effective 
and commercially viable drug. Due to the complex nature of the drug discovery process, it is 
usually costly, risky, and generally time-consuming. On average, the development of one drug 
from discovery until it makes it to the market takes approximately 10-15 years, with an estimated 
average of $1.3 billion [1]. As such, viable alternatives such as CADD have widely gained traction 
in the pharmaceutical industry with its ability to accelerate the drug discovery process while 
cutting down the cost involved [2–4]. Computer-aided approaches significantly optimize the lead 
discovery stage of drug development, which is known to majorly contribute to the overall drug 
discovery expenses due to various lead testing procedures [2–5].  By unraveling the molecular 
mechanism of drug molecules by exploring drug-target interactions, CADD approaches can also 
identify potential therapeutic agents against biological targets, thereby minimizing the search 
space to be investigated by experimental methods. Also, because drug-target interactions 
culminate into the eventual change in function/behavior of biological targets [6–9], the in silico 
elucidations of these interactions further establish CADD approaches current era of drug 
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discovery. CADD techniques also seek to augment traditional in vitro and in vivo experimental 
techniques and not to replace them since CADD approaches can also allow modeling of complex 
biological processes, which hitherto seemed impossible to explore using experimental methods.   
According to the World Health Organization (WHO), featuring prominently in the top ten causes 
of death are cancer, lower respiratory tract infection, tuberculosis, and viral infections such as 
HIV/AIDS.  Collectively, these diseases are of global health concerns, considering the large 
number of associated deaths yearly. Over the years, several therapeutic interventions have been 
employed to treat, manage, or cure these diseases, including; chemotherapy, surgery, and 
radiotherapy. Of these options, small molecule inhibitors have constituted an integral component 
in chemotherapy, thereby undoubtedly playing an essential role in patient management. Although 
significant success has been achieved using existing therapeutic approaches to the emergence of 
drug resistance, the drug design processes against these diseases remain innovative, including 
combining existing drugs and establishing improved therapeutic options that could overcome 
resistance. Therefore, an exploration of drug-target interactions as performed in the reports in this 
thesis is relevant since target interaction prediction plays a vital role in the drug discovery process, 
aiming to identify new drug compounds for biological targets. 
In all, the structural and conformational elucidations unraveled this thesis coupled with 
investigated mechanisms of actions of the studied small molecule inhibitors culminates into vital 
chemical information that can contribute significantly towards the discovery of next-generation 
lead compounds with improved potency in the treatment of cancer, viral infections, and 
tuberculosis. Thus, this thesis investigates molecular and structural insights on some selected 
protein and enzyme targets implicated in the pathogenesis of the studied diseases and therefore are 
proven therapeutic targets for currently existing chemotherapies. These implicated biological 
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targets include; SARS-CoV-2 RNA dependent RNA polymerase (SARS-CoV-2 RdRp), Human 
Rhinovirus B14 (HRV-B14)  and human N-myristoyltransferase (HNMT) in viral infections, 
Dihydrofolate reductase (DHFR)  and Flavin-dependent thymidylate synthase (FDTS) in 
tuberculosis, as well as Protein Tyrosine Phosphatase Receptor Zeta (PTPRZ) and human variants 
of  CD1d-restricted T Cell Receptor (TCR-CD1d)  in cancer. Moreover, resulting insights are 
essential towards the structure-based design of highly specific small-molecule antagonists of these 
biological targets. Also reported herein are strategic optimization methods for enhancing some of 
the studied small molecule compounds' biological activity to minimize their toxic tendencies 
 
1.2 Aims and objectives of this study 
 
The primary intent of this study is to provide structural mechanistic actions and molecular insights 
on crucial therapeutic targets coupled with the in silico application of strategic drug design 
methods for optimizing the therapeutic activities of bioderived compounds and improving their 
pharmacokinetics in relation to their use in the treatment of viral infections, tuberculosis, and 
cancer. Target proteins investigated in this thesis include SARS-CoV-2 RdRp, HRV-B14, and 
human NMT in viral infections, DHFR  and FDTS in tuberculosis, human variants of  TCR-CD1d 
and PTPRZ in cancer, while the optimization methods for enhancing the biological activity of 
some of the studied small molecule compounds to minimize their toxic tendencies were also 
investigated. 
The specific goals of this thesis are highlighted below: 
1. To provide sufficient and current details on druggability and drug-likeness and principles 
their recent advancements in the drug discovery field while presenting the different 





1.1 To highlights the principles and methods that underline the assessment of the 
druggability of biological target 
1.2 To highlights and establish the reliability of available druggability predictive 
methods 
1.3 To outline methods for the identification of lead molecules by assessing drug-
likeness 
1.4 To highlights physiochemical properties and pharmacokinetic properties in 
determining drug-likeness 
1.5 To highlights currently available in silico techniques of predicting drug-
likeness whiles buttressing on their reliability in augmenting experimental 
methods 
 
2. To provides an understanding of the binding mechanism of Remdesivir by unraveling the 
structural and conformational implications on SARS-CoV-2 RdRp upon Remdesivir 
binding and identify its crucial pharmacophoric moieties: 
 
2.1 To model the structure of SARS-CoV-2 RdRp through homology modeling 
in the absence of its X-ray crystal structure.    
2.2 To perform molecular dynamics simulations on the modelled structure of 
SARS-CoV-2 RdRp complexed with Remdesivir 
2.3 Investigate the conformational and structural changes on SARS-CoV-2 
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RdRp upon Remdesivir binding relative to the unbound conformation 
2.4 To measure the MM/PBSA-based free binding energy of Remdesivir 
2.5 To calculate the per-residue energy decomposition of individual amino acid 
residues that interact Remdesivir  
2.6 To calculate the per-residue energy decomposition of individual amino acid 
residues that interact Remdesivir  
2.7 To construct a pharmacophore that highlights the prominent interacting 
moieties of Remdesivir using ZINCPharma 
2.8 To screen the ZINC database for potential SARS-CoV-2 RdRp inhibitors 
using the generate pharmacophore 
 
3. To provide the molecular and structural mechanism of action of a novel benzothiophene 
derivative shown to inhibit HRV viral replication: 
3.1 To obtain the X-ray crystal structures of HRV-B14 capsid 
3.2 To model the structure of the novel benzothiophene derivative and 
subsequently subject it to molecular docking to generate complexes of the 
inhibitor and the HRV-B14 capsid. 
3.3 To perform molecular dynamics simulations on the generated HRV-B14 
inhibitor complex and the unbound conformation of HRV-B14  
3.4 To explore the impact of the binding of the novel benzothiophene derivative 
on the structural dynamics of HRV-B14 upon binding to it “canyon region” 
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3.5 To explore the impact of the binding of the novel benzothiophene derivative 
on the residue interaction network of HRV-B14 upon binding to it “canyon 
region” 
3.6 To explore the impact of the binding of the novel benzothiophene derivative 
on the motion the North-South Wall of HRV-B14 upon binding to it 
“canyon region” 
3.7 To estimate the binding free energy profile of the the novel benzothiophene 
relative the known the known capsid inhibitor, Pleconaril 
3.8 To quantify the individual energy contributions of binding site residues 
towards the binding of the novel benzothiophene using per-residue energy 
decomposition approach 
 
4. To unravels molecular and structural bases behind the dual inhibitory potential of the novel 
inhibitor IMP-1088 against human N-myristoyltransferase (HNMT) subtypes 1/2 toward 
common cold therapy using augmentative computational and cheminformatics methods. 
The study also highlights the pharmacological propensities of IMP-1088: 
 
4.1 To perform a sequence of alignment of HNMT subtypes 1/2 to assess their 
sequence similarity 
4.2 To obtain the X-ray crystal structures of HNMT subtypes 1/2 and subject to 
molecular dynamics simulations complexed with IMP-1088 
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4.3 To quantify the individual energy contributions of binding site residues 
towards the binding of IMP-1088 in both subtypes 1/2 using per-residue 
energy decomposition approaches  
4.4 To estimate the relative conformational and structural changes on both 
HNMT subtypes upon binding of IMP-1088 
4.5 To perform in silico physicochemical and ADMET profiling of compound 
IMP-1088 
 
5. To unravel the molecular mechanisms and structural dynamics that are associated with the 
dual inhibitory activity of bioactive metabolite of Para-amino Salicyclic Acid (PAS-M) 
towards dihydrofolate reductase (DHFR) and flavin-dependent thymidylate synthase 
(FDTS): 
 
5.1 To highlight the crucial role of DHFR and FDTS as therapeutic targets in 
tuberculosis treatment 
5.2 To obtain the X-ray crystal structures of DHFR and FDTS and subject to 
molecular dynamics simulations complexed with PAS-M 
5.3 To measure the MM/PBSA free binding energy of PAS-M and per-residue 
interactions of interacting residues upon binding with both DHFR and 
FDTS. 
5.4 To assess the concomitant effects of PAS-M binding on the overall 
structural stability of DHFR and FDTS. 
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5.5 To reflect the dynamical interactions elicited by the PAS-M at the 
hydrophobic grooves (binding sites) of DHFR and FDTS and identify 
crucial residues involved in high-affinity binding. 
5.6 To apply appropriate metrics to evaluate the structural dynamics of the 
hydrophobic deep pockets of DHFR and FDTS upon binding of PAS-M 
 
6. To describe the structural dynamics that explicate the experimentally reported antagonistic 
features of Bedaquiline (BDQ) in halting ion shuttling by the mycobacterial c-ring by 
binding Mycobacterium tuberculosis ATP synthase: 
 
6.1 To obtain the X-ray crystal structure Mycobacterium tuberculosis ATP 
synthase complexed with BDQ and subject the complex to molecular 
dynamics simulations  
6.2 To investigate the dynamical and corresponding structural effects of the 
binding of BDQ on the primary structure of Mtb ATP synthase 
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6.3 To investigate how dual molecule or single molecule binding of BDQ on 
Mtb ATP synthase influence the inhibitory potency of BDQ. 
6.4 To perform a time‐bound analysis of the interaction of BDQ at the c‐ring 
F1F0 synthase 
6.5 To quantify the energetics of the individual residues to the total binding 
affinity of BDQ with particular emphasis on the electrostatic and van der 
Waal energy contributions using MM/PBSA calculations 
 
7. To explore the impact of triple mutations on F1F0 structure and the consequential effect 
on the binding of BDQ: 
 
7.1 Model the non-existent crystal structure of F1F0 subunit C of Mtb using 
online modelling tools such as SwissModel  
7.2 To generate a mutant Mtb F1F0 by substituting these three residues 59(Leu 
→ Val), 61(Glu → Asp) and 66(Ile → Met) in its amino acid sequence. 
7.3 To perform a 150ns MD simulation on the mutant system and also a wild 
system with BDQ binding. In all two systems resulted including Mutant-
BDQ and Wild-BDQ systems 
7.4 To assess the systems stability and other conformational dynamics such as 




7.5 To perform a Residue Interaction Network to assess the effect of mutation 
on the binding of BDQ 
7.6 To employ post-MD analysis such MM/GBSA based binding free energy 
calculation to estimate the binding affinity of BDQ with and without the 
triple mutation 
7.7 To conduct Hydrogen bond analysis on the simulated systems to ascertain 
the impact of the mutation of hydrogen formation 
 
8. To explore the structural mechanism of inhibition of Protein Tyrosine Phosphatase 
Receptor Zeta (PTPRZ) by NAZ2329, a novel allosteric inhibitor: 
8.1 To highlight the role of PTPRZ as a therapeutic target in glioblastoma  
8.2 To prepare PTPRZ complexed with NAZ2329 and followed by molecular 
dynamics simulation studies to investigate the interaction dynamics over the 
simulation period 
8.3 To assess the impact of NAZ2329 binding on the structural stability of 
PTPRZ 
8.4 To monitor the structural and conformational dynamics of the WPD-loop 
upon the binding of order NAZ2329. 
8.5 To assess the physicochemical and drug-likeness of NAZ2329  
 
9. To gain atomistic insights into the structural dynamics and selective mechanisms of AH10-




9.1 To highlight the pharmacological ability of α-galactosylceramide 
derivatives as immunotherapeutic agents that in cancer treatment 
9.2 To retrieve the X-ray crystal structure of 2C12 TCR-CD1d in complex with 
AH10-7 and KRN7000 and subject them to molecular dynamics 
simulations 
9.3 To investigate the mechanistic selective binding affinity mediated by the 
incorporated hydrocinnamoyl ester on the “C6” of the sugar of AH10-7 
using MM/PBSA calculations 
9.4 To investigate the atomistic binding profiles of dually modified α-GalCer 
with individual hydrophobic pocket residues through per-residue energy 
decomposition 
9.5 To explore how the dual sphinganine base and hydrocinnamoyl ester 
modification of αGalCer enhances binding interactions with TCR-CD1d 
9.6 To examine the conformational changes on human TCR-CD1d upon 
binding of AH10-7 and KRN7000  
 
 
 1.3 Novelty and significance of study 
 
Despite the availability of several therapeutic interventions against viral infections, tuberculosis, 
and cancer, these conditions persist, with these diseases featuring prominently in the top ten causes 
of death globally. Their persistence as global health concerns has been due to incidences of 
chemotherapeutic resistance and associated toxic effects over the years. Reports in this thesis 
implement several computational techniques towards augmenting experimental methods as an 
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avenue of potentially accelerating the drug discovery process of novel inhibitors that overcome 
challenges associated with existing conventional therapeutic remedies against these diseases. By 
unraveling the molecular mechanism of small molecule inhibitors against therapeutic targets 
investigated in this study, the employed CADD approaches reveal crucial atomistic and structural 
insights that could aid in designing small molecule inhibitors against the respective biological 
targets that possess improved therapeutic properties. This could also reduce the search space to be 
investigated in laboratory experiments while leading to the discovery of lasting therapeutic 
solutions since the biological targets investigated in this thesis are prominently implicated in the 
studied diseases' pathogenesis. With the use of CADD techniques, a comprehensive in silico 
perspective is offered to shed light on possible structural characteristics that allow for the inhibition 
of these implicated therapeutic targets while also revealing the amino acid residues implicated in 
the biological functions of the targets. Also, by defining these therapeutic targets' binding 
landscape, the reports in this thesis will present a prospective design of selective and unique 
inhibitors with critical pharmacophoric features that will aid in developing targeted and effective 
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2.0 Background on the Application of Computer Drug Design in Drug Discovery 
2.1 Introduction to Computer-Aided Drug Design 
 
Small molecule compounds play a crucial role in modern-day medicine due to their ability to either 
prevent, treat, cure, relief, or restore a diseased system to a non-diseased state. Over the years, 
development of small molecule compounds for therapeutic purposes have usually involved the 
conventional route of obtaining lead molecules and subsequently developing a scientifically 
structured process for finding small molecule compound that would possess essential biological 
properties through several trial-and-error processes. Identification of a single small molecule 
compound for patient use usually begins with an initial screening of over 10,000 candidates 
followed by hundreds of animal testing in preclinical stages and finally concluded by several 
clinical trial stages involving thousands of healthy volunteers and diseased individuals. However, 
the identification of the small molecule compounds is usually preceded by years of scientific study 
to determine the biochemistry behind a disease, for which pharmaceutical intervention is possible. 
These subsequently result in determining specific biological targets (receptors, enzymes, protein) 
whose functions must be modulated by the small molecule compounds to induce a therapeutic 
outcome [1]. 
 
With the advancement in technology, this process has gradually evolved into a more purposeful 
design, synthesis, and evaluation of the candidate small molecule compounds referred to as a 
“rational drug design process”, a process that thrives on the collaborative efforts of multiple 
disciples such as process chemistry, animal pharmacology, drug metabolism, medicinal chemistry 
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and clinical research [2].  However, this conventional process is time and resource-consuming, 
with a recent study by Wouters et al. [3] revealing that an estimated median cost of $985 million 
and an average cost of $1.3 billion is required to get a small molecule compound from the 
laboratory to the market over a 7-to-12-year period. Aside from the huge cost and time-consuming 
nature of conventional drug discovery processes, studies have shown that only 1 out of 10 
compounds that make it to clinical trials will successfully reach the market, suggesting a very low 
success rate of less than 0.001% [4,5]. These challenges have motivated the incorporation of new 
approaches into the drug discovery and development process, some of which aim to facilitate, 




Figure 2.1: Schematic showing the different phases of the drug discovery process [1] 
 
One such approach is Computer-Aided Drug Design, which has proven to save time, money, and 
resources [1,6–9]. Since its introduction, it is estimated that CADD currently accounts for about 10% 
of pharmaceutical research and development expenditure and continue to increase [4,10]. The 
incorporation of CADD in the drug discovery pipeline cuts across various stages of the process from 
lead discovery in its early years of application to its current application in target identification, target 
validation through to clinical trials through its ability to predict pharmacokinetic properties [4,7,11]. 
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CADD's predictive power augments the drug design and development process by screening out only 
the most promising drug candidates from large compound libraries. Thus, CADD can prune 
compounds that could result in a “dead-end” due to their unfavorable pharmacological and 
pharmacokinetic properties, thereby accelerating getting drugs to the market. CADD also provides 
thorough atomistic binding features derived from the modeling of drug-target interactions [12]. These 
detailed atomistic scale insights are nearly impossible to assess in any other way yet are crucial in the 
design of new and improved small molecules compounds. 
 
Once the possible binders are identified, combinatorial chemistry can be used to generate a series of 
derivatives. However, in the absence of a biological target, a QSAR pharmacophore can be created 
based on the structure and activity information of a ligand. The crucial pharmacophoric features can 
screen for new binders with similar features that bind to the same target. Further, properties such as 
absorption, distribution, metabolism, excretion, and toxicity can also be predicted using CADD tools 
and used to compare with bio-assay data. Compounds that make it through all preclinical assessments 
become eligible compounds for the following clinical trials. 
Figure 2.2: In silico Computer-aided drug design [13,14] 
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Over the years, CADD's application led to the successful discovery and design of some small-molecule 
compounds, notably the design of thymidylate syntheses inhibitors as anticancer inhibitors by Appelt 
et al. in 1991[15]. Similarly, in 1994, Thaisrivongs (1994) reported HIV protease inhibitors that were 
also discovered through screening or via structural-based design based upon crystal structures of HIV 
protease complexes. The crystal complexes of HIV proteases allowed for a thorough evaluation of 
enzyme-inhibitor interaction and a practical effort toward the iterative cycle of structure-based design 
of inhibitors [16]. There have also been reports of the applications of CADD techniques in the 
successful discovery of neutrophil elastase inhibitors in 1998[17]. Other notable compounds 
discovered via CADD approaches include the carbonic anhydrase inhibitor discovered in 1989 by 
Baldwin et al. as an antiglaucoma agent inhibitor and a set of synthetic sweeteners that were also 
reported in 1990. Several of these CADD interventions have resulted in the discovery of many small 
inhibitors which have either been approved or in various stages of development as presented in table 
2.1 amongst many others [18–20]. CADD has since become an essential part of the preliminary stages 
of the drug discovery pipeline of most renowned pharmaceutical companies, which has consequently 
expedited the drug development process in a more cost-efficient way towards minimizing failures in 












Table 2.1:  Highlights of drugs designed using CADD  
 
Drug  Year of Approval Therapeutic action 
Cimetidine 1979 H2 -receptor 
antagonist[21,22] 
Captopril 1981 Antihypertensive [23] 
Imatinib 1990 Tyrosine kinase 
inhibitor[24,25] 
 
Saquinavir 1995 Human immunodeficiency 
Virus (HIV) inhibitor [26] 
Dorzolamide 1995 Carbonic anhydrase 
inhibitor [27] 
Indinavir 1996 Human immunodeficiency 
Virus (HIV) inhibitor [26] 
Ritonavir 1996 Human immunodeficiency 
Virus (HIV) inhibitor[26,28] 
Triofiban 1998 Fibrinogen  antagonist[29] 
Norfloxacin 1998 Inhibitor of bacterial 
DNA gyrase[30,31] 
Oseltamivir 1999 Neuraminidase inhibitor[32] 
Zanamivir 1999 Active against influenza A 
and B viruses.[33] 
Gefitinib 2003 EGFR kinase 
inhibitor[34,35] 
Fosamprenavir 2003 HIV protease 
inhibitor[36,37] 
Atazanavir 2004 HIV protease 
Inhibitor[38,39] 
Sorafenib 2005 VEGFR kinase inhibitor[40–
42] 
Erlotinib 2005 EGFR kinase 
inhibitor[43,44] 
Tipranavir 2005 Nonpeptidic HIV-1 protease 
inhibitor[45] 
Darunavir 2006 Nonpeptidic HIV-1 protease 
inhibitor[46,47] 
Lapatinib 2007 EGFR / ERBB2 
inhibitor[48,49] 
Raltegravir 2007 Human immunodeficiency 
Virus (HIV) inhibitor[50] 
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Aliskiren 2007 Human renin inhibitor[51] 
Boceprevir 2011 Hepatitis C virus (HCV) 
inhibitor[52] 
Abiraterone 2011 Androgen synthesis 
inhibitor[53–55] 
Crizotinib 2011 ALK inhibitor[56,57] 
Rupintrivir Phase II clinical trials Human  rhinovirus  (HRV)  3C  
protease[58] 
TMI-005 Phase II clinical trials In Rheumatoid arthritis[59] 
LY-517717 Phase II clinical trials Serine protease Inhibitor[60] 
Nolatrexed Phase III clinical trials In Liver cancer[61] 
NVP-AUY922 Phase II clinical trials Inhibitor for HSP90[62] 










2.2 Genesis and Chronological Evolution of Computer-Aided Drug Designs 
 
Although CADD is now very popular, with most globally renowned pharmaceutical companies 
extensively employing computational tools to design and discover therapeutic products for various 
life-threatening diseases [13], CADD has been around for several years. CADD became widely 
accepted as a concept at the beginning of the 20th century after the “lock and key” concept propounded 
by P. Eh-rich (1909), and E. Fisher (1894) had occupied a better of the 19th century   This was followed 
by subsequent incorporation of statistical techniques with biological activities of compounds to 
generate a new concept call Quantitative Structure-Activity Relationships (QSAR) a few decades later.  
[66] A publication titled “Next Industrial Revolution: Designing Drugs by Computer at Merck” in the 
Fortune magazine in 1981 heightened the popularity of CADD and its ensuing relevance in the drug 
discovery process [7,68]. This was in addition to the rising popularity of the combination of CADD 
with existing molecular biology concepts and its incorporation in the prediction of structures via 
Nuclear Magnetic Resonance and X-ray crystallography [7]. Several innovations that followed, 
including advancements in combinatorial chemistry, increased the number of compound databases 
covering large chemical spaces aided in expanding drug discovery and the eventual development of 
high-throughput screening (HTS) [69–71]. The advent of HTS expedited the drug discovery and 
development process by facilitating the rapid screening of large compound libraries for compounds 
that could elicit desirable therapeutic responses against new targets [72].  HTS eventually gained 
prominence in 1992 when about 40% of drug portfolios obtained their hits from HTS [72]. Regardless 
of the ability of HTS to facilitate the rapid screening of millions of compounds and its cost-
effectiveness, the rates of obtaining successful hits are low, and identified hits might also not make it 
beyond preclinical and clinical investigations.  The failure of hits was attributed to their poor 
pharmacokinetics and physicochemical properties such as adsorption, distribution, metabolism, 
excretion, and toxicology (ADME/T). Therefore, CADD presented a viable alternative that augmented 
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the existing methods by enhancing the success rates of hit compounds, making it as drugs while 
reducing the associated colossal cost of drug discovery and development. CADD thus improves the 
bioactive molecules, develops therapeutic alternatives, and understands biological events at the 
molecular level. The onset of the 21st witnessed a rise in CADD's prominence, with the advancement 
in computational power and the development of many models and new tools. With these 
improvements, CADD application in the pharmaceutical industry has taken center stage in the drug 
discovery process, particularly when combined with advanced forms of previous computational 
techniques such as HTS and X-ray crystallography. This has allowed for the application of CADD to 
find solutions to complex pharmaceutical solutions and discover numerous drugs in the treatment of 
diseases such as glaucoma, nonsmall-cell lung cancer, and acquired immunodeficiency syndrome 
(AIDS) [73–77]. 
 
2.3 Classification of Computer-Aided Drug Design 
 
CADD has been classified mainly into two types, namely; Structure-based drug design (SBDD) 
and Ligand-based-drug design (LBDD). However, more recently, other subtypes have gained 
prominence, notably Pharmacophore-based drug design (PBDD) and Fragment-based drug design 
(FBDD), collectively referred to as hybrid-based methods. 
 
2.3.1 Structured-Based Based Methods of Drug Design 
Considered one of the most influential and innovative methods in drug design, structure-based 
drug design utilizes the three-dimensional (3D) structure of a biological target as the basis for drug 
design[9,69,71,78].  SBDD relies on understanding the mechanism of action of the bound ligands, 
the specific binding on the biological target, and thorough elucidation of the molecular dynamics 
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of the ligand-biological target complex [30,79–81]. As such, an existing X-ray crystal, Nuclear 
Magnetic Resonance (NMR) spectroscopy, or cryo-electron microscopy (EM) structures of the 
biological target complex is usually required to begin with [71,82,83]. In the absence of X-ray or 
NMR structures, molecular modelling techniques such as homology modelling is used to generate 
3D structures of biological structures of interest [84–86]. These structures are retrieved from the 
known databases; Protein Data Bank (PDB) [87] and the Protein Data Bank in Europe (PDBe) 
[88] for further evaluation. To generate ligand-biological target complexes in the absence of 
deposited complexes, known computational techniques such as molecular docking are then 
employed.  
Subsequently, molecular dynamics (MD) simulations are used to unravel the mechanism of action 
and interaction dynamics at an atomistic level [30,79–81]. Because the 3D structure of the 
biological target is the crux of SBDD, its identification of a valid biological target and 
understanding its structural dynamics is usually the first step in the entire SBDD process. SBDD 
is further sub-categorized into two approaches: de novo drug design and the ligand docking 
approach.  In de novo drug design, large compound libraries are screened to identify new ligands 
that complementarily bind to a known biological target [84]. The recent advancement in 











2.3.2 Ligand-Based Drug Design 
 
This approach of drug design is employed when no information about the biological target is known. 
However, instead, enough information on the ligand that modulates that biological target's function is 
known [89,90]. Even though LBDD incorporates experimental approaches, its success rate is still lower 
than SBDD.  In LBDD, notable computational techniques employed in quantitative structure-activity 
relationship/quantitative structure properties relations (QSAR/QSPR) are employed to select ligands 
with potential activity-based 2D/3D structural and physicochemical properties [9,84,90–92].  The 
selection of these molecular descriptors that inform the drug design process in LBDD is usually based 
on assuming that compounds that possess structural similarities could equally possess similar 
biological activity towards a given biological target [71,93]. The knowledge of QSAR/QSPR allows 
for identifying moieties on the ligands that could influence a particular therapeutic effect and inform 
any structural modification on the ligand to improve its therapeutic potency [9,84,94]. 
 
2.3.3 Hybrid Drug Design Methods 
 
Interspersed between both SBDD and LBDD are methods that have gained prominence as CADD 
techniques, namely pharmacophore-based (PBDD) and fragment-based drug design. Hybrid 
methods also employ both SBDD and LBDD, thus in cases where there are a known biological 
target and a known ligand. In PDDD, the design of small molecules is based on the knowledge of 
chemical features of a known chemical compound required for the biological activity of that 
chemical compound [67,84,95–97]. These chemical features, referred to as pharmacophores, 
dictate the chemical compound's interaction with specific sites of a given biological target. PBDD 
has been widely explored because of its reliability over the years as a drug design method. Widely 
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explored methods under PBDD include; 3D-QSAR based pharmacophore modeling, common 
feature pharmacophore modeling, and 3D-pharmacophore modelling [84,98]. 
Fragment-based screening as an approach connects molecular fragments that have been shown to 
interact with specific sites on binding pockets to generate a small molecule compound that can be 
synthesized and be therapeutically useful [84,99].  The process of FBDD usually involves either a 
replacement of a chemical scaffold or a growing of new fragment for the purpose [84,99,100]. 
Several compounds designed via FBDD have made it through to clinical studies establishing its 
crucial role in the current day drug design and development [99,101]. 
 
2.4 Challenges of the application of CADD in drug design development 
 
Although CADD is undoubtedly a substantial part of the drug design process, it has known 
challenges that impede its overall success. As a multidisciplinary specialty, CADD requires highly 
skilled professionals with intellectual proficiency in all relevant fields, a requirement that tends to 
be a significant challenge.  Another considerable challenge of CADD is the accuracy and 
efficiency of computational techniques since, in scientific computing, several factors need to be 
considered, including; theoretical assumptions and algorithmic shortcuts, which could affect 
outcomes and predictions. This consequentially influences the quality and reliability of online 
computational resources and computational techniques such as virtual screening and ADMET 
predictions [102]. Other notable challenges include; deficiencies of CADD in chemo-genomics, 
the challenge of designing drugs with multi-targeting properties, improving the predictive capacity 
of toxicity models and side effects, and strengthening interaction with other disciplines to optimize 
the search for bioactive molecules for the treatment and/or prevention of diseases.  
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Although CADD has gained prominence, its application in the drug design and development 
process is still limited by many scientists' reluctance in integrating computational approaches with 
experimental techniques. Therefore, efforts should be made to ensure that CADD is successfully 
integrated with existing methods such as high throughput screening, combinatorial chemistry, and 
natural product-based drug discovery but not treated as a stand-alone technique of drug discovery 
[103–108]. 
 
2.6 Application of CADD in Developing Therapeutics for Viral Infections 
 
Viral infections are the most notorious of all infectious diseases.  
Viruses are obligate intracellular organisms that contain either ribonucleic acid (RNA) or 
deoxyribonucleic acid (DNA) genetic material enclosed within a capsid that causes numerous 
diseases in organisms. Several viruses have emerged in the last 40 years and have been the cause 
of significant disease outbreaks, notably; human immunodeficiency virus (HIV), influenza viruses, 
Hepatitis B virus,  Ebola virus, Zika virus,  severe acute respiratory syndrome coronavirus (SARS-
CoV), Middle East respiratory syndrome (MERS) and the most recently SARCoV-2 amongst 
many others [109–117]. As viruses continue to evolve with the emergence of drug-resistant strains, 
there is a need for new therapeutic agents to be designed as well. Available antivirals have targeted 
various viral proteins and enzymes whiles attempting to strengthen host immune responses.  The 
earliest reported antiviral application in treatment was in the 1960s in which thiosemicarbazone 
was used to treat smallpox [118]. Many approved antivirals target viral replication; however, many 
of the structures required for the process, such as ribosomes, originate from humans, whiles some 
known antiviral have associated side effects. As such, the search for safer antiviral continues. 
Although the process of designing new antivirals may be expensive, tedious, and time-consuming, 
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technological advancement has allowed for the application of cheaper and less time-consuming 
approaches such as computer-aided techniques towards designing novel and more efficient 
antivirals. Computer-aided have been employed at various stages to discover and design various 
antivirals, with some even getting approved for clinical use, as presented in table 2.1, amongst 
many others [119,120].  
With the aid of CADD techniques, the 3D structures of several structures in viruses have been 
determined via X-ray crystallography or homology modeling. Other molecular modeling 
techniques such as MD simulation and thermodynamics calculations have also allowed for the 
unraveling of atomistic insights and binding interaction dynamics that could help design novel 
antivirals with improved pharmacokinetics and physicochemical properties [118,121–123]. MD 
simulations have also helped identify hidden or allosteric binding pockets and augment existing 
antiviral drug discovery and development methods. To ensure efficient preclinical, experimental 
analyses of antiviral compounds in the CHEMBL dataset,  Vásquez-Domínguez et al. proposed a 
Perturbation-Theory Machine Learning model (PTML) [124]. The PTML model allowed for 
simplifying the management of the data in CHEMBL by considering multiple features that 
combined with preclinical, experimental anti-retroviral tests.  The application of CADD techniques 
such as virtual screening has also allowed for screening large compound libraries to identify 
potential ant-viral agents [125,126]. Some of these techniques, such as QSAR, also allow for the 
optimization of drugs against several viruses, which consequently optimize the metabolic profiles 







2.6.1 Anti-Viral Targets Explored in This Thesis 
 
This section will describe viral therapeutic targets that have been extensively investigated in 
relation to their interaction with specific small molecule inhibitors. The structure, functions, and 
implicated roles in viral disease pathogenesis will be discussed in detail. 
 
2.6.1.1 SARCOV-2 RNA dependent RNA polymerase 
 
One of the extensively investigated therapeutic targets in search of treatment methods against 
COVID-19 is the RNA-dependent RNA polymerase (RdRp) because of its crucial role in the 
replication and transcription of the SARSCOV-2 viral genome [129,130]. RdRp functions by 
controlling RNA strand elongation characterized by the addition of ∼30,000 nucleotides. 
SARSCOV2 RdRp is the product of the cleavage of the polyproteins 1a and 1ab from ORF1a and 
ORF1ab [131]. Structurally, RdRp consists of three subunits a catalytic non-structural protein 
(nsp) 12 (398-919) and two nsp8 and nsp7 accessory subunits [132–134].  Nsp12 houses the 
polymerase domain in a cupped “right hand” shape with palm domains, a thumb, and fingers 
[131,135,136]. The majority of the catalytic motives (A-E)  are located in the palm domain, known 
to be the most conserved.  The remaining two domains (F and G) are located in the finger domains 
[136–138]. Several reports have explored the effectiveness of RdRp as a therapeutic target for the 
treatment of COVID-19 [139,140] due to their uniquely conserved core structure the similarities 
of the motifs essential for the catalytic activity of RdRp [141,142]. Its suitability as a therapeutic 
target is based on the fact that there is no homolog of RdRp in humans [130]. Targeting RdRp over 
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the years has involved nucleoside and nucleotide analog inhibitors, which antagonize the native 
nucleosides and nucleotides and thus block viral RNA synthesis while inhibitors others induce 
mutations in the viral genome [143,144]. Due to structural similarity in conserved amino acids 
between SARCOV-2 RdRp and other different positive-sense RNA viruses, several therapeutic 
agents targeting other RdRp have been repurposed as potential therapeutic agents in COVID-19 
treatment [138,145]. Particularly at the  Notable SARSCOV-2 RdRp inhibitors include at various 
advanced stages of clinical trials includes Remdesivir [146–149], Favipiravir [150–152],  
Ribavirin[153–155] and Galidesivir [130,156,157] 
 
Figure 2.5: Linear structure of RNA Dependent RNA Polymerase (RdRp) showing the N-terminal 
domain and the main polymerase domain showing sub-domains (Finger, Palm, Thumb as well a 









2.6.1.2 Icosahedral Viral Capsid polyproteins of Human Rhinovirus B14 (HRV-B14) 
 
Consisting of four viral capsid proteins, namely VP1, VP2, VP3, and VP4, which enclose the viral 
(+)-ssRNA strand, the icosahedral capsid polyprotein has been extensively explored as a 
therapeutic target for the treatment of HRV infectious [158,159]. Structurally, the capsid proteins' 
arrangements form a unique icosahedral symmetry, which houses 60 copies of each protein [160]. 
VP1, VP2, and VP3, which are the largest of the capsid proteins, make up the viral capsid 
polyprotein's external surface. At the same time, VP4 encompasses the polyprotein's inner surface, 
thus forming an interface between the viral (+)-ssRNA and the external capsid protein (VP1, VP2, 
and VP3). Peculiar narrow ditches around the 5-fold apex of the viral capsid called “canyons” are 
used for cell-receptor-binding, which results in the uncoating of the capsid for subsequent cell 
entry [161]. A hydrophobic groove within the “canyon” made up of residues; Leu25, Ala21, 
Leu106, Phe124, Tyr128, Iso130, Tyr152, Val176, Tyr197, Met221, Asp219A, and Ser172 has 
been targeted by many capsid inhibitors. Upon binding to the hydrophobic groove in the “canyon”, 
some of these capsid inhibitors stabilize the viral capsid dynamics and subsequently impede viral 
uncoating [162]. Notable viral capsid stabilizing inhibitors include; pleconaril (WIN-63843) and 







Figure 2.6: Structure of icosahedral viral capsid demonstrating the unique VP1-VP3 domain 
orientations and the characteristic “canyon” drug-binding pocket. [162] 
 
2.6.1.3 Human N-myristoyltransferases 
 
N-myristoyltransferase (NMT) is a wildly conserved enzyme in eukaryotes that responsible for the 
post and co-translational modifications characterized by the transfer of myristate from myristoyl 
coenzyme A (Myr-CoA) to the N terminus of specific substrates [167,168]. NMTs belongs to the 
superfamily GCN5-related N-acetyltransferase (GNAT) [169].  In humans, NMT is expressed as 
two isoenzymes, namely; NMT1 and NMT2, and is implicated in several diseases, including viral 
infections such as common cold [170]. The implication of NMT in viral infection was evidenced 
by a mutagenesis study involving Poliovirus. It was suggested that the N-myristoylation of the 
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capsid proteinVP0 is a crucial capsid assembly and viral infectivity [171–174]. This evidence 
presents human  N-myristoyltransferase as a viable therapeutic target that is minimally affected by 
any potential mutation in the virus as well as an serotypic variation since the host N-
myristoyltransferase is an invariant factor in the replication of the virus. 
 
Figure 2.7: A) Human N-myristoyltransferase (NMT1) with Myristoyl-CoA and IMP-1088 
inhibitor bound (PDB:5MU6). B) Human N-myristoyltransferase isoform 2 (NMT2) 
(PDB:4C2X) 
 
2.7 Application of CADD in developing therapeutics for tuberculosis 
 
Tuberculosis (TB) remains a major global health threat considering its persistence as one of the 
leading causes of death worldwide. TB is caused by the “tuberculosis complex,” namely; 
Mycobacterium tuberculosis (Mtb), Mycobacterium bovis, and Mycobacterium Africanum 
[175,176] of which Mtb is the most predominant causative agent amongst the complex. In 2018, 
about 10 million people reportedly contracted  TB, of which over half a million were reported 
attributed to Rifampin resistant TB (RR-TB) An estimated total of 1.5 million reported died from 
34 
 
these infections [177]. Considering the center stage, the drug resistance has assumed in the number 
of deaths associated with TB,  novel antitubercular agents with the improved mechanism of actions 
are of urgent need towards overcoming the burden of TB. The increase in biological data, changes 
in the number of identified biological targets, and advancement in HTS technologies and other 
technological tools have also resulted in a change in the drug discovery process for novel 
antitubercular agents. As such, CADD has gradually taken a center in the design of TB 
therapeutics. Nonetheless, the applications still have some challenges as elaborated in a report by 
Ekins et al. in 2011, which informed their recommendation that CADD techniques should be 
ideally incorporated with experimental procedures to ensure an acceleration of the TB drug 
discovery process [178]. Several in silico techniques such as virtual screening, molecular dynamics 
simulations, molecular docking, homology modeling, QSAR, and pharmacophore modeling, 
amongst many others, have been employed over the years towards designing novel TB therapeutics 
[179]. A report by Taira et al. employed virtual screening to identify compounds that could interact 
with the mycobacterial CmaA1 [180]. The virtual screening process was based on the structural 
similarity between the selected active compounds in the study. It resulted in the identification of 
two compounds that could potentially inhibit mycobacterial growth. In a more recent report by 
Kumar et al., virtual screening was combined with MD simulation and binding free energy 
calculations to identify potential inhibitors of the promising TB target, decaprenylphosphoryl-β-
d-ribose 2’-epimerase (DprE1). Their report also identified four compounds (ChEMBL2441313, 
ChEMBL2338605, ChEMBL441373 and ChEMBL1607606) as potential inhibitors of DprE1. In 
another study, Billones et al. identified potential inhibitors of Mtb l,d-transpeptidase 2 (LdtMt2), 
an enzyme responsible for the catalyzation of  3-to-3 cross-linking between amino acids in linear 
amino sugar chains needed to form the peptidoglycan layer of mycobacteria [181]. Billones et al. 
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again in 2017 also combined molecular modeling techniques and experimental methods to 
discover novel inhibitors of  Mtb 7, 8-diaminopelargonic acid synthase ( Mtb BioA )[182]. Using 
similarity search, QSAR models, and pharmacophore hypotheses, Mehra et al. also screened the 
ChemBridge database [183] for potential inhibitors of the GlmU protein that plays a key role in 
the biosynthesis of peptidoglycans and liposaccharides, molecules that promotes the growth of 
Mtb [184]. Among many others, as highlighted in table 2.2, these reports showcase some of the 
immense contributions of CADD in TB pharmaceutical research. 
 
Table 2.2: Highlights of some studies that have employed virtual screening in identifying anti-
tubercular agents [179] 
System Function PDB Anti-Mtb-
Activity 
Cyclopropane mycolic acid 
synthase 1[180] 
 
Cell wall 1KPH MIC50/5.1 μM 
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2.7.1 Anti-tubercular targets explored in this thesis 
 
This section will describe anti-tubercular therapeutic targets that have been extensively 
investigated in relation to their interaction with specific small molecule inhibitors. The structure, 
functions, and implicated roles in the pathogenesis will be discussed in detail. 
 
2.7.1.1 Mycobacterial  folate biosynthetic pathway  
 
The folate biosynthetic pathway has been extensively explored as an avenue to the development 
of novel treatment measures for tuberculosis due to the many druggable targets available in the 
pathways [202].  Inhibitors that target the folate biosynthetic pathway, referred to as antifolate, 
impede the production of reduced folate cofactors via the inhibition of crucial enzymes in the 
pathway.  To synthesize folates, the enzyme dihydrofolate reductase encoded (DHFR) by folA 
gene is known to catalyze the conversion of dihydrofolate (DHF) into tetrahydrofolate (THF). The 
process employs Nicotinamide adenine dinucleotide phosphate (NADPH) as an electron donor.  
The generated THF is subsequently converted to N5, N10 Methylene tetrahydrofolate, catalyzed 
by serine hydroxymethyltransferase (SHMT).  The resultant N5, N10 Methylene tetrahydrofolate 
(mTHF), subsequently serves as a precursor for the synthesis of thymidylate in a processed 
catalyzed by the enzyme thymidylate synthase (TSase). In thymidine synthesis, TSase converts 
mTHF and 2′-deoxyuridine-5′-monophosphate (dUMP) to 2′-deoxythymidine-5′-monophosphate 
(dTMP) DHF, and the cycle repeats itself using DHFR. The mycobacterium then employs the 
generated dTMP for the synthesis of DNA. Due to this established vital role of DHFR in the 
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pathway and its powerful influence on mycobacterial DNA synthesis, it presents a viable 
therapeutic target in the design of new TB therapeutics [203,204].  
Nonetheless, many of the known available Mtb DHFR inhibitors have not achieved therapeutic 
success due to their inability to permeate the cellular membranes or a generally poor potency 
against the enzyme [205]. Other notable enzymes in the pathway that have been explored for 
therapeutic purposes in TB include the enzymes flavin-dependent thymidylate synthase (FDTS) 
and the Rv267, a functional analog of DHFR [204,206]. Encoded by the gene, thyX FDTS 
reportedly facilitates dTMP production by catalyzing the conversion of DHF to mTHF, with 
several inhibitors having been designed to target it [207,208]. Therefore its inhibition will 
consequently reduce the production of mTHF.  
Inhibitors of the folate pathways towards TB therapy over the years have included dapsone (DDS) 
and sulfamethoxazole (SMX), which inhibits dihydropteroate synthase (DHPS) [209,210], para-
aminosalicylic acid (PAS) [211], a combination of trimethoprim and sulfamethoxazole as Mtb 
DHFR inhibitors  [212] amongst many others. However, there is currently no approved treatment 
agents that target DHFR. Targeting the foliate pathways at various points using antifolates impedes 
the activated methyl cycle, which results in a decrease in the mycolic acids of the mycobacterium.  
Most recently, reports of multi-targeting agents of the cycles are gaining since these have been 
shown to possess higher therapeutic potency against the mycobacterium in relation to single 





  Figure 2.8: The Folate Biosynthetic pathway in Mtb [204] 
 
 




The c-rotor ring of Mtb F1F0 ATP synthase has been established as an essential structure in 
mycobacterial ATP synthesis. Hence, several inhibitors, notably Bedaquiline (BDQ) of the 
diarylquinoline class of compounds, have therapeutically targeted it towards TB therapy [213–
219]. As a part of the membrane-embedded F1F0 ATP synthase, the c-rotor ring is harbored in the   
F0 domain. In mycobacterium, the F0 domain exists in identical forms of the c-subunit, assuming 
the shape of an hourglass-shaped cylinder and forms a central pore referred to as the c-ring 
[220,221]. As an integral of the  F1F0 ATP synthase, the c subunit is made up of two 
transmembrane helices responsible for proton translocation. Both helices also house crucial 
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residues (D28, L59, E61, A63, I66) required for sensitivity to diarylquinolines like BDQ [214,222–
224].  Structurally, F1F0 ATP synthase consists of two domains; the F1 and F0 domain. The F1 
complex facilitates the transfer of H+ from the periplasmic space to the cytoplasmic space [225–
227]. The F1 complex, which is also water-soluble, converts Adenosine Diphosphate (ADP) and 
inorganic phosphate (Pi) to ATP using H+-motive force [225,226,228] by a process referred to us 
the rotary mechanism [225,228,229]. As a crucial enzyme in the synthesis of ATP in the three 
catalytic active pockets of the F0 domain, F1Fo‐ATP synthase facilitates the shuttling of ions 
across cellular membranes [228].  
 
 
Figure 2.9: Structure of Mtb ATP synthase modelled from the structure of E. Coli ATP synthase. 






2.8 Application of CADD in developing therapeutics for cancer 
 
As a disease, cancer has significantly contributed to the growing mortality worldwide, with more 
than half of cancer cases in low- and middle-income countries [230]. Treatment and management 
of cancer remain a challenge, with many available interventions been halted or not making it 
beyond the clinical phases of drug development. The challenges with existing cancer therapeutics 
are mainly due to cancerous cells' multifactorial characteristics, thus evading and developing drug 
resistance to cancer therapeutics [231,232]. Targeted therapies and precision medicine have 
gradually gained prominence as an advanced therapeutic intervention to address these challenges. 
However, disease relapse,  adverse side effects, expensive treatment options, and drug resistance 
persist [233–238]. As such, the search for alternative cancer therapeutics with enhanced potency, 
cheap, minimal adverse effects, and overcome resistances remains unabated.  Conventional drug 
discovery methods in cancer therapeutics are time-consuming and expensive. However, the advent 
of CADD has sort to ameliorate some of these challenges with the hope of developing novel cancer 
therapeutics with high selectivity and minimal toxicities [8,239]. Together with experimental 
methods, these computer-aided techniques have contributed to the identification and selection of 
crucial oncogenic targets coupled as well as the strategic development of highly selective 
inhibitory methods using low cost less toxic therapeutic molecules that have significantly 
contributed towards the discovery of next-generation lead compounds with great potency in cancer 
treatment. Several reports have reported the involvement of CADD in the development of cancer 
therapeutics. For instance, in the report by Mutata et al., structure-based pharmacophore modeling 
was employed to identify potential inhibitors of p53 upregulated modulator of apoptosis (PUMA), 
whose inhibition leads to a deficiency in apoptosis and thus minimizing the risk of cancer 
development as well as drug resistance. In a separate report by Liu et al.,  a combinatorial 
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computational approach was employed in discovering potential insulin-like growth factor-1 
receptor (IGF-1R) inhibitors [240]. Considering the implication of IGF-1R in several tumors such 
as lung cancers, prostate, and breast cancers due to its crucial role in signaling various cancer 
hallmarks including cell growth, proliferation, and apoptosis, a successful inhibition could be a 
therapeutic breakthrough. In their report, virtual and pharmacophore modeling were employed to 
identify 15 compounds that exhibited potential inhibitory activity against IGF-1R. Another 
reported application of CADD in the discovery and design of anticancer inhibitors is a study by 
Chiang et al. in which ligand-based methods were used to identify tubulin inhibitors [241]. Cell 
cycle progression and cell division require tubulin polymerization. Therefore its inhibitions present 
a powerful avenue for cancer therapy. Another report by Liou in 2006 used a structure-activity 
relationship (SAR) to generate a model on a set of indole-derivatives to improve the potency and 
solubility of anticancer drug candidate BPR0L075. Computational techniques were also employed 
in a study by Noha et al. in 2011, where small molecules inhibitors of I-Kappa-B Kinase β were 
identified(IKK-β) [242]. The crucial role of IKK-β in the NF-κB signaling pathway presents them 
as viable cancer targets. Employing ligand-based pharmacophore modeling, they identified novel 
inhibitors with an affinity toward IKK-β. These studies and many others establish CADD's 
application toward the design of anticancer agents in the last couple of years. 
 
2.8.1 Anti-cancer targets explored in this thesis 
 
This section will describe therapeutic targets in cancer that has been extensively investigated in 
relation to their interaction with specific small molecule inhibitors. The structure, functions, and 
implicated roles in tuberculosis disease pathogenesis will be discussed in detail. 
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2.8.1 Anti-cancer targets explored in this thesis 
 
This section will describe cancer therapeutic targets that have been extensively investigated in 
relation to their interaction with specific small molecule inhibitors. The structure, functions and 
their implicated roles in tuberculosis disease pathogenesis will be discussed in detail. 
 
2.8.1.1 Protein Tyrosine Phosphatase Zeta (PTPRZ) 
 
Protein Tyrosine Phosphatase Receptor Zeta (PTPRZ) is a member of the R5 subfamily of 
receptor-type protein tyrosine phosphatases (RPTPs), which also has Protein Tyrosine 
Phosphatase G (PTPRG) as the other member [243,244]. Although Protein Tyrosine Phosphatases 
(PTPs)  have been implicated in many cellular processes and diseases, they are generally classified 
as "undruggable" due to the positively charged active pockets which are highly conserved 
[244,245]. PTPs are known tumor suppressors, unlike the protein tyrosine kinases (PTKs), whose 
phosphorylation regulates many cellular functions. Simultaneously, its dysregulation has also been 
linked to the cause of many cancers such as gliomas [246,247]. Structurally, PTPRZ and PTPRG 
are made of carbonic anhydrase (CAH)-like domain that occurs in extracellular, two tyrosine 
phosphatase domains which are intracellular, and a fibronectin type III-like domain [248]. 
Although PTPRZ has been extensively investigated as a viable therapeutic target for glioblastoma 
treatment due to its strong expression in gliomas, the pathophysiological implication of PTPRG is 
unclear even though it is significantly expressed in advanced astrocytomas [249–251]. By 
regulating the process of protein tyrosine phosphorylation, PTPRZ leads to the survival of 
glioblastoma cells, thus enhancing tumor growth [246].  Therefore, in glioblastoma cells, reports 
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have shown that the inhibition of PTPRZ interrupts cell proliferation, reduces the formations of 
tumors in vivo, and reduces the migration of malignant cells in vitro hence its extensive 
exploitation as a therapeutic target [251–254]. The structural architecture of the PTPRZ active site 
consists of 5 loops, namely; the P-loops (phosphate-binding loop), the WPD-loop (catalytic 
acid/base harboring), Q-loop (conserved glutamine containing), pTyr-loop (pTyr-recognition), and 
the E-loop (contains multiple conserved residues) [255,256]. By its flexible nature, the WPD loop 
encloses the catalytic site assuming the role of a gate. In the active form of PTPRZ, the flexible 
WPD-loop assumes a closed conformation, while an open conformation is assumed in an inactive 
form of PTPRZ[257]. When substrates bind to the flexible WPD-loop, it assumes a closed 
conformation, which allows the catalytic aspartate on the loop to partake in catalysis [255]. As 
such, a successful inhibition of the WPD-loop mobility could subsequently impede the process of 
catalytic activity of the PTPRZ [258,259]. Although several phosphotyrosine competitive 
inhibitors have been developed over the years, none have been able to achieve success in cancer 
therapy due to their inability to permeate cell wall or as a result of the highly conserved and 





Figure 2.10: Structural and corresponding sequence representation of the unique regions of the 
PTPRZ protein; active site-red, allosteric site- green and WPD-loop- yellow[256].  
 
2.8.1.2 Human CD1d-restricted Invariant natural killer T cells  
 
Therapeutic targeting of human CD1d-restricted Invariant natural killer T (iNKT) cells has been 
proven by several reports to have potential therapeutic applications in supplementing immune 
responses against cancer and infections. iNKT cells form part of unconventional T cells involved 
in both innate and adaptive immune response [261,262]. A distinguishing characteristic of iNKT 
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cells, when compared to conventional T cells, is their ability to recognize lipid-based antigens 
rendered by  MHC class I-like CD1d protein [263]. Also,  a unique feature of iNKT cells in the 
presence of a semi-variant T cell receptor (TCR) found  in both humans (Vαl24Jα18) and mice 
(Vα14Jα18) which have been therapeutically exploited toward stimulating iNKT cells responses 
for anti-cancer purposes [264,265]. This has also expanded immunotherapeutic options as well as 
vaccine research [266–268]. iNKT cells exhibit selectivity towards CD1d-expressing thymocytes, 
unlike other natural killer cells that interact with class two MHC molecules [261,269,270]. The 
presence of TCR in iNKT cells also allows for their therapeutic targeting by prototype alpha-
galactosylceramide inhibitors. iNKTs dominate in the adipose but occur in low frequency in the 
blood [271,272]. Activation of iNKTs results in an increased expression of NKTs, which leads to 
the stimulation of the conventional T cells through the secretion of cytokines and mature dendritic 
cells [273,274].  When triggered by antigens, iNKT s release cytokines (Th1, Th2, and Th17) 
within a space of some few hours together with the expression of CD40L, characterizing iNKTs 
role in immune response [269,275]. The antitumor immune response of iNKTs, on the other hand, 
is characterized by inducing the release of cytotoxic lymphocytes (CTLS), activation of other 
natural killer cells, and the modulation of the immunosuppressive tumor microenvironment, which 
altogether results in the killing of cancerous cells [266,276–278]. This has informed the extensive 
investigation of iNKT as immunotherapeutic targets [266,269,278]. Notable activators of iNKTs 
towards cancer therapy have included alpha-galactosylceramide (α-GalCer) and their resulting 
derivatives and synthetic forms; KRN7000 and the more recent AH10-7 [264,265,279–282]. 
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3.0 Principles of Computational Chemistry and Molecular Modeling Techniques as 





As a fast-emerging field, computational chemistry entails the modeling and computational 
simulation of systems such as polymers, drugs, organic and inorganic molecules, and 
biomolecules, amongst many others [1,2]. Initially introduced in the 1960s, computational 
chemistry has gained immense prominence in the last several decades due to the remarkable 
improvement in computer hardware and the continuous development of advanced computational 
software [3–5]. Technological advancement has substantially increased computing power since 
faster and more efficient computational algorithms are being developed. Computational chemistry 
has simplified the hitherto complex biological and chemical problems by integrating physics, 
chemistry, biology, and mathematics. As applied in this research, computational chemistry has 
enabled the investigation of the structural mechanisms of actions and inhibitory activities 
associated with the binding of some small molecule inhibitors against some therapeutic targets 
against viruses, Mycobacterium tuberculosis, and cancer. Experimental techniques are associated 
with the high cost and time-consuming, based on proven theories, computational chemistry, and 
molecular modeling, which can address these challenges using software and computational tools 
based on empirical information. To ensure the reliability of molecular modeling procedures, 
models prepared must adhere to standard computational techniques and consider all the factors 
that ensure that the simulated models assume similarity to natural systems. Molecular modeling 
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methods incorporate the appropriate application of computational chemistry and molecular 
modeling, which in turn have been developed into several techniques such as molecular dynamics 
(MD) simulations, free binding energy analysis, molecular docking, 3D-QSAR, cheminformatics, 
and drug repurposing techniques, among several others as applied in the studies of this thesis. This 
chapter principally discusses the computational theories governing many of these computational 
techniques as employed in this thesis. The unique approaches that allow for the description of the 
interaction between atoms and molecules in the application of computational models to study 
chemical and biological systems include; quantum mechanics (QM) [6–13], molecular mechanics 
(MM)[14–16], hybrid QM/MM[17–20] and the ‘Our own N-layered Integrated Molecular Orbital 
and molecular mechanics’ (ONIOM) [21,22]. Also described are molecular force fields (MFF). 
These approaches enable a versatile and apt description of chemical, biological systems so long as 
the systems' parameters are impeccably attuned and balanced among each other [4]. Collectively, 
these approaches have allowed for the biological and chemical challenges, including but not 
limited to systems biology [23], enzyme catalysis [24], bioenergy transduction [25]  biomimetics, 
and ligand design [26]. The subsequent sessions describe these approaches as applied to achieve 
the objectives outlined in this thesis. The ensuing sessions also describe other computational 




Figure 3.1: The scientific domains in which Applications of Quantum and Molecular Mechanics 
fit into 
 
3.2 Quantum Mechanics 
Quantum mechanisms describe biological and chemical systems by portioning the atoms that make 
up the system into two components: the nuclei and the electrons that enclose the nuclei. A 
characteristic feature of QM description is that it considers all shifts in electron density that 
emanates from charge transfers, polarization, and many-body contributions. Therefore, as applied 
in molecular modeling, QM allows for the investigation of the electronic behavior of molecules 
and spatial interactions. The application of QM in addressing biological challenges has been 
widely explored in areas such as structured based drug design, protein structure and solvation, and 
refinement of biological structures by X-ray spectroscopy and NMR [27]. As employed in this 
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thesis, QM methods also allow for the unraveling of the fundamental physical basis of the catalysis 
of enzymes, a phenomenon that inspired the Noble prize winning work in chemistry by Karplus et 
al. in 2013 [28–30]. QM approaches do not require empirical parameters; as such, their application 
is not restricted to specific molecule class. Comparatively, although QM has these advantages, it 
demands increased computational effort and resources relative to MM. QM employs Schrödinger’s 
wave function to measure the system's energetics, whereas electron mapping is performed using 
the electron density approach  [31,32]. On the other hand, the electron density in QM is also 
estimated using the Born-Oppenheimer approximation theory [33]. The Schrödinger’s wave 
function and the Born-Oppenheimer approximation theory are discussed in detail in the following 
sections. The model proposed by Schrödinger’s wave function forms the basis for the current-day 
concept of an atom. 
 
Figure 3.2: Schematic showing the Application of QM Methods to Biological Problems[27] 




3.2.1 The Schrödinger’s wave function 
Inspired by De Broglie’s doctoral thesis in 1925, Schrödinger initiated a study to obtain a wave 
equation applied to the hydrogen atom.  Schrödinger added his ideas, such as his interest in 
establishing stationary waves in three dimensions, analogous to sound waves in cavities [34]. In 
wave mechanics, the Schrödinger equation is used as a wave function for a particle and enables 
creating a complete model for an atom [34]. As an improvement in De Broglie’s work, the 
Schrödinger wave equation addresses De Broglie’s theory's limitations, such as its inability to cater 
to accelerated motions and rotations [34]. Schrödinger’s wave equation also attempted to reconcile 
the theoretical assumptions propounded by Heisenberg and those postulated by De Broglie while 
also showcasing a 3D orbital model for each energy sub-level described and thus assumed that 
electrons could be described as matter waves [34].  This eventually allowed for the molecular 
geometry of numerous chemical substances to be determined [34]. The Schrödinger’s wave 
equation also addresses significant challenges associated with Bohr’s model, which treated 
electrons as particles that existed in precisely-defined orbits. The basic form of Schrödinger’s 
equation is described as follows; 
 Hѱ = Eѱ             (Eq. 3.2.1) 
 
The equation's wave function is denoted by Ѱ, whereas the H and  E represent the Hamiltonian 
operator and electron binding energy, respectively. The wave function cannot predict the exact 
location of electrons, although it can describe the probability of the electrons' locations. For the 
Schrödinger equation to present a physically relevant model, the wave function must be 
normalized, continuous, single-valued, and anti-symmetric. The molecular Hamiltonian operator 
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(H) is obtained by a sum of the potential energy (V) and the kinetic energy (T) and mathematically 
described as follows; 
 
H = T + V     (Eq. 3.2.2) 
 
 
However, the Hamiltonian operator constitutes all kinetic and potential energy operators for all the 
electrons and nuclei in a molecule when relativistic effects are neglected, and particles are 
described as end masses. Subsequently, the advanced form of the equation is represented as 
follows; 
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-.                             (Eq. 3.2.3) 
 
Where i and j represent  the electrons, mj represent mass of  electron j while rij being the distance 
between i and j electrons.   
Due to the highly complex nature of the Schrödinger’s  wave equation and its associated limitations 
in solving for molecular systems which usually consists of thousands of atoms, the Born-
Oppenheimer approximation theory as described in the ensuing session has been shown to 











Figure 3.3:  Schrödinger’s 1927 model of an atom 
 
3.2.2 The  Born-Oppenheimer Approximation  
As one of the underlying fundamental concepts in quantum mechanics that describe the quantum 
states of molecules, the Born-Oppenheimer approximation allows for the separation of nuclei and 
electrons motions [38,39]. In doing so, the Born-Oppenheimer approximation can address the 
significant limitation of Schrödinger’s wave equation. Propounded by Max Born and J. Robert 
Oppenheimer in 1927, the approximation thus describes the wave function's uncoupling to that of 
the electrons [18,27,40–42]. Electrons are considered to be lighter in weight than nuclei; thus, they 
have increased velocity and move instantaneously relative to the movement of nuclei [43]. The 
difference in weight between the electrons and nuclei is accounted for by the Born-Oppenheimer 
approximation. Therefore, the electrons can almost instantaneously respond to nuclei displacement 
[44–47]. Therefore the distribution of electrons within molecules is described by nuclei location 
[44,45].  The Born-Oppenheimer approximation makes it possible for the Schrödinger equation to 
be solved for the kinetic energy of the electrons alone since the nuclei's kinetic energy will remain 
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constant.  The difference in velocities of the nuclei and electrons allows for the Born-Oppenheimer 
approximation to be applied, minimizing the complexity of the wave function of the Hamiltonian 
equation [40].  The approximation of the Hamiltonian is shown below: 



















         (Eq. 3.2.4) 
 
Where A and B denote the nuclei, while i and j represent  the electrons. MA represent the nucleus 
A mass while me denote an electron mass. RAB represents a nuclei A and B inter-distance with rij 
being the distance between i and j electrons.  ZA is nucleus A charge while rAi represents nucleus 
A and electron i inter-distance.  
 
The complexity of the Hamiltonian equation's wave function is minimized due to the variance in 
the velocities of the nuclei and the electrons when the Born-Oppenheimer is applied [40]. When 
simplified as a result of the instantaneous response of electrons to nuclear motions,  the wave 
function is subsequently expressed as follows; 
(𝒓𝒆𝒍𝒆𝒄) = 𝝍(𝒓𝒆𝒍𝒆𝒄)(𝒓𝒏𝒖𝒄𝒍)                                                                       (Eq. 3.2.5) 
 
Which is subsequently changed to 
 𝜢𝜠𝜨𝝍(𝒓𝒆𝒍) = 𝜠𝜠𝜨𝝍(𝒓𝒆𝒍)                                                                                (Eq. 3.2.6) 
 HEN symbolizes a difference between terms based on their dependence on fixed nuclear positions 
(VNN) or their dependence on the non-fixed electron positions (Hel).  An energy term EEN is 
integrated, which is derived from two sources; one being the fluctuating electron co-ordinates E 




 𝜢𝒆𝒍 + 𝑽𝑵𝑵)	𝝍(𝒓𝒆𝒍) = 𝜠𝜠𝜨𝝍(𝒓𝒆𝒍)                                                                  (Eq. 3.2.7) 
The application of Born-Oppenheimer approximation to electrons in the ground states is more 
accurate than when applied to electrons in the excited states [31,43]. Upon solving the equation, it 
enables the construction of a molecular potential energy curve and a potential energy surface of a 
polyatomic molecule [43] while also permitting the identification and assessment of the 
equilibrated conformations given molecule with the lowest point on the surface [43,46]. 
 
3.2.3 Potential Energy Surface Function 
A potential energy surface is an efficient mathematical function that gives a molecule's energy as 
a function of its geometry [31]. Originating from the Born-Oppenheimer approximation, the 
potential energy surface functions play a crucial role in modeling molecular systems, describing 
and simulating molecular systems by presenting a basis for comprehending the processes 
associated with nuclear motions in molecules [48]. A full dimensional and accurate potential 
energy surface provides insights into spectroscopy, structure, and reactivity of molecules by 
probing further than the usual stationary points and barriers and solving the time-dependent 
Schrödinger equation [49–51]. In a Potential energy surface, the regions dominated by van der 
Waals interactions are vital for low-temperature phenomena and molecular stacking, which are 
essential in understanding DNA and RNA molecules. On the other hand, most stable structures on 
potential energy surfaces are covalent or ionic bond related. As displayed in the figure below, high 
potential energy regions displayed specifies high-energy nuclear arrangements or molecular 
conformations, whereas low energy regions signify low nuclear energy conformation and can be 






Figure 3.4: A graphical representation of a two-dimensional potential energy surface 
 
3.3 Molecular Mechanics 
 
Molecular mechanics (MM)  describes bonds, valence angles, and Coulomb and Lennard-Jones 
interactions to account for charge-charge and non-bonded contributions by incorporating classical 
type models [1,53]. In doing, so MM methods can predict the energy of a molecular system as a 
function of their conformation [1]. Relative to QM methods, MM force fields dominate as the 
preferred method choice for protein simulations towards understanding conformational dynamics 
of these protein structures because potential energy functions in MM methods provide a relatively 
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more accurate representation of dispersion interactions while adhering to the Newtonian laws of 
classical mechanisms [54,55]. MM has been employed to study a wide range of systems, including 
hydrocarbons, nucleic acids, membrane fragments, and material assemblies, which consist of 
thousands of atoms. The application of MM in more complex phenomena such as polarization and 
many-body contributions has also gained attention in recent years [4,56–58]. MM has also allowed 
for the study of areas (solid-state interfaces, semi-conducting systems, metals, alloys, etc.) in 
which the application of simplistic force field methods was deemed undependable [4]. s 
corresponding to the minimum-energy geometry – or more precisely, to the various probable 
potential energy surface minima [59,60]. Nonetheless, MM is appropriate for bond-breaking 
reactions, just like most ab initio methods [61]. MM or the force-field method is mathematically 
described as follows; 
             𝜠𝒕𝒐𝒕 = 𝜠𝒔𝒕𝒓 + 𝜠𝒃𝒆𝒏𝒅 + 𝜠𝒕𝒐𝒓𝒔 + 𝜠𝒗𝒅𝒘 + 𝜠𝒆𝒍𝒆𝒄                                       (Eq. 3.3.1) 
 
Where, 
Etot  = total energy,                                 Estr =  bond-stretching energy, 
Ebend = angle-bending energy               ,Etors = torsional energy,      




Figure 3.5: Diagrammatical depiction of bonded and non-bonded interactions acting in molecular 
motion [62]. 
 
Also, MM accounts for energy contributions from hydrogen bonding and stretch-bend coupling 
interactions. In methodical force fields, all constituent atoms are considered building blocks, 
whereas electrons are not described as separate particles. As such, rather than implementing the 
Schrödinger equation, more descriptions about the bonds are provided. This accounts for the ball-
and-spring model earlier mentioned with different atomic sizes and bond lengths while the atoms 
themselves are treated as spheres. This model was therefore termed “atom types,” which is 
dependent on the atomic number and the interconnecting chemical bonds [31,63]. From Eq. 3.8;  
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Bond stretching, which occurs between directly bonded atoms, is mathematically represented as: 
  Estr = ΣKr(r-r0)2     (Eq. 3.3.2) 
Angle bending, which occurs between atoms that are surrounded by the same central atoms is 
mathematically expressed as: 
   Eθ = ΣKθ(θ – θ0)2     (Eq. 3.3.3) 
Also, bond torsion is expressed as  
  Eϕ = ΣKϕ[1 + cos(nϕ – ϕ0)]                (Eq. 3.3.4) 
In all,  non-bonded interactions, which constitute van der Waals and electrostatic forces, we have  
 
Where, Kr, Kθ and Kϕ depict the force constants for bond, angle and dihedral angles while r0, θ0 
and ϕ0 represent the equilibrium distance, angle and phase angle. Moreover, the parameter for 
distance is rij while Aij and Bij depict the parameters for van der Waals forces. The molecular 










3.4 Hybrid Quantum Mechanics/Molecular Mechanics (QM/MM) 
Pioneered in the 1970s by Martin Karplus, Michael Levitt, and Arieh Warshel, QM/MM attempts 
to harness the advantages of both QM and MM [4,17,18,64,65]. In studying a molecular system 
with hybrid QM/MM approaches, the QM component is employed to treat the most significant 
part of the system, whereas the classical MM component is subsequently employed to model the 
rest of the system [4]. The crux of QM/MM as a method centers around the electrostatic interaction 
between QM and MM subsystems. As an advantage over individual QM and MM,  hybrid 
QM/MM methods give more accurate quantum calculations and are associated with lesser 
computational cost [66,67].  The technique of QM/MM encompasses two steps-wise domains, a 
QM, and an MM phase  [130]. In the QM phase, the reactive domain, which includes ligands and 
amino acids, is treated with QM techniques, which defines molecules' electronic structures [129]. 
This MM phase defines interactions between atoms by incorporating a force field, acting as a 
potential energy function [128,131]. Amidst the notable advantages of the hybrid QM/MM method 
over QM and MM, it may not be appropriate for every structure-based drug design study; hence 
further exploration of the technique may be required [129]. In drug discovery research, the 
application of QM/MM encompasses areas such as simulation of chemical reactions such as the 
catalytic mechanism of enzymes,  the investigation of electronic properties, and calculation of 




3.5 Molecular Dynamics Simulations 
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MD simulation is a widely used computational technique based on classical Newtonian mechanics 
that employs MM force fields to provide essential atomistic insights on biomolecular structures by 
simulating particulate motion as a function of time [71–74].  MD simulation was primarily 
employed in achieving the objectives of the various reports in this thesis by providing an atomistic 
time-scale insight into the conformational and structural dynamics of the studied biological targets 
with their respective bound small molecule inhibitors. Based on varying accuracy requirements, 
all forms of MD simulations including; coarse-grained (CG), united-atom (UA), and all-atom 
(AA), including explicit/implicit solvent models which are known to permit simulations of 
temporal and spatial scales, have been shown to play a vital role in drug discovery in recent years 
[75–77]. The application of MD simulation in drug discovery has included; exploring the 
mechanism of actions of therapeutic agents, identifying potential binding sites, and calculating 
binding free energies of therapeutic agents, amongst many others [77–79]. Originating in the late 
1950s, MD simulations have gained center stage in drug design in recent years, evolving to include 
the simulation of complex macromolecules such as DNA and RNA even though it began with its 
application in the simulation of simple gasses [80,81]. In the late 1970s, the first protein MD 
simulation was also reported [82]. The modeling of complex systems in MD simulations are 
carried out at atomic levels. At the same time, the equation of motions is mathematically solved to 
depict the motions and dynamics of biomolecules undergoing simulation, which allows their 
kinetic and thermodynamic properties to be derived [71,83]. MD simulation techniques are divided 
into two, namely classical and Monte Carlo (MC) MD simulation. In a Classical MD simulation, 
atoms and molecules' trajectories are generated by mathematically solving Newton’s equation of 
motion for a system of interacting particles, in which molecular mechanics defines forces between 
the particles and potential energy force fields as presented below [145]. Trajectories specify the 
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particle position and velocity, which varies with time [146]. In performing a Classical MD, the 
positions and velocities of particles, the force field, and boundary conditions must be initially 
considered.  
 
                 𝑭𝒊 = 𝒎𝒊
𝒅𝟐𝒓𝒊(𝒕)
𝒅𝒕𝟐
                                                                                 (Eq. 3.5.1) 
From the equation, ri (t) = (xi(t), yi(t), zi(t)) represents the (i) vector of the particulate position with 
a force, Fi, acting on the (i) particle at time t and particle mass mi 
 
On the other hand, MC methods seek to create an ensemble of representative configurations under 
specific thermodynamics conditions for a complex macromolecular system [84]. The preference 
of Classical MD to Monte Carlo is attributed to its ability to permit time-dependent response and 
rheological properties, amongst other dynamical properties [140]. Moreover, in classical MD, 
Newton’s equation of motions is integrated into computational algorithms (highly-advanced 
physical and mathematical algorithms), which in turn enables near-accurate real-time mechanistic 
and conformational definitions of occurring chemical reactions [85,86].  




Figure 3.6: Schematic description of basic MD algorithm where potential energy is Epot; 
simulation time = t, iteration time is given by dt; x is atom coordinates; force component is F; a is 
given by acceleration; atomic mass is m and v represents velocity (Image adapted from [80].   
 
The trajectories generated from the simulated systems' time-scale atomistic motions are further 
analyzed to assess dynamical occurrences in simulated systems at the atomic level [87]. A 
summary of the steps followed in performing MD simulations for studies in this thesis is presented 




vi (t+dt) = v(t)i + ai dt










Figure 3.7:  Flow chart showing steps involved in MD simulation of a drug-target complex[88] 
 
3.6 Force Fields 
 
Force fields refer to a set of potential energy functions through which force can be obtained and 
can be used to describe the energies associated with conformations of molecules [89]. 
Mathematically, force fields consist of set parameters that describe the correlative function 
between a system's energy and the coordinate of its constituents. In MD simulations performed for 
all investigations in this thesis, the AMBER force field [83] was employed for protein 



















of bound inhibitors. However, several other force field has been widely used in performing MD 
simulations for various biomolecular systems, notably; CHARMM [90], GROMOS [91], NAMD 
[87] OPLS-AA [87] and ENCAD [49,92] amongst many others. Most force fields applied in MD 
simulation of proteins are harmonic motions and a description of bond lengths and angles [89]. 
The main variations between the different force field results come from the varied approaches to 
obtain the individual parameters. However, they mainly yield similar findings which corroborate 
with experimental results [75]. 
 
3.7 Post-Molecular Dynamics Analytical Methods 
 
Molecular dynamics simulations generate trajectories that encode the events that have occurred 
across the biomolecular system over a specified time-frame, either through a visual or graphical 
representation. These visual or graphical occurrences along the simulation are essential in 
unraveling appropriate events or insights, which could explain the structural activities or attributes 
of biological and non-biological molecules. These trajectories can also typify sequential snapshots 
described by velocity vectors and positional coordinates, while the time-scale evolution of the 
systems in phase space is also captured [71,93]. Several techniques and calculations have been 
established to analyze these trajectories depending on the type of MD simulation study though 
specific quantitative analyses are necessary to assist any visual systemization. In these studies, 
post analysis was required to ascertain the system's conformational stability and energetics, the 
dynamics of the biomolecular system, and the ligands binding landscape and thermodynamic 




 3.7.1 System Stability, Convergence and Structural Deviations 
 
A system's convergence describes its dynamics based on typical angular vibrations of atomic bonds 
during a folding or unfolding event until it attains a state of equilibrium. Convergence measures 
the reproducibility and accuracy of a trajectory and unveiling details on whether the system has 
reached an energetically stable conformation [38]. For MD trajectories to be accurate, it is essential 
to consider the equilibrium points, conformational plateaus, and ultimate energetics. Metrics that 
are used to predict the stability of a system coupled with corresponding structural events include 
the Cα root mean square deviation (RMSD), the Cα root mean square fluctuation (RMSF), the 
radius of gyration (RoG), Surface accessible surface area (SASA) and Dynamic Cross-Correlation 
Matrix (DCCM).  
  
 
3.7.1.1 Root Mean Square Deviation (RMSD) 
 
The Cα RMSD is used to predict a biomolecular system's stability by estimating the corresponding 
deviations and motions that occur across the protein’s backbone atoms compared to their starting 
structure over the simulation time. In other terms, the spatial alterations that occur between two 
static structures of a steady trajectory can be used to evaluate system divergence. Mathematically, 












The total number of atoms in the system is N. The vector position of the Cα atom of particle i is 
R1, which is predicted from the starting conformation (O) after alignment with the ultimate 
conformation with the aid of the least square fitting. Therefore, the RMSD is suitable to calculate 
the conformational alterations that occur within ligands, receptors, or complex systems during a 
simulation period and can be obtained by estimating the frame number average in each resulting 
trajectory [94,95]. In most conformational studies, an increase in atomistic motions or deviations 
depicts an unstable structure, while a decrease in these deviations is an indication of atomistic 
stability.   
 
3.7.1.2 Root Mean Square Fluctuation (RMSF) 
 
While the RMSD focuses on the whole macromolecular structure, each protein residue's 
corresponding motions can be estimated using the RMSF metrics. RMSF measures fluctuations of 
discrete amino acid residues relative to their average positions during the simulation. This, 
therefore, quantifies the relative motions of constituent residues of a protein and forms an 
important determinant in predicting the flexibility of such proteins since a high residual fluctuation 
can correlate with an increase in flexibility while low fluctuation in residual motions can indicate 





                                                                          (Eq. 3.7.2) 
 
Where the RMSF of the ith residue, is RMSFi, from which the average RMSF is subtracted and 




3.7.1.3 Radius of Gyration (RoG) 
 
The RoG of a protein can be defined as the root mean square atomistic distance from the center of 
gravity and is essential for predicting structural compactness in a protein [98,99]. Several studies 
have been used to reflect the RoG metrics' accuracy in determining protein compactness [100,101]. 





                                                                                    (Eq. 3.7.3) 
 
Where the position of the ith atom is denoted as ri and the center weight of atom i is shown as r. 
 
3.7.1.4 Solvent Accessible Surface Area 
 
SASA has been used over the years to depict the transitional occurrence of protein atoms between 
the hydrophilic and hydrophobic regions. In other words, the mechanistic motions of constituent 
atoms from the initially exposed outer environment to the hydrophobic core region of the protein 
can be estimated. Since this transitional event can likely correlate with massive structural changes 
in proteins relative to the initial structure, this parameter has been previously adopted to predict 







3.7.1.5 Dynamic Cross Correlation Matrix 
 
 
Dynamic cross-correlation matrix (DCCM) is a computational technique used to quantify correlation 
coefficients of motions between atoms within a simulated system [110]. DCCM presents a 3D matrix that 
allows for a graphical depiction of time-correlated insights on the amino acid residues that make up the 
protein structure that undergoes MD simulation.  The cross-correlation coefficient varies from -1 
(completely anticorrelated motion) to +1 (completely correlated motion). The formula used to describe 
dynamic cross-correlation is presented as follows: 
 






                                                                                            (Eq. 3.7.4) 
 
i and j represents the ith and jth residue respectively. The displacement vectors that correspond to 
the ith and jth residue respectively is represented as Δri or Δrj .  
 
3.7.2 Free binding energy predictions 
 
Assessing binding energy is vital in protein-ligand interaction systems and other aspects of 
computational drug design discovery, such as protein-protein system behaviors [105,106]. 
Computer-based free binding energies of macromolecules and other varying molecular systems 
are calculated using either the Molecular Mechanics/Poisson-Boltzmann Surface Area 
(MM/PBSA) or Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) techniques. 
Both computational tools have been applied widely in protein-ligand interactions and are known 
for accurate results. Both methods were also used to calculate the energy contributions of 
individual residues using the per-residue energy decomposition approach after each MD  
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simulation. The binding free energy (DGbind) was determined by the equation: 
DGbind = Gcomplex - Greceptor + Gligand          (1)                                                         (Eq. 3.7.5) 
DGbind = DGgas + DGsol -TDS,                   (2)                                                         (Eq. 3.7.6) 
 
where DGbind is considered to be the summation of the gas phase and solvation energy terms less 
the entropy (TDS) term 
DEgas = DEint + D Evdw + D Eelec         (3)                                                               (Eq. 3.7.7) 
 
DEgas denotes the sum of AMBER force field internal energy terms DEint (bond, angle and torsion), 
the covalent van der Waals (DEvdw) and the non-bonded electrostatic energy component (DEelec). 
The solvation energy can be estimated from the following equation: 
 
Gsol = GGB + Gnon-polar                 (4)                                                                          (Eq. 3.7.8) 
 
Gnon_polar = gSASA + b               (5)                                                                           (Eq. 3.7.9) 
 
 GGB is the polar solvation contribution and the non-polar solvation contribution is represented as 
Gnon-polar . Both of which are determine from SASA, derived from a 1.4 A° water probe radius. 
 
3.7.3 Residue Interaction Network 
 
Residue interaction network (RIN) is a computational tool used to explore macromolecular 
systems' structural complexity. RIN makes it possible to easily visualize the kinds of interaction 
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between the residues that make up a protein and the interaction of these residues and a drug 
molecule [107,108]. The type of interactions exhibited by amino acids gives insights into the 
functional dynamics of a protein and may also account for the stronger binding of a drug [109]. In 
the studies reported herein, snapshots were taken during the molecular dynamic simulations at 
different time intervals and visualized on Discovery studio, a molecular visualization software. 
 
 
3.7.4 Principal Component Analysis 
 
As a covariance-matrixed-based method, Principal Component Analysis (PCA) is a covariance-
matrix-based approach that can be used to elucidate the vital dynamics of a simulated system on a 
low-dimensional free energy landscape [111]. PCA also allows for an elucidation of any 
displacement of atoms and any associated structural dynamics that may have occurred over a 
simulation period with a protein structure [112]. PCA symbolizes a linear transformation that 
diagonalizes the covariance matrix of a simulated system and thus deletes any instantaneous linear 
correlations in the simulated system [111,113]. The fluctuations in a simulated system can be 
described by the first few principal components of a simulated system through a decreasingly 
ordering of the eigenvalues of the transformation [111,114–116]. PCA as employed in this study 
involves the calculation of the first two principal components (PC1 and PC2) and covariance 
matrices of the C-α atoms of the simulated structure. A 2x2 covariance matrix is subsequently 
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The drug discovery process typically involves target identification and design of suitable drug 
molecules against these targets. Despite decades of experimental investigations in the drug 
discovery domain, about 96% overall failure rate has been recorded in drug development due to 
the “undruggability” of various identified disease targets, in addition to other challenges. Likewise, 
the high attrition rate of drug candidates in the drug discovery process has also become an 
enormous challenge for the pharmaceutical industry.  To alleviate this negative outlook, new trends 
in drug discovery have emerged. By drifting away from experimental research methods, 
computational tools and big data are becoming valuable in the prediction of biological target 
druggability and the drug-likeness of potential therapeutic agents. These tools have proven to be 
useful in saving time and reducing research costs. As with any emerging technique, however, 
controversial opinions have been presented regarding the validation of predictive computational 
tools. To address the challenges associated with these varying opinions, this review attempts to 
highlight the principles of druggability and drug-likeness and their recent advancements in the 
drug discovery field. Herein, we present the different computational tools and their reliability of 
predictive analysis in the drug discovery domain. We believe that this report would serve as a 
comprehensive guide toward computational-oriented drug discovery research. 
 






The design and development of several therapeutic agents centered on their ability to interact with 
crucial biomolecules involved in disease progression. These biological molecules majorly include 
proteins and enzymes that drive pathogenic pathways and could represent therapeutic avenues for 
halting undesirable pathogenic development such as in cancer, TB, and neurodegenerative 
diseases, some of which have been termed ‘undruggable’ (1–4). Of the 10% of the human genome 
representing druggable targets for therapeutic agents, only half of those are relevant to disease (5–
7).  Over the years a significant advancement has been in the experimental and computational 
techniques employed in the drug discovery process,  nonetheless,  a remarkable failure of about 
96% overall failure rate been recorded in diverse drug discovery projects due to the 
‘undruggability’ of various identified protein targets, amidst other challenges (8–10).  The drug 
discovery process is usually a time-consuming process and substantial financial investment, as 
such, a 96% failure of the process due to target undruggability and other challenges necessitates 
an understanding of challenges associated with target’s undruggability. 
As essential as lead identification and lead optimization techniques are in drug discovery, the 
concept of protein druggability remains vital, usually descriptive of members of expressed protein 
cohort (proteome) that can selectively be bound and modulated by high-affinity ligands with innate 
drug-likeness (11,12). Studies have shown that among the disparate protein families that constitute 
the human proteome, about 3,000 have been targeted by small synthetic/organic drug molecules 
with regards to therapeutic intervention in diseases (13–16). As such, there remains a large pool 




The concept of druggability has also expanded to encompass the ‘druggable genome,’ which 
describes encoding genes for proteins that are not only physiologically relevant but whose activity 
can also be regulated by high-affinity ligands (11,14,16). It is also important to mention that 
druggability as a term is more suitable to describe protein targets than DNA and RNA sequences, 
even though they may also serve as active sites for drug molecules (12,17). 
An integral component of drug development in recent years has, therefore, been target validation. 
Existing conventional processes of target validation techniques are known to investigate the 
interplay between alteration in protein biological functionality and corresponding therapeutic 
impacts. Thus, druggability incorporates a structure-based approach to evaluate tendencies that 
small drug-like molecules possess innate potencies to bind and modulate protein activities (11,13). 
Consequently, several approaches have emerged over the years to investigate the druggability of 
potential protein targets as succinctly discussed by Egner and Hillig (18). 
 
Approaches employed to determine the druggability of a protein have been categorized based on 
1) those that employ empirical analyses of established associations between drugs and proteins 2) 
structural analyses of target proteins (13,19–23). Moreover, when the protein in question is a 
member of a well-studied family with closely related homologs from which drug association 
details can be retrieved, the former method is more suitably applied (15,16). On the other hand, 
where there is no prior knowledge about the potential target or in cases where the target protein 
belongs to families for which no drug candidates are known, the latter method that employs 
structure-based predictive models is most appropriate (13).  
121 
 
A notable and pioneering contribution to the development of the structural predictive model was 
carried out by Hajduk et al., wherein they measured druggability using hit rates of NMR-based 
fragment screening for a diverse set of 23 proteins. This model incorporates a simple regression 
analysis that defined descriptors of the binding pocket such as the surface area, roughness, 
polar/apolar contact area, and the number of charged residues (21,24). Their analysis generated a 
predictive ‘druggability score,’ which is defines the logarithm of the predicted rate of NMR hit. 
Over time, a variety of methods have been developed to improve the prediction of protein 
druggability (11,13,19,23,25–27), some of which form an integral part of this review.   
 
Drug-likeness is a significant consideration in the early stages of the drug discovery process when 
selecting compounds as it helps to optimize pharmacokinetics and pharmaceutical attributes. These 
include chemical stability, solubility, bioavailability, and distribution profile (12). Drug-like 
compounds also describe chemical molecules that possess functional groups and or have physical 
properties consistent with the majority of known drugs and hence can be inferred as compounds 
that might be active biologically or might show therapeutic potential (28,29). Thus these 
compounds fall within critical physicochemical thresholds such as molecular mass, 
hydrophobicity, and polarity when compared to the narrow range distribution of approved drugs 
(30,31). Regardless, drug-like compounds hold no apparent structural similarity to any approved 
drug. Although high rates of attrition have shown in drug discovery, the preferential selection of 
compounds with innate drug-likeness increases the likelihood of surviving this occurrence (32). 
A critical understanding of the concepts of target druggability coupled with the drug-likeness of a 
chemical molecule could, therefore, further potentiate the success rate of novel chemical molecules 




Therefore, in this review, we discuss the underlying principles of both druggability and drug-
likeness as it relates to the drug discovery process. Also, we list the various methods that have 
been employed over the years the predict, determine, and achieve the druggability of a novel 
protein target as previously studied. We extend this methodical review to cover evolutionary 
advances made in determining the drug-likeness of a compound coupled with relevant 
experimental and computational techniques aimed at enhancing the drug-likeness of a non-drug 
hit compound. 
 
2.0 Assessing   Druggability of Biological targets 
Advancements in the computational domain have paved a path toward algorithms that assess the 
druggability of a target and store any information in large virtual libraries. We now have access to 
a plethora of data, including protein and gene expression profiles, protein-protein interactions, and 
gene regulatory networks, thus making it possible to build combined predictive models. Initial 
algorithms used to assess druggability were designed to reproduce nuclear magnetic resonance 
(NMR) fragment screening hit rates (21,33,34). This approach, however, leads to proprietary data 
that was expensive to obtain and difficult to access publicly. Another method of assessing 
druggability was reported by Cheng et al. in which the maximum achievable affinity for a binding 
site based on the structure of the pocket was estimated (17). Likewise, a separate report by Sheridan 
et al. also described an equation that could approximate the “bindability” of a given binding pocket 
on a protein, based on similar functions and some particular descriptors as methods for assessing 
druggability(19). Experimental druggability assessments involved soaking protein crystals in 
various solvents and identifying binding sites based on X-ray diffraction data. Although this 
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method was the most reliable and validated technique, the crystallized protein was required 
(34,35).  
Various computational tools that have been developed over the year to assess the druggability of 
a target based on the availability of a protein’s 3D structure. Some of these tools are based on 
algorithms that consider structural features of a protein, including surface polarity, surface 
hydrophobicity, and pocket dimensions. The algorithms used are roughly classified into geometric 
and energetic approaches (36,37). In the geometric approach, the shape of the protein is 
investigated to identify any voids between the protein’s atoms. The energetic approach uses 
interactive molecular energies, which are mapped onto the 3D structure of the protein through 
molecular dynamics simulations. The binding pockets are then identified based on the interaction 
energy profiles that are generated (34,37). The downfall of the approaches mentioned above is that 
a 3D structure of the protein is needed, the process may be slow, and the predictive pockets cannot 
be validated until an experimental analysis is performed.  Because not all druggable targets are 
proteins, there are a few databases that identify other druggable targets, notably Therapeutic Target 
database (38), LncRNA2Target (39), and MiRBase (40). 
Four primary methods are currently used for assessing druggabilit; these include the precedence-
based, ligand-based, structure-based, and sequence-based methods, as highlighted in figure 4.1 
(11). Although each method comes with its benefits, numerous caveats need to be considered and 
accounted for when identifying an ideal target. One of the most important considerations that are 
frequently overlooked is that compounds do not always target a protein. Other existing biological 
targets include; nucleic acids, other small molecules, protein-protein interactions and nucleic acid 




2.1 Sequenced-based druggability assessment methods  
The basic unit of proteins, amino acids, which determine the function of a protein, has also been 
employed in predicting the druggability of protein drug targets. As such, sequence-based 
druggabilty assessment methods analyze sequence alignments of protein targets, identifying 
possible conserved regions that may be deemed predictive binding pockets(34). Assessment of 
potential target sequence also provides insights into essential physicochemical properties like 
solvent accessibility,  hydrophobicity, charge, and polarity, amongst other properties(41). 
Sequence-based methods have also been wildly employed in Machine-learning algorithms in 
assessing protein target druggability(41). Even though a knowledge of the target sequence could 
aid in the prediction of functional domains on the target, the target sequence alone is insufficient 
in providing an overall structural and functional insight of a protein target. Thus, the knowledge 
of target sequence alone is unable to provide details on the accessibility of these domains to either 
gene expression level, a drug molecule, or its relevance in the interactome(41).  
2.2 Structure-based druggability assessment 
Structure-based druggability assessment methods rely on a knowledge of the binding pocket 
located on the biological target to which a ligand can bind (34). Thus, for a small drug-like 
molecule to bind a protein, it requires a binding site that contains complementary characteristics, 
including an appropriate size that can accommodate a molecule and a deep hydrophobic pocket 
that can bury the drug within the protein. Large exposed polar binding sites are considered less 
druggable than smaller hydrophobic pockets (34,42).  The structure-based assessment methods 
generally involve an initial identification of possible binding pockets followed by sorting the 
identified binding pockets based on the physicochemical properties of the pocket. Sorted binding 
pockets are then compared to a reference set of known biological targets to access their degrees of 
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difficulty or druggability (43). Numerous software and online platforms have been developed to 
aid in the accurate identification of binding pockets, notably; DOGSiteScorer (26), Metapocket 
(44), PockDrug Server (45), SiteMap (23), Sitehound (46) and Open Targets (47). These online 
platforms provide essential binding pocket information, which could in determining the 
druggability of given biological targets.  
 
2.3 Ligand-based druggability assessment 
In ligand-based druggability assessment methods, the druggability of a therapeutic target is based 
on a knowledge of endogenous compounds that could bind to the target and are yet to reach clinical 
trials (34).  Several databases available online contains sufficient information about several ligands 
that could be used in predicting the druggability of a given target. Notable examples of these online 
platforms include BindingDB (48), PubChem (49), SwissTargetPredict (50), TargetHunter (51), 
Guide to pharmacology (52), National Centre for Biotechnology Information(NCBI) (53) and 
Protein data bank (54).  
2.4 Precedence-based druggability assessment 
In employing precedence-based methods for assessing druggability, knowledge of established 
proteins or drug targets is required. Precedence-based methods also rely on a knowledge of 
chemical molecules that are already undergoing clinical trials (55). This method demonstrates the 
highest level of druggability as the given target has already been proven to be safe. However, 
precedence-based methods of assessing druggability are still not a guarantee of success for 
different and or product profiles (42,56).Various databases contain information about compounds, 
targets, and published works that could be employed in precedence-based druggability 
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assessments. Notable examples of some of these freely available databases include DrugCentral 
(57), Clinicaltrials.gov (58), and Drugbank (59).  As of February 2020, the latest release of 
DrugBank(2020-01-03) alone contained about 13,491 drug entries, including 2,641 approved 
small molecule drugs, 1,364 approved biologics (proteins, peptides, vaccines, and allergenics), 
130 nutraceuticals and over 6,347 experimental (discovery-phase) drugs. 
 
 







3.0 Are Predictive Druggability Assessment Methods Reliable? 
 
While investigations of most disease targets have potential inhibitors, there is minimal 
experimental data associated with the research. This observation has led to almost all scientific 
domains to turn to machine learning and predictive computational tools. Not only do these methods 
save laborious hours in the wet-laboratory setting, but it also saves elaborate amounts of money 
that would have been spent on unnecessarily large stocks of reagents. Therefore, the use of 
predictive tools without validation proves to be controversial. Thus, the reliability of the results is 
questioned at every stage. 
 
Druggability assessment methods utilize a wide range of algorithms, as discussed. It may be noted 
that according to the choice of predictors and parameters, bias results may be obtained. A 
geometry-based method may find the most suitable pocket based solely on the orientation and 
shape of the protein, whereas the energy-based method may find greater molecular forces in a 
different pocket of the same protein. It is, therefore, essential to choose the appropriate predictive 
software when identifying potentially druggable pockets of a protein since the principle and level 
of accuracy of each predictive model vary. For instance, in binding pocket prediction, several 
improved approaches have been developed over the years, since many of the existing prediction 
provide varying results. One such improved binding pocket methods is the metapocket method 
(44), which combined four different methods namely, SURFNET(60), PASS(61), 
LIGSITE(cs)(62) and Q-SiteFinder(63) towards improving its binding pocket prediction success 
rate.  Therefore, although most of the various algorithms that have been employed by many 
existing druggability prediction models have been validated against different training sets, a 
comparative study of ten representative prediction methods suggest that,  of the top three 
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performing methods, 30% of clinically known binding sites were not detected with existing 
prediction tool (64). Another shortfall of druggable models is that they do not adequately account 
for dynamic protein-ligand binding interactions (35). Thus, the relevance of binding site target 
interactions further indicates that although binding pocket prediction methods are useful in 
identifying putative druggable sites, they have limitations, and are thus not allowing for validation 
analysis. Therefore, the further integration of druggability information with other parameters, 
including the lead compound’s drug-likeness, would provide a more effective and holistic 
mechanism of disease management. 
 
4.0 Identification of lead molecules by assessing drug-likeness 
The concept of drug-likeness has advanced extensively over the years, taking into consideration 
the structural, physicochemical, biochemical, pharmacokinetic (PK), and toxicity characteristics 
of a compound, thus a drug-like compound possesses sufficiently acceptable ADME properties, as 
well as sufficiently acceptable toxicity properties (65,66). Understanding these properties have 
become an integral part of drug discovery and has enabled the accurate selections of hits that are 
suitable starting points for the identification of new clinical candidates. These properties also allow 
a streamlining of drug discovery efforts towards the identification of a compound that possesses a 
higher chance of pharmacokinetic success and overall safety.  
The time-consuming nature and enormous resources required in performing in vivo studies to 
determine the drug-likeness of a compound have presented computational techniques as a viable 
alternative. Christopher Lipinski and coworkers reported the earliest report on a decisive criteria 
for identifying drug-like compounds at Pfizer in the mid-1990s (67). Since then, several reports 
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have attempted to describe the drug-likeness of compounds, including the report by Sadowski et 
al. (68) in 1998, in which, for the first time, a scoring function was employed in predicting the 
drug-likeness of the compounds using neural networks (NN). Subsequently, many other reports 
have also employed neural networks in prediction of drug-likeness (69–71). Other computer-based 
approaches and molecular descriptors that have also been employed over the years in the prediction 
of drug-likeness include, recursive partitioning(RP) (72,73), support vector machine (SVM) 
(69,74) and genetic algorithm (GA) (75,76), amongst others. Over the years, these techniques have 
gained prominence in their ability to predict drug-likeness of compounds from non-drug 
compounds satisfactorily. This eventual incorporation of in silico techniques in predicting drug-
likeness of compounds has allowed for the analysis of large compound libraries to identify 
compounds that could be subsequently prioritized for synthesis, in vitro and in vivo, and for 
thorough experimental evaluation. In silico approaches have thus minimized time and resources 
that would have been wasting in assessing non-drug molecules. Several molecular descriptors have 
been applied in profiling chemical compounds towards their drug-likeness. A report by Feher and 
Schmidt succinctly highlights several molecular descriptors that can be used in characterizing 
chemical compounds as employed in their study (77).  Nonetheless, these are usually of little 
practical help to medicinal chemist since the assessment of drug-likeness with these molecular 
descriptors are usually based on any type of countable feature or computable property instead of 
profiling based on biologically relevant parameters.  
 
4.1 Physiochemical properties and Pharmacokinetic properties in determining drug-likeness 
Assessing the pharmacokinetic and physicochemical properties of compounds in determining their 
drug-likeness occurs in the early stages of the drug discovery process. This process takes into 
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consideration structural features and physicochemical properties that complement a given 
pharmacophore without affecting it. These pharmacokinetic properties inform the behavior of 
compounds in the body with regards to absorption, distribution, and excretion. Early 
pharmacokinetics and physicochemical assessment relied on molecular properties such as polarity 
(polar surface area (PSA) and topical surface area), number of aromatic rings, and number of heavy 
atoms, lipophilicity, molecular mass, number of chiral centers, number of hydrogen bond donors 
and acceptors and number of rotatable bonds. However, recently these have been expanded to 
include complex properties such as metabolic stability, permeability, transporters, solubility, 
physiologically based pharmacokinetics, and pharmacokinetic/pharmacodynamic modeling (78–
80). A combination of all these complex properties allows for the optimization and identification 
of drug-like molecules while taking into consideration safety, selectivity, efficacy, and 
pharmacokinetics (81). Based on these molecular properties several guidelines for predicting drug-
likeness of chemical molecules have been proposed, notably, the Lipinski's rule of five (67), Veber 
rules(82), Waring drug candidate permeability (83) and Golden triangle rules(84) amongst 
numerous other existing guidelines for the prediction of drug-likeness. 
   
4.1.1 Lipinski’s rule of five (RO5) 
As one of the earliest guidelines proposed for predicting the drug-likeness of compounds, the RO5 
emerged from the deposition criteria where analysis of drug-likeness is based on lipophilicity, 
molecular weight, and counts of hydrogen bond acceptors and hydrogen bond donors (85,86). 
According Lipinski, compounds with sufficiently acceptable ADME/T properties (thus a 
molecular weight not greater than 500 Da, log P not greater than 5, hydrogen-bond donor not more 
than 5 and hydrogen bond acceptor (nitrogen and oxygen atoms) not more than 10) to survive 
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through the Phase I clinical trials, were considered drug-like. As a guideline, the Lipinski’s RO5 
is conceptually simple and straightforward to implement, hence its widespread adoption. However, 
it does not apply to natural products or substrates of biological transporters (87). Based on 
Lipinski’s assumptions, chemical molecules that violate these rules are less likely to possess many 
desirable characteristics of drugs. Nonetheless, there are plenty of examples available for RO5 
violation amongst the existing drugs, notably antibiotics, antifungals, vitamins, and cardiac 
glycosides, but yet these are orally bioavailable(88). These classes of compounds are orally 
bioavailable because they possess groups that act as substrates for transporters(88). In RO5, the 
consideration of the number of bonds is due to their direct correlation with an increase in aqueous 
solubility and a decrease in lipid bilayer permeability. On the other hand, molecular weight directly 
correlates with the size of the compounds, since large molecular weighted compound could hinder 
the diffusion of molecules across lipid bilayer membranes as well as reduce the molecule 
solubility. High lipophilicity (logP>5) often contributes to high metabolic turnover, aqueous 
solubility, and reduced intestinal absorption. However, high lipophilicity of compounds is also 
associated with an increased risk of promiscuity and toxicity since these compounds tend to bind 
to hydrophobic biological targets other than the desired target. 
 
4.1.2 Golden triangle rules 
The golden triangle as criteria for selecting drug-like compounds takes into consideration the 
metabolic stability and permeability of the compound (84). In the report by Johnson et al. structural 
properties that were assessed included molecular weight and lipophilicity (log D7.4) since these 
parameters affected almost all other drug-likeness properties, could represent other molecular 
properties such as rotatable bonds, hydrogen bond acceptors and donors, molecular volume, 
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heteroatoms and PSA (84,89). Lipophilicity and molecular weight are also good predictors of the 
survival of compounds in development and are also compatible with chemistry tools ligand 
efficiency (LE) and ligand-lipophilicity efficiency (LLE) (90).  
Drug-like compounds under the golden triangle rule, therefore, possess high membrane 
permeability and exhibits favorable metabolic stability if they have a triangle baseline: molecular 
weight of 200 and lipophilicity of -2<logD7.4<5 as well as a triangle apex: molecular weight of 
450 and logD7.4=1.0-2.0. 
 
4.1.3 Waring drug candidate permeability guideline 
The membrane permeability of small molecule compounds is a crucial metric in the drug design 
pipeline that is essential in the overall potency and in vivo efficacy of the compounds since 
membrane permeability ensures the compounds reach their intended target. As such, using 
membrane permeability as a parameter, the drug-likeness of compounds could be predicted. Using 
permeability as a parameter, Waring et al. (83), propounded a guideline for the prediction of highly 
permeable drug-like compounds with particular consideration of the apparent permeability (Papp) 
of the compounds. In their report, the Papp of the studied compounds was set within a range of 
<100nm/s(low) and >100 nm/s (high). In generating the guideline, the set range of Papp was 
statistically contrasted with other molecular property predictors such as total hydrogen bonding, 
hydrogen bond acceptors and hydrogen-bond donors, molecular weight, rotatable bonds, logD, 
PSA and logP. Their report concluded that close to property limits, the probability of obtaining 
high permeability compounds was lower. Their report also showed that the permeability of the 




5. 0 In silico Techniques in predicting drug-likeness 
The advent of computer-aided drug design has influenced a paradigm shift towards incorporating 
computational techniques in identifying drug-like compounds while eliminating compounds that 
may be unsuccessful in the drug discovery process.  Over the years, experiment filters have been 
at the forefront in the drug discovery process as the reliable methods are isolating drug-like 
compounds. However, these conventional approaches are time demanding and resource-intensive 
(28,91). As such, computational approaches have gained prominence in the last two decades as 
reliable approaches in the prediction of drug-like compounds with much ease.  Computational 
techniques have typically been involved the filtering out of non-drug compounds as well as 
compounds regarded as unfit for screening purposes by taking into consideration fundamental 
physiochemical and pharmacokinetic properties (29,92,93). In recent decades, several 
computational software and online platforms have been developed in predicting essential 
molecular properties of compounds towards the identification of drug molecules with promising 
potential of achieving success in the drug discovery process, as highlighted in Table 4.1. 
Table 4.1: In silico tools utilized in the prediction of molecule drug-likeness (94) 
In silico tool Function 
 
QikProp(https://www.schrodinger.com/qikprop) 
Distributed by Schrodinger 
Predicts and evaluates the ADME 
properties of thousands of compounds 





/volsurf/) Distributed by Molecular Discovery Ltd. 
(moldiscovery.com) 
A computational tool that calculates and 
predicts essential ADME properties of 
compounds using predictive 3D molecular 




studio/) Distributed by Simulation Plus, Inc 
A platform commonly used by medicinal 
chemists and computational chemists for 
identifying lead compounds. It could also 
be employed for the optimization of the 
identified lead compounds as well as the 
prediction of ADME properties. MedChem 
studio is a complete computer-aided drug 
design package that can also be used for 
ligand-based drug design and the 
categorization of libraries of compounds.  
 
ADMET Predictor (https://www.simulations-
plus.com/software/admetpredictor/) Distributed by 
Simulations Plus, Inc 
A computational software that allows for 
the prediction of essential physiochemical 
ADMET properties as well crucial CYP 
metabolism kinetics of molecular 
structures.  ADMET Predictor can also be 
used to generate predictive models of 
entirely new properties from the user’s 
library of structures using the inbuilt 
ADMET Modeler module 
 
ADMEWORKS ModelBuilder 
(https://www.fqs.pl/en/products) Distributed by 
Fujitsu 
ADMEWORKS ModelBuilder generates 
QSAR/QSPR models that can be employed 
in predicting physicochemical and 
pharmacokinetic properties of compounds.  
 
ADMEWORKS Predictor 
(https://www.fqs.pl/en/products) Distributed by 
Fujitsu 
An in silico tool for evaluating and 
predicting essential pharmacological 
properties of compounds by employing 






f.html) Developed by PharmaInformatic, Germany 
A reliable tool made up of QSAR models 
for evaluating the human oral 




modeler/) Distributed by Simulation Plus, Inc 
A plugin of the ADMET Predictor that 
addresses the tedious process of building 
reliable QSAR/QSPR models from 
experimentally derived data sets by 




Distributed by ACD/Labs 
Employs fragment-based models to rapidly 
predict various physicochemical and 
pharmacokinetic properties of compounds 
such as lipophilicity (logD, logP), aqueous 





.php)  Distributed by ACD/Labs 
A computational tool that predicts the 
ADME properties of compounds by 
estimating various molecular descriptors 
such as oral bioavailability, blood-brain 





.php)  Distributed by ACD/Labs 
Predicts solubility in DMSO solution. 
 
Discovery Studio ADMET Software 
(https://www.3dsbiovia.com/products/collaborativ
e-science/biovia-discovery-studio/qsar-admet-and-
predictive-toxicology.html) Distributed by 
Accelrys 





Distributed by Simulation Plus, Inc 
ADMET properties predicting tools that 







it.html) Distributed by Silicos-it 
Based on pre-programmed molecular 
descriptors, the Filter-it tool screens out 
compounds with undesirable properties 
from a set of compounds.   
 
PreADME (https://preadmet.bmdrc.kr/) hosted by 
Yonsei University, Seoul, Republic of Korea. 
An in silico tool for predicting the drug-
likeness of compounds as well as the 




Distributed by CompuDrug 
Employs both neural network methods and 
linear methods towards the prediction of 
the lipophilicity (logP/logD) of 
compounds. 
 
Web Services for predicting drug-likeness 
Chemicalize (https://chemicalize.com/). Provided 
by ChemAxon 
Online service for the prediction of 
physicochemical and pharmacokinetic 
properties such as logP, molecular weight, 
hydrogen bond donors, and acceptors. It 
also calculates molecular properties such 
as tautomers and PSA.  
 
SwissADME (http://www.swissadme.ch/). 
Developed and maintained by the Molecular 
Modeling Group of the SIB Swiss Institute of 
Bioinformatics 
A robust and reliable online service for 
predicting drug-likeness of compounds as 
well as their pharmacokinetic and 
physicochemical properties based on 
reliable inhouse methods notably; the 
Bioavailability rader, BOILED-Egg, 
synthetic accessibility score and, iLOGP.   
 
AqualSol(http://cdb.ics.uci.edu/cgibin/tools/AquaS
olWeb.py).  Provided by the University of 
California, Irvine 
Employs UG-RNN ensembles to predicts 






). Provided by the University of California, Irvine 
An online platform for predicting various 
essential molecular properties of 




Maintained by Indraprastha Institute of Information 
Technology 




t.html) Maintained by the Institute of Chemistry, 
University of Tartu, Estonia 
An online that predicts the chances of 
chemical structural being categorized as a 
drug or a non-drug compound Web service 
to predict the probability of a compound. 
DrugLogit also performs the classification 




Maintained by Shanghai Key Laboratory of New 
Drug Design, School of Pharmacy, East China 
University of Science and Technology 
A web server that predicts ADMET 
properties of compounds. A peculiar 
feature of this server is its ability to predict 
about 50 ADMET endpoints using a 




Developed by the University of Cambridge, UK. 
This online service employs graph-based 
signatures to calculate the pharmacokinetic 
properties of compounds.  
 
MODEL-Molecular Descriptor Lab 
(http://jing.cz3.nus.edu.sg/cgi%E2%80%90bin/mo
del/model.cgi) Maintained by the University of 
Singapore. 
Based on 3D structures, this online service 
calculates the physiochemical and 
structural properties of compounds.  
 
OSIRIS Property Explorer (https://www.organic-
chemistry.org/prog/peo/) Maintained by the Virtual 
Computational Chemistry Laboratory 
This web service allows for the calculation 
of the druglike properties of drawn 
structures as well as the prediction of 
toxicity profiles. It forms part of the 
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Provided by mcule 
Generate the physicochemical properties 
of chemical structures. 
 
PreADMET (https://preadmet.bmdrc.kr/) 
Maintained by the Bioinformatics and molecular 
design research center of Yonsei University, Korea 
An online web service that calculates the 
ADME properties of compounds. It also 
generates a drug-like compound library 





Maintained by the Dept. Computational Science. 
NUS 
ADME-AP is a database that houses a vast 
library of data about drug targets such as 
tissue distributions, functions, substrates, 
and known ADME linked targets.  It 
simplifies the search for drug ADME 
related proteins.  
 
The ADME database 
(https://www.fujitsu.com/jp/group/kyushu/en/solut
ions/industry/lifescience/admedatabase/) 
Distributed by Aureus 
An extensive database of structurally 
different compounds coupled with known 
ADME features.  
 
 
Nonetheless, the challenge with many of such tools is the unavailability of validating sets of 
compounds, thus some compounds are likely not to fall under any of the criteria being used by the 
computational tool.  Also, many of these computational tools identify drug-like compounds based 
on features of existing drugs, hence drug-like compounds with new properties could easily be 
mistaken as non-drug compounds (91,95). Therefore, these computational tools play an essential 
role in the early stages of the drug discovery process, where they aid in the prioritization compound 




In this review, the fundamental principles and the central concepts of druggability and drug-
likeness have been briefly communicated. There are vast amounts of information and opinions in 
the assessment and analysis of both the drug-likeness of a molecule and the identification of its 
biological target. In this study, however, computational approaches were categorized and briefly 
explained. This provided a deeper appreciation of how online predictive tools and techniques 
streamline the drug discovery process by not wasting a copious number of years with “trial and 
error” experimental investigations. Although these “click of a button” procedures may shorten the 
rational drug discovery process, it is always important to keep in mind that predictive data is only 
ever “potential” information, until validated with experimental findings. We deduce that the 
synergistic capabilities of predictive and experimental investigations may lead to a greater 
understanding of drug-resistance in diseases, thereby allowing for more rapid and efficient 
treatment regimes. 
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Aim: We seek to provide an understanding of the binding mechanism of Remdesivir unravel the 
structural and conformational implications on SARS-CoV-2 virus RNA-dependent RNA 
polymerase upon its binding and identify its crucial pharmacophoric moieties. 
Background: The coronavirus disease of 2019 (COVID-19) pandemic has infected over a  million 
people, with over 65,000 deaths as of the first quarter of 2020. The current limitation of effective 
treatment options with no approved vaccine or targeted therapeutics for the treatment of COVID-
19 has posed serious global health threats. This has necessitated several drug and vaccine 
development efforts across the globe. To date, the farthest in the drug development pipeline so far 
is Remdesivir. 
Objectives: We perform molecular dynamics simulation, quantify the energy contributions of 
binding site residues using per-residue energy decomposition calculations, and subsequently 
generate a pharmacophore model for the identification of potential SARS-CoV-2 virus RNA-
dependent RNA polymerase inhibitors. 
Methods: Integrative molecular dynamics simulations and thermodynamic calculations coupled 
with advanced post-molecular dynamics analysis techniques were employed. 
Results: Our analysis showed that the modulatory activity of Remdesivir is characterized by an 
extensive array of high-affinity and consistent molecular interactions with specific active site 
residues that anchor Remdemsivir within the binding pocket for efficient binding. These residues 
are ASP452, THR456, ARG555, THR556, VAL557, ARG624, THR680, SER681, and SER682. 
Results also showed that Remdesivir binding, induces minimal individual amino acid 
perturbations, subtly interferes with deviations of C-α atoms and restricts the systematic transition 
of SARS-CoV-2 RNA-dependent RNA polymerase from the “buried” hydrophobic region to the 
“surface-exposed” hydrophilic region. We also mapped a pharmacophore model based on 
observed high-affinity interactions with SARS-CoV-2 virus RNA-dependent RNA polymerase, 
which showcased the crucial functional moieties of Remdesivir and was subsequently employed 
for virtual screening. 
Conclusion: The structural insights and the optimized pharmacophoric model provided would 
augment the design of improved analogs of Remdesivir that could expand treatment options for 
COVID-19 
Keywords: COVID-19; SARS-CoV-2 RNA-dependent RNA polymerase; Remdesivir, 









The current global pandemic, Coronavirus disease (COVID-19), is caused by coronavirus SARS-
CoV-2, a severe acute respiratory syndrome virus [1]. Even though the origin of the disease is still 
not clear yet [2], the COVID-19 pandemic manifested first in the city of Wuhan in China in 
December of 2019[1,3–5]. As of the end of July 2020, COVID-19 has caused about 666,285 
deaths, with about 17,042,890 confirmed infected cases globally [6].  
SARS-CoV-2 is a member of an enveloped positive-sense RNA family of viruses that are about 
60nm-140nm in diameter. They possess spike-like projections on their outer surfaces, as shown in 
figure 5.1, that gives them a crown-shape appearance under an electron microscope [7]. The first 
severe acute respiratory syndrome caused by coronaviruses, SARS-CoV, occurred in 2003 [8–10]. 
SARS-CoV affected five different, with an 11% lethal rate and a global total of 8422 cases [8,9,11].  
The Middle East respiratory syndrome coronavirus (MERS-CoV)  diseases that also emerged in 
2012, affecting 2494 individuals with a 34% lethal rate was also caused by coronaviruses[12,13]. 
Although SARS-CoV-2 is less lethal compared to MERS-CoV and SARS-CoV, it however, has a 







Figure 5.1: Diagram of a Coronavirus virion structure 
Transmission of COVID-19 amongst humans is through the inhalation of large droplets released 
through coughing and sneezing of an infected individual [3,14,15]. Infection of the virus can also 
occur through the touching of contaminated surfaces and then touching one’s eyes, nose, and 
face[16]. This is because the virus has been shown to survive on surfaces for days if the atmosphere 
is favourable [14,16]. Transmission via aerosolization/feco oral route has also been postulated[17]. 
Reports have shown that infected individuals can continue to transmit the disease as the symptoms 
persist, and even after the individual has clinically recovered [3,15]. Transmission can also occur 
in asymptomatic individuals before the onset of disease symptoms [14,18]. Symptomatic 
individuals usually experience fever, dyspnea, respiratory symptoms, and shortness of breath 
[14,19,20]. Severe acute respiratory syndrome, kidney failure, pneumonia, and even death may 
occur in individuals with severe forms of the disease [19]. Although COVIDS-19 affects all ages 
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with an overall fatality rate of 3%, fatality is higher in the elderly population and individuals with 
underlying co-morbidities [6,14]. 
There is currently no approved vaccine or targeted therapeutics for human coronavirus treatment, 
particularly COVID-19 [21]. Thus there is a limitation of effective treatment options. As such, all 
available treatment protocols are mainly supportive [22–24]. However, several drug development 
efforts are underway. The World Health Organisation is also currently focusing on four therapies 
which, include; Remdesivir, Chloroquine, and Hydroxychloroquine, a combination of Lopinavir 
and ritonavir with the possible addition of interferon-beta [25–27].  
As one of the small molecule inhibitors being considered for COVID-19 therapy,  Remdesivir is 
probably the most advanced of all the compounds in clinical trials [28]. It is an adenosine analog 
with broad-spectrum antiviral activity in animal models, both in vitro and in vivo, which failed as 
an Ebola drug [29]. Remdesivir has also been shown to inhibits coronaviruses that cause SARS 
and MERS [30–32]. It impedes viral replication by inhibiting the RNA-dependent RNA 
polymerase, thereby causing premature termination of RNA transcription [30,33]. 
Although Remdesivir has been shown to display potent in vitro activity against SARS-CoV-2 
RNA-dependent RNA polymerase with an EC50 at 48 hours of 0.77 µM in Vero E6 cells, and 
hence it's advancement in clinical trials, the conformational, and structural changes associated with 
SARS-CoV-2 RNA-dependent RNA polymerase upon Remdesivir binding remains unexplored. 
Conformational changes of enzymes are the hallmarks of their dynamics that have a correlation 
with the overall functions of these enzymes [34]. Conformation changes may be induced by the 
binding of ligands or other biological molecules that can modulate the function of the enzyme [35]. 
In this case, the binding of Remdesivir would have induced significant conformations. Therefore 
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to unravel these conformational changes, we used molecular dynamics simulation, a formidable 
tool that allows for an atomistic time-resolved investigation of the properties of enzyme structures 
[36,37]. Based on the structural dynamics and associated interaction profile, we also construct a 
pharmacophore model that can be used in the design of novel inhibitors with improved therapeutic 
activity against all other coronaviruses. A pharmacophore model elucidates and identifies the 
common chemical moieties of ligands which, are crucial in eliciting a biological function [38–44]. 
Therefore the model that will be generated in this study would reveal for the first time, the crucial 
moieties of Remdesivir required for its inhibition of SARS-CoV-2 RNA-dependent RNA 
polymerase using a per-residue-based energy decomposition technique. This model could 
subsequently be employed in virtual screening towards the discovery of novel SARS-CoV-2 RNA-
dependent RNA polymerase inhibitors with improved pharmacokinetics and pharmacodynamics 
properties [45] and could possibly overcome any potential drawbacks limiting the efficacy of 
existing inhibitors such as cross-resistance [46]. 
 
 
2.0 COMPUTATIONAL METHODOLOGYY 
2.1 System preparation 
2.1.1 Homology modelling model validation of SARS-CoV-2 RNA-dependent RNA polymerase 
 
The unavailability of an experimentally resolved X-ray crystal structure of SARS-CoV-2 RNA 
dependent RNA polymerase at the time of the study  prompted a construction of a putative model. 
We, therefore, retrieved the amino acid sequence of SARS-CoV-2 RNA-dependent RNA 
polymerase from the NCBI database with reference sequence YP_009725307.1. Using the online 
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server, SWISS model, [47,48], we performed structural modelling of the 3D structure of SARS-
CoV-2 RNA-dependent RNA polymerase. The homology model of SARS-CoV-2 RNA-dependent 
RNA polymerase constructed in this study was based on the experimentally resolved X-ray crystal 
structure of chain A of SARS-CoV RNA-dependent RNA polymerase structure (PDB ID: 6NUR) 
[49]. The chain A of SARS-CoV RNA-dependent RNA polymerase possessed a sequence 
similarity of 96.35%, with SARS-CoV-2 RNA dependent RNA polymerase and hence was the 
most suitable template  to be used in the construction of our model. To ensure the reliability of 
assumptions derived from the structural investigations of modelled structure, we performed a 
thorough model validation using the online platforms RAMPAGE [50] ProSA [51] and VERIFY-
3D [52]. We visually analysed the structural and similarities of the constructed model and the 
template employed by superimposing the two structures on UCSF Chimera [53].  This also allowed 








Figure 5.2: Comparative sequence alignment of the constructed homology model of SARS-CoV-
2 RNA-dependent RNA polymerase and the accompanying template employed. Insert highlights 
the active site residue, VAL557 as previously reported 
 
2.1.2 Remdesivir acquisition and preparation 
In preparing for molecular docking, Remdesivir was modelled using the MarvinSketch software 
(39). The modelled structures were then taken through energy minimization using Avogadro 1.2.0 
software (40). Avogadro is integrated with UFF forcefield, and this force field was used to 
optimize the molecular geometries of the compounds and a steepest descent algorithm for 
structural minimization. The pdbqt formats of all the compounds were then generated using 
AutoDock Vina (41). In preparation for molecular docking, hydrogen ions removed, and Gasteiger 
charges added using the Graphical User Interface (GUI) of UCSF Chimera [54]. The structure was 
subsequently saved in mol2 format. 
 
 
2.2 Molecular docking and active site identification 
According to recent reports by Lung et al., the active site of SARS-CoV RNA-dependent RNA 
polymerase encompasses VAL557 and its surrounding residues [49,55]. As such, the active site 
was mapped by considering residues that were within a 5Å radius of VAL557. A grid box that 
encompassed a 5Å radius around VAL557 was used to map out the corresponding coordinates 
with the AutoDock Vina [56] incorporated in UCSF Chimera [53]. The defined coordinates of the 
Remdesivir binding site region on the modelled structure were obtained from the grid box 
coordinates x = 144.452, y = 148.961, z = 163.495 for the centre and coordinates x=10.9051, 
y=18.7302, z= 15.2392 for the size of the grid box. In preparing for molecular docking, the pdbqt 
formats of Remdesivir and the SARS-CoV-2 RNA dependent RNA polymerase model were 
generated using AutoDock Vina [56]. Molecular docking was subsequently performed using 
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AutoDock Vina. In preparing for molecular docking, the SARS-CoV-2 RNA dependent RNA 
polymerase structure was prepared using the Graphical User Interface (GUI) of UCSF Chimera 
[54], which involved the addition of hydrogen atoms. The output of the docking was viewed on 
UCSF Chimera using the integrated ViewDock module after docked complexed were saved for 
further analysis. Residues that interacted with Remdesivir in the best binding pose of the docking 
results are shown in figure 5.3. The docked complexed were then prepared for MD simulation 
following in-house pre-MD preparation protocols [57,58].  Two systems were then set up for the 
MD simulation, an apo conformation of SARS-CoV-2 RNA dependent RNA polymerase  and the 




Figure 5.3: 3D representation of the SARS-CoV-2 RNA-dependent RNA polymerase model 
employed  in this study, which was pruned to minimize computational cost. Also present in the 










2.3 Molecular dynamics (MD) simulations  
To reveal the conformational changes that occurred on SARS-CoV-2 RNA-dependent RNA 
polymerase upon Remdesivir binding, we performed an atomic-scale MD simulation using the 
AMBER 18 GPU with an integrated PMEMD module [59,60].  This method is reliable and has 
been employed extensively in several previous studies [57,61–64].  Prior to molecular dynamics 
(MD) simulations, additional co-crystalized molecules such as crystal water, which were not 
applicable to this study, were removed from the enzyme structure using the graphical user interface 
of UCSF Chimera. In preparing Remdesivir for the MD simulation, the ANTECHAMBER module 
was employed for its parameterization, in which atomic partial charges (AM1BCC) gaff, using the 
bcc charge scheme were created [65].  On the other hand, the studied SARS-CoV-2 RNA-
dependent RNA polymerase model was also parameterized using the FF14SB AMBER force field 
[66]. Protonation of histidine residues was performed using the pdb4amber script at a constant pH 
(cpH) to ensure the compatibility of the prepared enzyme model with the LEAP module.  
Subsequently, hydrogen ions were added, followed by a neutralization of the entire prepared 
system using the LEAP module. Neutralization was carried out by the addition of either of the 
counter ions, Na+ or Cl-. Afterward, topology and coordinate files for Remdesivir, SARS-CoV-2 
RNA-dependent RNA polymerase, and their resultant complex were generated. Using a TIP3P 
orthorhombic box size of 12Å, water molecules were then added to explicitly solvate the entire 
system [67]. The two prepared systems (apo and complex) were  subjected to an initial 2000 
minimization steps at a restraint potential of 500kcal/mol. This was subsequently followed by a 
1000 steps minimization of steepest descent with no restraint. The systems were gradually heated 
from 0K to 300K for 50ps. After heating, a 500ps equilibration was performed at a constant 
pressure of 1bar. The pressure was maintained constant using Berendsen barostat [68]. Using the 
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SHAKE algorithm [69]to constrict all atomic hydrogen bonds, a 100ns MD simulation was 
performed on all systems. The MD production run was performed using a 1fs time step. 
Coordinates for generated trajectories were saved at 1ps interval and were further analysed using 
the PTRJ and CPPTRAJ modules of AMBER 18 [70]. Graphical plots for analysis of the generated 
trajectories created with the Microcal Origin analytical software [71]. 
2.4 Per-residue energy decomposition calculations 
The quantification of the energy contributions of  individual binding site residues were performed 
using per-residue decomposition analyses technique. The Per-residue decomposition analysis is 
incorporated in the Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) [72–75] 
method. This allows for the identification of crucial residues required for the efficient binding and 
stabilization of Remdesivir to the SARS-CoV-2 RNA-dependent RNA polymerase.  
2.5 Pharmacophore model creation. 
Following the MD simulation of  Redemsivir complexed with RNA-dependent RNA polymerase 
of SARS-CoV-2, the online platform, ZincPharmer [76], was used to construct a pharmacophore 
model. The pharmacophore model was constructed using the pharmacophoric moieties that 
exhibited prominent interaction with the highest energy contributing amino acids, as identified in 
the per-residue energy decomposition analysis. 
3.0 RESULTS AND DISCUSSION 
3.1 Validation of modelled 3D structure of SARS-CoV-2 RNA-dependent polymerase 
The homology model of the SARS-CoV-2 RNA-dependent RNA polymerase investigated in this 
study was built using the X-ray crystal structure of  SARS-CoV  RNA-dependent RNA polymerase 
[49] due to its highest sequence identity of 96.35%. To guarantee the reliability of the atomistic 
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predictions postulated in this report based on the modelled structure, we validated our model using 
the online server, RAMPAGE. From RAMPAGE, it was revealed that 98.1% (786 amino acids) 
of the amino acid residues that constitute our model were within the favour region, as shown in 
the Ramachandran plot on figure 5.4A. Also,  only 15 amino acid residues (1.9%) of our model 
were in the allowed region, while no residue was found in the outlier region. The high percentage 
of residues in the favoured and allowed regions suggested a reliable accuracy of the dihedral and 
backbones of our constructed homology model.  To further ensure the reliability of our postulations 
from the model, the structure was also validated the PROSA online web server with the resultant 
Z-score plots presented in figure 5.4B. Validation of the PROSA web server allows for an 
evaluation of a homology model with regards to its acceptability within experimental X-ray and 
NMR limits. As shown in the Z-core plot,  our modelled SARS-CoV-2 RNA-dependent RNA 
polymerase structured exhibited a Z-score of −13.23, consistent with a relatively good quality 






Figure 5.4: A) Ramachandran plots for the built homology model SARS-CoV-2 RNA-dependent 
RNA polymerase created on the RAMPAGE online webserver. B) Overall model quality of the 
homology  model of SARS-CoV-2 RNA-dependent RNA polymerase by Z-score of ProSA. C) 
Overall model quality of the homology model of SARS-CoV-2 RNA-dependent RNA polymerase 
by Z-score of ProSA 
Finally,  the quality of our model was also accessed using the online server, Verify_3D, a platform 
that employs empirical and energetic techniques to ascertain model quality. Verify_3D also 
assesses individual residue quality, as presented in figure 11.4C.  As shown,  our modelled SARS-
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CoV-2 RNA-dependent RNA polymerase recorded a Verify-3D score of 89.91%, with an average 
3D-1D score >= 0.2 score. 
3.2 Validation of model with experimentally resolved X-ray crystal structure of SARS-CoV-
2 virus RNA-dependent RNA polymerase 
Upon completion of this study, the X-ray crystal structure of SARS-CoV-2 virus RNA-dependent 
RNA polymerase bound with Remdesivir was released on the 8th of April 2020. However, a 
structural comparison and subsequent sequence alignment of our homology model and the 
experimentally resolved structure revealed a 90.78% sequence identity between both structures, as 
presented in supplementary figure S1. Particularly, the active site region of both structures 
exhibited a 100% sequence identity. The only notable difference is the incorporation of two 
catalytic magnesium ions in the experimental structure. Therefore, in light of the results, authors 
do not see any significant deviation from our results on the modelled structure. To further validate 
the reliability of the structural analysis revealed in this study from the modelled complex, we 
estimated the binding free of Remdesivir in both the modelled structure and the recently reported 
experimental complex by Yin et al.[77]. As shown in table 5.1, Remdesivir exhibited a binding 
free energy of -13.28kcal/mol  and -10.16kcal/mol in the experimental structure and the homology 
model respectively. With a minimal binding free energy difference of about -3kcal/mol between 
both structures as observed, it further suggests that there would be minimal difference in the 
binding site interaction dynamics of Remdesivir within both structures as well. Therefore, the 
structural elucidations from the homology model that are provided in this report would be similar 







Table 5.1:Comparative MM/GBSA-based binding free energy profile of compound Remdesivir 
ΔEele = electrostatic energy; ΔEvdW = van der Waals energy; ΔGbind = total binding free energy; ΔGsol = 
solvation free energy ΔG = gas phase free energy. 
 
3.3 Insights from binding mode exploration  of Remdesivir within  SARS-CoV-2 RNA-dependent 
RNA polymerase active site toward COVID-19 therapy 
Molecular docking was used to predict the best binding pose of Remdesivir within the active site region 
of modelled of SARS-CoV-2 RNA-dependent RNA polymerase. As presented in figure 5.5, several 
binding poses of Remdesivir were postulated with the corresponding docking score provided. The best 
binding pose, which is consistent with the most negative docking, was identified with a docking score of 
5.9kcal/mol. Complexes generated from molecular docking, however, only mimic the static “key and 
lock”  mechanism of ligand-receptor binding [78] and do not provide insights on the accurate dynamics 
of ligand-target interactions since both are flexible in reality. As such, assessment of the conformational 
changes of SARS-CoV-2 RNA-dependent RNA polymerase after molecular docking would not be 
truly representative of what would happen in reality upon Remdesivir binding. We, therefore, 
proceeded with molecular dynamics simulation of the best docked complex.   
 
 


























Figure 5.5: Binding poses of Remdesivir in the active sites of SARS-CoV-2 RNA-dependent RNA 
polymerase and their accompanying docking score. Best binding pose of Remdesivir has a docking 







3.4 Structural And Conformational  Dynamics Of SARS-Cov-2 RNA-Dependent RNA 
Polymerase Upon Remdesivir Binding 
Conformational changes of enzymes are the hallmarks of their dynamics that have a correlation 
with the overall functions of these enzymes [34]. In many cases, such conformation changes may 
be induced by the binding of ligands or other biological molecules that are able to modulate the 
function of the enzyme [35]. In this case, the binding of Remdesivir would have induced significant 
conformations. We, therefore, proceeded to investigate the structural and conformational dynamics 
of SARS-CoV-2 RNA-dependent RNA polymerase as relates to Remdesivir binding using MD 
simulation. This reliable computational technique allows the study of time-resolved properties of 
protein or enzyme structures in atomic details [36]. Post-MD simulation metrics such as C-α root 
mean square fluctuation (RMSF), C-α radius of gyration (RoG), and Solvent Accessible Surface 
Area (SASA) was thus employed assess the conformational dynamics of SARS-CoV-2 RNA-




Figure 5.6: Comparative conformational analyses of the unbound (black) and Remdesivir-bound 
(red) SARS-CoV-2 RNA-dependent RNA polymerase model. [A] C-α RMSD plot showing the 
degree of atomistic deviations and instability. [B] C-α RMSF plot showing individual residue 
flexibility. Blue highlight show the SARS-CoV-2 RNA-dependent RNA polymerase active site 
region and corresponding 3D representation is shown in the blue inset. Comparative radius of 
gyration plots of the unbound (black) and Remdesivir-bound (red) SARS-CoV-2 RNA-dependent 
RNA polymerase mode. [C] C-α ROG plot showing the degree of compactness of SARS-CoV-2 
RNA-dependent RNA polymerase. [D] Comparative SASA plots of the unbound (black)   





C-α RMSF can be employed to describe per-residue fluctuations across the enzyme’s secondary 
structure, while C-α RoG can be used to predict structural compactness, perturbations, and 
atomistic mobility [79–83]. C-α RMSF calculations for the unbound and Remdesivir bound   
SARS-CoV-2 RNA-dependent RNA polymerase are presented as line plots in figure 5.6B, which 
revealed that the binding of Remdesivir generally induced minimal fluctuations of individual 
residues in the overall structure when compared to unbound conformation while showed relatively 
higher residual fluctuations. On the average, unbound SARS-CoV-2 RNA-dependent RNA 
polymerase had RMSF values of 1.20Å, while Remdesivir-bound conformation had an average 
RMSF of 1.06Å. Presumably, the minimal perturbation in the structure SARS-CoV-2 RNA-
dependent RNA polymerase upon Remdesivir binding could highlight a possible mechanism by 
which Remdesivir exhibits its therapeutic modulatory activity against SARS-CoV-2 RNA-
dependent RNA polymerase. Specific peak fluctuations regions of interest occurred between 
residues “517-717”, which encompassed most of the active site residues. Thus, although there was 
minimal flexibility of residues in the entire structure of SARS-CoV-2 RNA-dependent RNA 
polymerase upon Remdesivir binding, there was an apparent disruption of the active site residues, 
as shown. This could be attributed to the direct strong molecular interactions elicited upon 
Remdesivir binding. These presumptions were further verified by calculating the C-α RMSD, 
which is able to depict the stability of SARS-CoV-2 RNA-dependent RNA polymerase across the 
MD simulation. As shown in figure 5.6A, C-α atomistic deviations of both simulated models were 
almost the same, with a difference of 0.7Å. This suggested that the binding of Remdesivir barely 
interfered with deviations of C-α atoms of SARS-CoV-2 RNA-dependent RNA polymerase, 
corroborating with the minimal residue fluctuations observed. The mean RMSD values estimated 
for the Remdesivir bound and the unbound  SARS-CoV-2 RNA-dependent RNA polymerase were 
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2.14Å and 2.07Å, respectively. Furthermore, the conformational dynamics of SARS-CoV-2 RNA-
dependent RNA polymerase were assessed from the MD simulation by estimating the C-α RoG, 
which provides insights on enzyme structure compactness. As shown in figure 5.6C, the 
Remdesivir-bound SARS-CoV-2 RNA-dependent RNA polymerase exhibited an average RoG of 
29.00Å, while the unbound conformation exhibited an average RoG 28.68Å. This suggested that 
Remdesivir binding induced a less compact structure consistent with structural unfolding.  
Nonetheless, the difference in comparison with the unbound is 0.32Å, further suggesting the 
structural unfolding with regards to Remdesivir binding is minimal. Estimations of the SASA 
provided more insights into the mechanistic perturbations of SARS-CoV-2 RNA-dependent RNA 
polymerase from the hydrophobic region (buried) to the hydrophilic phase (surface-exposed) 
according to previous studies [80,84–86]. As shown in the SASA plot on figure 5.6D, residues of 
the Remdesivir-bound SARS-CoV-2 RNA-dependent RNA polymerase appeared to be less 
surface-exposed when compared to the unbound conformation with an average SASA value of 
35164.07Å2. The unbound  SARS-CoV-2 RNA-dependent RNA polymerase exhibited a higher 
average SASA of  35641.23Å2. This could then imply that Remdesivir binding restricts the 
systematic transition of SARS-CoV-2 RNA-dependent RNA polymerase the hydrophobic region 
(buried) to the hydrophilic phase (surface-exposed) 
3.5 Extensive Redemsivir-active site modulation favour SARS-CoV-2 RNA-dependent RNA 
polymerase inhibition 
To understand the basis for the observed conformational and structural changes that occurred on 
SARS-CoV-2 RNA-dependent RNA polymerase upon Remdesivir binding, an investigation of the 
enzyme’s fundamental interaction profile, particularly at the active site, is essential. Based on 
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previous studies, it has been established that the active site of SARS-CoV, a homolog with 96.35% 
sequence similarity, is located at VAL557 [49,55]. Sequence alignment of both SARS-CoV and 
SARS-CoV-2 RNA-dependent RNA polymerase, as presented in figure 5.2, showed VAL557 was 
conserved in both enzymes. This conserved pattern of VAL557 on both structures suggests it could 
be the active site of  SARS-CoV-2 RNA-dependent RNA polymerase, whose therapeutic 
modulation, in addition to other binding pocket residues, could interfere with the overall activity 
of RNA-dependent polymerase coronaviruses. Therefore to ascertain the role of VAL557 and 
accompanying binding pocket residues in Remdesivir binding, we performed a molecular 
visualization of the interactions it elicited with Remdesivir upon binding, over a 100ns MD 
simulation using representative snapshots, 20 ns, 40 ns, 60 ns, 80 ns, 100 ns. This allowed for 
visualization of specific interactions that the active site residues engaged in with Remdesivir, 
which have also influenced its stability and binding affinity. The nature of these interactions could 
further establish or discredit the role of VAL557 in therapeutic inhibition of coronavirus RNA-
dependent RNA polymerase by Redemsivir. Also, the exploration of the molecular interactions of 
other residues that were within 5Å radius from VAL557 could highlight other crucial residues that 
influence the therapeutic efficiency of Remdesivir against SARS-CoV-2 RNA-dependent RNA 





Figure 5.7: Molecular visualization of Remdesivir at the active sites (hydrophobic pockets) of 
SARS-CoV-2 RNA-dependent RNA polymerase. Inter-molecular interactions between 
Remdesivir and active site residues in SARS-CoV-2 RNA-dependent RNA polymerase at 20 ns, 
40 ns and 60ns are shown in a, b and c respectively. A1,  B1 and B1 and C1 shows a 3D 
representation of the hydrophobicity of the Remdesivir bound at SARS-CoV-2 RNA-dependent 
active site. 
 
As shown in figure 5.7A, at 20 ns into the MD simulation, it can be observed that Remdesivir 
engages in an extensive array of strong intermolecular interactions with residues within the active 
site, including VAL557. Predominantly, Remdesivir engages in conventional hydrogen bond π-π 
stacked interactions with the hydrophobic residues. Particularly, VAL557  engages in a carbon-
hydrogen interaction Remdemsivir. Other notable interactions included salt-bridge interactions 
with both ASP623 and ARG555. At 40 ns, as shown in figure 5.7B, many of the interactions that 
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occurred at 20 ns were maintained. Again VAL557 retains in carbon-hydrogen bond interaction 
with Remdesivir, while ARG624 is also shown to engage in a π-anion interaction. At 60 ns, as 
shown in figure 5.7C, even as many interactions were again maintained, the number of 
hydrophobic interactions increased relative to interactions at 40 ns. However, the salt bridges 




Figure 5.8: Molecular visualization of Remdesivir at the active sites (hydrophobic pockets) of 
SARS-CoV-2 RNA-dependent RNA polymerase. Inter-molecular interactions between 
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Remdesivir and active site residues in SARS-CoV-2 RNA-dependent RNA polymerase at 80 ns 
and 100ns are shown in a and b respectively. a1 and b1 shows a 3D representation of the 
hydrophobicity of the Remdesivir bound active site. 
 
Towards the end of the simulation at 80 ns, as shown in figure 5.8A, the number of hydrophobic 
interactions with Remdesivir increased with many interactions observed from the beginning of the 
simulation again maintained. In addition to the conventional hydrogen bond interactions, other 
notable interactions included π-π stacked interactions with residues such as LYS676, VAL667, 
MET542, ALA688, ARG555, and TYR456. At the end of the MD simulation at 100 ns, as shown 
in figure 5.8B, the extensive pool of strong molecular interactions observed at the beginning of the 
simulations was sustained. Also, the two salt bridge interactions occurring between Remdesivir 
and ASP623, as well as ARG624, were again observed. From the observed interaction dynamics 
of Remdesivir in the SARS-CoV-2 RNA dependent RNA polymerase active site, it could be 
deduced specific residues interacted consistently, steadily, and intermittently across the 100ns MD 
simulation time. The consistency in engaging in strong interactions with Remdesivir implies that 
these interactions are essential to its therapeutic function against SARS-CoV-2 RNA dependent 
RNA polymerase. Notable interactions elicited included strong ionic and hydrogen bond formation 
and salt bridges. Thus, these interactions could have favoured the high-affinity binding and 
stability of Remdesivir in the active site of  SARS-CoV-2 RNA dependent RNA polymerase and 
could also suggest the possible structural mechanism of its therapeutic efficacy.  Also, the observed 
increase in interacting residues as the simulation proceeded further suggests that Remdemsivir 
assumed various binding orientations that allowed it to interact with more hydrophobic residues 
towards achieving stability and via favourable molecular interactions as observed. Altogether, the 
observed interaction dynamics of Remdesivir could relatively provide necessary details and 
insights into the molecular basis and mechanisms of its high-affinity binding and therapeutic 
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modulation of SARS-CoV-2 RNA dependent RNA polymerase towards as considerations as 
therapeutic for COVID-19. 
3.6 Quantitative insights into the contributions of active sight residues towards Remdesivir 
binding 
The critical roles of the putative active site residues of SARS-CoV-2 RNA dependent RNA 
polymerase were further revealed via per-residue decomposition analyses, which provided energy 
contributions of individual residues that interacted with Remdesivir at over the 100ns MD 
simulation duration. Overall, energies were decomposed into van der Waals and electrostatic 
energy, polar solvation energy, non-polar solvation energy, including their total energy 
contributions. As shown in figure 5.9 and table 5.2, many of the active site residues contributed 






Figure 5.9. A) 3D homology model of model of the SARS-CoV-2 RNA dependent RNA 
polymerase complexed with Remdesivir.  B) Per-residue energy contributions plot of the 
interacting residues at the SARS-CoV-2 RNA dependent RNA polymerase active site upon 
Remdesivir binding. C) The residue ligand interaction network illustrates stabilizing hydrophobic 










Table 5.2: Tabular presentation of the estimated energy contribution of individual active 
residues 












ASP 452 -0.78±0.58 -6.56±1.19 3.37±1.21 -0.01±0.01 -3.99±1.06 
TYR 453 -0.57±0.19 0.01±0.04 0.09± 0.05 -0.01±0.01 -0.47±0.17 
TYR 456 -1.51±0.39 -0.57±0.26 0.72±0.18 -0.16 ±0.08 -1.53±0.47 
THR 540 -0.46±0.11 0.03±0.04 0.12± 0.06 -0.02±0.01 -0.34±0.11 
GLN 541 -0.09±0.01 0.05±0.04 0.05±0.05 0.00±0.00 0.01±0.03 
MET 542 -1.12±0.27 0.38±0.08 -0.04±0.09 -0.08± 0.01 -0.87±0.29 
ASN 543 -0.11±0.01 -0.19±0.10 0.24± 0.10 0.000±0.00 -0.06±0.05 
LYS 545 -0.14±0.06 -1.04±0.73 1.38±0.82 -0.00 ±0.00 0.20±0.10 
ARG 553 -0.99±0.39 -6.25±1.89 7.41±2.03 -0.22±0.07 -0.04±0.39 
ALA 554 -0.69±0.16 1.13±0.32 -0.24±0.27 -0.03 ±0.02 0.16±0.30 
ARG 555 -4.04±0.70 -6.79±2.14 9.33±2.01 -0.38±0.06 -1.88±0.77 
THR 556 -0.92±0.71 -3.18±0.78 2.71± 0.30 -0.14 ±0.02 -1.52±0.56 
VAL 557 -1.68±0.25 -0.79±0.21 1.05±0.25 -0.11±0.04 -1.53±0.27 
ALA 558 -0.84±0.27 0.05±0.01 -0.01±0.09 -0.05±0.01 -0.85±0.29 
GLY 559 -0.08±0.16 -0.08±0.03 0.12±0.03 0.00 ±0.00 -0.04±0.03 
VAL 560 -0.05±0.01 0.01±0.01 0.04±0.02 0.00±0.00 0.001±0.2 
LYS 621 -0.08±0.02 -0.59±0.34 0.72±0.38 -0.00 ±0.01 0.06±0.08 
CYS 622 -0.08±0.02 -0.01±0.05 0.08±0.06 0.00±0.00 -0.02±0.03 
ASP 623 -1.74±0.30 0.23±0.95 1.93 ±1.09 -0.23±0.03 0.19±0.69 
ARG 624 -1.71±0.59 -2.60±1.61 1.72±1.13 -0.20±0.03 -2.80±0.99 
GLU 665 -0.25±0.07 -0.70±0.31 0.69±0.39 -0.00±0.00 -0.21±0.21 
VAL 667 -0.44±0.10 0.10±0.02 -0.06±0.03 -0.02±0.01 -0.41±0.11 
LYS 676 -0.54±0.13 0.61±0.42 -0.12±0.45 -0.02±0.01 -0.06±0.39 
THR 680 -2.60±0.46 -2.77±1.11 1.88±0.51 -0.19±0.03 -3.67±0.88 
SER 681 -1.99±0.43 -0.95±0.38 1.58±0.30 -0.07±0.02 -1.44±0.65 
SER 682 -2.58±0.50 -1.25±0.56 2.21±0.60 -0.35±0.04 -1.97±0.71 
GLY 683 -0.28±0.06 0.10±0.05 0.12±0.06 -0.00±0.00 -0.05±0.06 
THR 686 -0.77±0.29 0.08±0.26 0.07±0.22 -0.05±0.04 -0.68±0.42 
ALA 687 -0.62±0.29 0.02±0.11 -0.01±0.10 -0.14±0.06 -0.75±0.38 
ASN 691 -0.31±0.20 0.06±0.25 0.14±0.29 -0.03±0.04 -0.15±0.26 
SER 759 -0.13±0.05 0.24±0.18 -0.08±0.22 -0.00±0.01 0.02±0.08 







Also, many of these high energy contributing residues are amongst residues that consistently 
interacted with Remdesivir. The high energies estimated are also consistent with the strong 
molecular interactions elicited upon Remdesivir binding, as highlighted over the simulation period. 
Many of these residues contributed total energies <-1kcal/mol establishing their essentiality in 
overall Remdesivir binding and stability [87]. The highest energy contributing residues with total 
energies <-1kcal/mol included, ASP452(-3.99kcal/mol), THR456(-1.53kcal), ARG555(-
1.88kcal/mol), THR556(-1.52kcal/mol), VAL557(-1.53kcal/mol), ARG624(-2.80kcal), 
THR680(-3.67kcal/mol), SER681(-1.44kcal/mol) and SER682 (-1.97kcal/mol). The identification 
of these residues could aid in the determinations of crucial pharmacophoric moieties of 
Remdesivir, which could be used in the design of improved Remdesivir analogs.  
 
3.7 Per-Residue based pharmacophore model generation reveals essential moieties of 
Remdesivir 
Previously, our research group has extensively published on methods that improve 
pharmacophore-based modelling. The earliest of such methods was the target-bound 
pharmacophore modelling approach, which highlighted the importance of incorporating the 
conformation of bound ligands in the pharmacophore model generation [88]. In improving this 
method, we outlined another pharmacophore workflow whereby the pharmacophore model was 
constructed based on high energy-contributing active amino acid residues to overall ligand binding 
[43,89,90]. High energy contributing residues are identified from per-residue energy 
decomposition analysis integrated with the MM/GBSA thermodynamics calculation. Identified 
high energy contributing residues are then mapped with corresponding interacting moieties on the 
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ligand. In this report, we followed the same protocol to generate an informative structural ensemble 
of steric and electronic features that may be in the supramolecular interaction of Remdesivir with 
SARS-CoV-2 RNA dependent RNA polymerase in figure 10B.  
 
 
Figure 5.10: A) Specific Remdesivir moieties (the 3,4‐dihydroxy‐5‐methyloxolane‐2‐carbonitrile 
moiety, pyrrolo[2,1-f][1,2,4]triazin-4-amine moiety and (1‐methoxy‐1‐oxopropan‐2‐
yl)(methyl)aminophosphonic acid) that interact with high energy contributing residues. B) 3-D 
pharmacophore model generated on ZINCPharmer (Green–hydrophobic/aromatic moiety, gold – hydrogen 
bond donor/acceptor). 
 
As observed in the ligand interaction plots many of the high energy contributing residues, notably, 
ASP452, THR456, ARG555, THR556, VAL557, ARG624, THR680, SER681 and, SER682 
interacted with specific moieties on Remdesivir by forming strong interactions with could have 
favoured its stability within the active site of  SARS-CoV-2 RNA dependent RNA polymerase. 
Specific moieties that these residues interacted with include; the 3,4‐dihydroxy‐5‐methyloxolane‐
2‐carbonitrile moiety, pyrrolo[2,1-f][1,2,4]triazin-4-amine moiety and the  (1‐methoxy‐1‐
oxopropan‐2‐yl)(methyl)aminophosphonic acid on Remdesivir as highlighted in figure 5.10A. The 
chosen essential pharmacophoric features of Remdesivir, as identified in the report, include 
aromatic/hydrophobic rings, hydrogen bond donors, and hydrogen bond acceptors, as shown in 
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figure 5.10A. To validate the pharmacophore model generated in this report, we screened the ZINC 
database for potential SARS-CoV-2 RNA dependent RNA polymerase inhibitors and identified 
11 hits compounds as presented in TableS1. A good pharmacophore model should successfully 
differentiate active compounds from inactive ones. As such, with this extensively explored 
technique used in constructing our pharmacophore model, we believe the model could be used in 
screening large compound libraries for hit identification. The pharmacophore model also presents 
a useful chemical scaffold that could serve as a starting point for the discovery of improved 
therapeutic analogs of Remdesivir that target SARS-CoV-2 RNA dependent RNA polymerase. 
Nonetheless, as an inconclusive predictive model, a further validation of the pharmacophore model 
is required  to guarantee its reliability. 
 
4.0 CONCLUSION  
In this study, we employed advanced computational techniques to understand the binding 
mechanism as well as structural and conformational implications that occur upon binding of 
Remdesivir to SARS-CoV-2 virus RNA-dependent RNA polymerase. Using a validated homology 
model of SARS-CoV-2 virus RNA-dependent RNA polymerase, our results revealed that 
Remdesivir binding is mediated by specific residues (ASP452, THR456, ARG555, THR556, 
VAL557, ARG624, THR680, SER681, and SER682) which engage in an extensive array of high-
affinity interactive with essential Remdesivir moieties.  Conformational changes observed upon 
Remdesivir included minimal individual amino acid perturbations, subtle interference in C-α 
atoms deviations, and a restriction in the systematic transition of SARS-CoV-2 RNA-dependent 
RNA polymerase from the “buried” hydrophobic region to the “surface-exposed” hydrophilic 
region. High energy contributing residues identified from per-residue energy decomposition 
184 
 
analysis were subsequently used in the construction of a pharmacophore model. This 
pharmacophore highlighted the essential moieties on Remdesivir required for SARS-CoV-2 RNA-
dependent RNA polymerase inhibition while presenting pharmacophoric features that could aid in 
the design of improved analogs of Remdesivir to augment the current treatment options for 
COVID-19. As an ongoing study, a future exploration of pharmacophore model generation 
towards hit identification  against SARS-CoV-2 RNA-dependent RNA polymerase would  involve 
the assembling of multiple inhibitors to constitute training sets that could in turn be employed in 
building a more robust pharmacophore  model via feature mapping. 
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The challenge in targeting human rhinoviruses (HRV) over the years has been attributed to the 
wide variety in HRV serotypes. Nonetheless, the search for therapeutic agents against HRV 
continues unabated. These efforts have been augmented by the recent discovery of the novel 
benzothiophene derivative shown to inhibit HRV viral replication. Bound to subtype HRV-B14, 
the compound showed similar inhibitory activity as Pleconaril, a known capsid inhibitor. However, 
the molecular and structural basis of this inhibition remains unclear. In this in silico report, residue 
interaction network analysis revealed that the binding of the benzothiophene derivative into the 
“canyon” region of the active site of HRV-B14 distorts its initially extensively networked and 
compact residue profile. This was characterized by fewer inter-residue hydrogen bonds, reduced 
van der Waals interactions, and increased residue flexibility. Interestingly, however, the binding 
of this benzothiophene derivative decreased the flexibility of the north-south wall around the 
canyon region possibly impeding the “breathing motion” of HRV-B14, hence its inhibition. 
Atomistic insights also revealed the cruciality of Tyr152 towards inhibitor binding at HRV-B14. 
This was justified by the amino acid’s high intermolecular interaction with both inhibitors. 
Findings provide important structural insights in the inhibitory activity the novel benzothiophene 
derivative and reaffirm its promising potential as an alternative capsid inhibitor towards common 
cold therapy upon further experimental validation. 
 









Coming from the picoviridae family, rhinoviruses (HRVs) are the most prominent causative agent 
of upper-respiratory infections [1]. First discovered in 1950, these viruses have evolved into at 
least 160 strains, which have been clustered into 3 subgroups (A, B and C) [2]. Although these 
viruses generally only cause acute infections, cases have been reported where HRV has been 
implicated in exacerbated chronic respiratory disease, immunodeficiencies, as well as chronic 
obstructive pulmonary diseases [3].  
 
Human HRV infections begin with the binding and translocation of the 30nm diameter, non-
enveloped virion into the cell. The genetic material is then released into the cytoplasm where the 
host ribosome translates the positive-sense, single-stranded RNA into a polyprotein that is cleaved 
to form 11 new viral proteins, eventually maturing into a new viral particle [4].   
 
The HRV polyprotein consists of 4 capsid proteins, VP 1-4, which encloses the viral RNA, as well 
as 7 non-structural proteins, including proteins 2A-C and 3A-D [1]. The capsid proteins are 
arranged in a unique icosahedral symmetrical structure, containing 60 copies of each protein [5]. 
The 3 larger proteins, VP1-3, are located at the external surface of the virus, whereas, VP4 lines 
the inner surface interfacing VP1-3 and the RNA. Crystallographic studies have indicated that 
VP1-3 comprises of 8-stranded, antiparallel beta-barrel folds and VP4 is an extended polypeptide 
[6]. This pentameric protomer structure (figure 6.1) contains structural channels, which are known 





Figure 6.1: Structure of icosahedral viral capsid demonstrating the unique VP1-VP3 domain 
orientations and the characteristic “canyon” drug-binding pocket.  
 
These “canyons” are used for cell-receptor binding and uncoating during entry into the cell [7,8]. 
Various sub-groups of HRV utilize small molecules, known as “pocket factors”, that bind in the 
“canyon” until a receptor becomes available. This hydrophobic binding pocket (Leu25, Ala21, 
Leu106, Phe124, Tyr128, Iso130, Tyr152, Val176, Tyr197, Met221, Asp219, and Pro172) found 
within the “canyon” has become a crucial target in several antiviral strategies against HRV [9].   
 
Over recent years, several lead molecules have been established against HRV, with capsid 
inhibitors such as Pleconaril and vapendavir showing potential to inhibit viral uncoating by 
stabilizing the cleft region [7]. These drugs, however, are yet to be approved as inhibitors of the 
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virus [9]. A study by Kim et al (2017) put forward a series of benzothiophene derivatives that were 
effective against both HRV subgroups A and B [7]. Of these compounds, Isopropyl 3-Methyl-6-
{[2-(methylcarbamoyl)pyridin-4-yl]oxy}- 
benzo[b]thiophene-2-carboxylate (compound 6g) demonstrated similar characteristics to 
Pleconaril, thus augmenting its use as a capsid inhibitor. The report by Kim et al (2017) also 
established that compound 6g binds to the Pleconaril binding site of HRV-B14 via molecular 
docking whiles also highlighting key interacting residues. Although their work identified 
compound 6g as a potential HRV capsid inhibitor, no available study currently exits to explain the 
structural mechanism by which it inhibits the capsid. 
In this investigation, we aim to develop on the above research by using a range of in silico tools to 
discover the structural mechanism of inhibition of HRV upon administration of the compound 6g. 
The binding landscape at the capsid’s “canyon” region upon binding of compound 6g will also be 
assessed, contrasted with Pleconaril. This computational approach will facilitate a further 
understanding of the machinery of the capsid protein in HRV therapy. 
 
2.0 COMPUTATIONAL METHODS 
2.1 System Preparation  
 
The X-ray crystal structures of HRV-B14 was retrieved from the Protein Data Bank with PDB 
codes 1NCQ. Using Molecular Molegro Viewer (MMV)[10] and UCSF Chimera [11], the 
structures were prepared for a 130ns Molecular Dynamics (MD) simulation. The 2D  structure of 
compound 6g was modeled using the MarvinSketch software [12]. Using the UFF [13] forcefield, 
energy optimization was performed on the 2D structure using Avogadro 1.2.0 software [13]. A 3D 
format of the structure was then saved for molecular docking and MD simulation. In preparing for 
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MD simulation hydrogen atoms and AM1-BCC charges were added to the 3D structure of 
compound 6g. Likewise, all co-crystallized non-standard residues on the 3D structures of HRV-
B14 were all removed to minimize computational cost. In all three systems were prepared for MD 
simulation; unbound HRV-B14, Pleconaril-HRV-B14 complex and compound 6g-HRV-B14 
complex. 
 
2.1.1 Molecular Docking 
 
The molecular docking protocol implemented in this study utilized AutoDock Vina tool [14] 
incorporated in UCSF Chimera with default docking parameters. Compound 6g was docked into 
the Pleconaril binding pocket of HRV-B14. In preparing for molecular docking, compound 6g was 
supplemented with Gasteiger charges followed by non-polar hydrogen bonds which were merged 
to the carbon atoms. Compound 6g was then docked into the Pleconaril binding pocket by defining 
a grid box with a spacing of 1 Å and size of 13.90 ×13.58× 6.65 pointing in x=36.34, y=4.79 and 
z=123.93 directions. The best-docked pose was then subjected to 130ns MD simulations. 
 
2.1.2 Molecular Dynamic (MD) Simulations 
 
Molecular dynamic (MD) simulations offer a robust tool to explore the physical movements of 
biological systems, providing an atomistic view of interactions that occur between atoms and 
molecules on a molecular level[15]. The insight extracted from MD simulations enable a deeper 
perspective into the dynamical evolution of biological systems and for these reasons, this 
computational technique was employed in this study [15–18]. The MD simulations were 
performed using the GPU version of the PMEMD engine supported by the AMBER 18 package 
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[19]. This was done in accordance with in-house standard MD simulation protocols employed in 
several of our previous reports [16,20,21]. The atomic partial charge for compound 6g and 
Pleconaril was determined using ANTECHAMBER using the General Amber Force Field (GAFF) 
protocol [22]. Each system was solvated using the Leap module of AMBER 18 implicitly within 
an orthorhombic box of TIP3P water molecules such that all atoms were within 10Å of any box 
edge. The Leap module was also employed to neutralize all systems by the addition of Na+ or Cl
- 
as counter ions. An initial minimization was carried out for 2000 steps with an applied restraint 
potential of 500 kcal/mol. This was closely followed by a full minimization of 1000 steps carried 
out by a conjugate gradient algorithm in the absence of all restraints. All systems were gradually 
heated from 0K to 300K for 50ps to ensure that all systems maintained a fixed number of atoms 
and a fixed volume. The solute molecules within each system were imposed with a potential 
harmonic restraint of 10kcal/mol and collision frequency of 1ps. Following the heating protocol 
that each system was subjected to, an equilibration step estimating 500ps for all systems was 
conducted with a constant operating temperature of 300K. An isobaric-isothermal (NPT) ensemble 
was mirrored by the addition of a number of atoms, and the pressure was also kept constant 1 bar 
using the Berendsen barostat.  
MD simulations on all systems were run for a total time of 130ns. In each simulation, the SHAKE 
algorithm was interpolated to constrict the bonds of hydrogen atoms. The step size of each 
simulation was 2fs, employing the SPFP precision model. Each simulation coincided with an 
isobaric-isothermal ensemble (NPT), with randomized seeding, constant pressure of 1 bar, a 
pressure-coupling constant of 2ps, a temperature of 300K, and Langevin thermostat with a 
collision frequency of 1ps. 
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2.2 Post-Dynamic Analysis 
The coordinates of the free HRV-B14 and bound complexes were then saved after every 1ps. The 
CPPTRAJ module employed in the AMBER 18 suit was employed for post dynamic analysis. The 
Root Mean Square Deviation (RMSD) and thermodynamic energy estimation of each system were 
then investigated.  
2.2.1 Residue Interaction Network Exploration (RIN) 
RIN analysis of the studied systems was performed using a snapshot generated from each system 
at the end of the 130ns MD simulation. The network of interactions with the selected snapshot was 
then obtained by uploading the .pdb file format of the snapshot onto the online platform RING 
server [23]. The generated network is downloaded in .xml format for visualization and on 
Cytoscape [24] and the RINalyzer plugin[25] was employed to visualize generated RIN. Residues 
of the HRV-B14 are represented by nodes whilst non-covalent interaction elicited between 
residues are denoted by edges. Interactions highlighted includes; hydrogen bond interactions, van 
der Waals interactions, ionic interaction amongst others. Variations in elicited interactions are 
represented by a unique color for each interaction. Incorporated in  Cytoscape is the 
NetworkAnalyzer [26] plugin, which was used to explore the node degree and node connectivity. 
Closeness centrality and shortest path betweenness of the simulated models were also analyzed 






2.2.2 Binding Free Energy Calculations 
 
The Molecular Mechanics/PB Surface Area method (MM/PBSA) [27] was employed to estimate 
the binding free energy of each of the systems. Binding free energy averaged over 130000 
snapshots which were extracted from the 130ns trajectory.  
The free binding energy (ΔG) computed by this method for each molecular species (complex, 
ligand and receptor) can be represented as: 
∆G[U\] = G^_`abcd − GTc^cae_T − GbUfg\]																																									(1) 
∆G[U\] = Efgh + Gh_b − TS																																																																		(2) 
Efgh = EU\e + Ei]j + Ecbc																																																																			(3) 
Gh_b = Gkl + Gmn																																																																																			(4) 
Gmn = γSASA																																																																																											(5) 
 
The term Egas denotes the gas-phase energy, which consists of the internal energy Eint; Coulomb 
energy Eele and the van der Waals energies Evdw. The Egas was directly estimated from the 
FF14SB force field terms. Solvation free energy, Gsol, was estimated from the energy contribution 
from the polar states, GGB, and non-polar states, G. The non-polar solvation energy, SA. GSA, 
was determined from the solvent accessible surface area (SASA), using a water probe radius of 
1.4 Å, whereas the polar solvation, GGB, contribution was estimated by solving the GB equation. 






3.0 RESULTS AND DISCUSSION 
 
3.1 Exploring the Impact of a Drug-filled “Canyon” Region on the Structural Dynamics of 
HRV-B14 
The capsid protein of HRV has been deemed a fascinating viral target due to its unique structural 
features. The capsid protein, comprising of VP1-4, contains a structural channel, known as a 
“canyon” region. This “canyon” region (Leu25, Ala21, Leu106, Phe124, Tyr128, Ile130, Tyr152, 
Val176, Tyr197, Met221, Asp219, and Pro172) mediates cell receptor binding and fusion with the 
host cell. In physiological conditions, small molecules, known as pocket factors, bind to the 
“canyon” region to stabilize the capsid until the virus locates a cell receptor [28,29]. In this study, 
the stability of the HRV-B14 was investigated upon binding of the novel benzothiophene 
derivative, Isopropyl 3-Methyl-6-{[2-(methylcarbamoyl)pyridin-4-yl]oxy}-benzo[b]thiophene-2-
carboxylate (compound 6g). This was contrasted against a known capsid inhibitor, Pleconaril. The 
stability of the MD simulation was determined by measuring the variations in the root mean square 
deviation (RMSD) of the C-α atoms across the 130ns trajectory (figure S1). RMSD calculations 
also allowed for an assessment of the reliability of the simulated models. It was evident from the 
analysis that the simulated models all achieved stability hence any further analyses performed on 
the MD trajectories were reliable. The lower RMSD of the bound HRV-B14 complexes relative to 
the unbound conformation suggests the binding of both compound 6g and Pleconaril induced a 
level of stability on HRV-B14 with respect to their C-α atoms. To ascertain the flexibility and 
conformation dynamics of the HRV-B14 upon the binding of compound 6g and Pleconaril, root 




Figure 6.2: Root mean square fluctuations of HRV Capsid protein. Increased fluctuations are seen 




Comparative analysis revealed that the compound 6g bound HRV-B14 exhibited a higher 
fluctuation of residues relative to the Pleconaril bound model. This implies the inhibitory activity 
of compound 6g resulted in an increase in residue flexibility, which could possibly interfere with 
the physiological activity of HRV-B14. Also, relative to the unbound HRV-B14, both inhibitor-
bound complexes exhibited higher flexibility of residues, suggesting their HRV-B14 inhibitory 
activity is generally characterized by a distortion an originally stiff residue conformation.  A 
calculation of the radius of gyration (Rg) was also performed to give insights into the distribution 
of atoms from the center of mass of HRV-B14 over the course of the MD simulations (figure S2). 
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Rg calculations also allowed for an assessment of the compactness of the HRV-B14 upon inhibitor 
binding. The highest Rg was observed in the compound 6g bound HRV-B14, suggesting a less 
compact protein structure relative to the other systems. This less compact protein structure 
observed in the compound 6g bound complex was consistent with the relatively higher residue 
flexibility observed in the RMSF calculations. In all, it could be presumed that the inhibitor binding 
in the canyon region of HRV-B14 induced residue flexibility and as well as a less compact protein 
conformation which could have impeded its functions. 
 
3.2 Novel benzothiophene derivative binding in “Canyon” region induces residue network 
perturbations  
The dynamics of the web of interactions elicited between residues in the active site of HRV-B14, 
particularly “canyon” region, prior to inhibitor binding and after inhibitor binding revealed 
essential atomistic insights that could form the basis HRV-B14  inhibition [30–32]. RIN as a post-
MD analysis technique has been explored extensively in previous reports for analysis of the 
residue-residue interactions for several simulation models, including mutant and wild protein 
structures [16,33,34]. Notable parameters assessed with RIN node degree, short path length, 
betweenness, and closeness centrality. Node degree described the number of connections between 
nodes is whereas the compactness of the protein network is described by the diameter (D) [35,36]. 
The betweenness and closeness centrality also revealed crucial residues within the residue 
interaction network of HRV-B14 [35,36].  The short path length parameter of analyses from the 
RIN provides insights on the flexibility of residue and takes which is described by interconnective 
edges between respective nodes [35,36].   
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Based on the residue network generated from average snapshots of each of the 130ns MD 
simulated systems, the residue-residue interactions of residues that constituted the HRV-B14 
binding site were investigated.  As shown in figure 6.3, prior to inhibitor binding, residues in the 
active site region were shown to possess an extensive broad network of interactions amongst each 
other, engaging in numerous van der Waals (̴ 45 interactions) and hydrogen bond interactions (̴ 32 
interactions). The conspicuous extensive network shown in the figure portrays a tight and compact 
residue network, with residues strongly interacting with each other to facilitate viral uncoating. 
This was characterized by a high node degree, notable betweenness, and closeness centrality of 
binding site residues within the unbound HRV-B14. The shortness in length of the connective 
edges also affirmed a compact residue network within the active site, consistent with the compact 






Figure 6.3: Residue Interaction Network of HRV-14 active site residues upon binding of 
compound 6g, Pleconaril and when unbound. The network shows an extensively tight and compact 
active site residue network in the unbound conformation which becomes distorted residue network 




However, upon inhibitor binding, there was an obvious perturbation of the compact residue 
network of HRV-B14. This perturbation was characterized by a decrease in the number of residue-
residue interactions. Both the Pleconaril and the compound 6g bound system elicited 
approximately 30 van der Waals interactions and roughly 22 hydrogen bond interactions amongst 
neighboring residues within the active site.  A clear increase in the length of connective edges, a 
decreased node degree, as well as less prominence in closeness and betweenness within the pocket 
relative to the bound conformation, was also noted. This coupled with the fewer interactions 
confers with a less compact and a disoriented residue interaction network relative to the unbound 
system, consistent with less compact overall protein structure observed in Rg and RMSF 
calculations.  There also an increase in short path lengths amongst active site residues of the bound 
HRV-B14 relative to the unbound conformation. It could, therefore, be presumed that the binding 
of an inhibitor into the “canyon” region within the active site of HRV-B14 induces a structural 
perturbation of the residue interaction network of the region, which could, in turn, interfere with 
the functions of the protein. It was observed that the binding of both compound 6g and Pleconaril 
imposed a similar impact on the residue network profile suggesting a possible similarity in their 
inhibitory activity.   
 
3.3 Inhibitor binding impedes North-South wall motion 
The “breathing motion” of the HRV-B14 remains crucial for its biological activity and requires 
conformational flexibility of the canyon region [4]. Therefore, impeding the flexible motion of the 
canyon region will block essential interactions that occurs at the base of the canyon. To access the 
flexibility of the North-South Wall, distance analysis was calculated to assess the motion between 
the north and south wall relative to the effectiveness of each inhibitor as depicted in figure 6.4. 
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The average distance between the north and south wall calculated from the simulations were 
9.90Å, 31.74Å and 32.21Å for the HRV-B14-compound 6g complex, HRV-B14-Pleconaril 
complex and the unbound HRV-B14 and systems respectively as shown in Table 6.1.  
 
Table 6.1: Measurement of the distance by which the north and south wall moves, measured in 
Angstroms. (Δa Change between maximum and minimum distance ) 
 
 
Overall, the difference between the maximum and minimum distance throughout the 130ns MD 
simulation in the inhibitor-bound HRV-B14 were shortened relative to the unbound system. As 
shown, the compound 6g bound system displayed a substantially lower change in distance as 
opposed to the apo and HRV-B14-Pleconaril systems This suggested that bound conformation 
exhibited reduced flexibility between the north and south wall located at the at base of the canyon. 
This suggests that the inhibitory activity of compound g probably allows its effective wedging into 
the ‘canyon’ region, holding the protein together in order to elicit its therapeutic activity. The 
shorter distance between the walls in the compound 6g bound complex as the simulation proceeded 
is indicative of a decline in flexibility of the canyon region, since these walls enclose the canyon 
region. This decreased flexibility as result of the binding of compound g could possibly impede 
the “breathing motion” of HRV-B14, hence its inhibition.  
 
	 HRV-B14	 COMPOUND	6G	 PLECONARIL	
MAXIMUM	 38.98	 13.33	 36.45	
MINIMUM	 28.97	 7.86	 28.24	
AVERAGE	 32.21	 9.90	 31.74	




Figure 6.4: Plot of the estimated distances between the north and south wall as well as a visual 
representation of the flexibility of walls at the base of canyon region of HRV-B14 (orange), HRV-
B14-Pleconaril (purple) and HRV-B14-compound 6g (pink) 
 
 
3.4 Comparative binding free energy profiles of novel benzothiophene derivative and 
Pleconaril 
 
The therapeutic binding of an inhibitor to any pharmacological target usually underpins the basis 
of activity of that inhibitor, as such an estimation of the binding affinity of the inhibitor is of critical 
importance [37]. To ascertain the binding affinity of compound 6g towards establishing the basis 
of its experimentally determined inhibitory prowess against HRV-B14, we calculated the binding 
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free energy of compound 6g using the MM/PBSA based approach. Binding free energy of the 
novel compound 6g was directly compared with the binding free energy of Pleconaril, the known 
HRV-B14 inhibitor. The estimated binding free energies, even though not absolute values as 
experimental values, are still reliable because the relative binding affinity between congeneric 
inhibitors can be computed. This is because binding free energies can be calculated relatively and 
efficiently using thermodynamic cycles that facilitate a small perturbation of phase space, in 
contrast to many other quantities of pharmaceutical interest that require much more computational 
resources [37]. As shown in table 6.2, compound 6g exhibited a total binding free energy of -
28.87kcal/mol, whilst Pleconaril exhibited binding free energy of -45kcal/mol. The relatively 
higher binding free energy of Pleconaril could be attributed to the increased van der Waals (-
54.50kcal/mol) and electrostatic interactions (-6.10kcal/mol) it elicited with HRV-B14 as shown 
in the MM/PBSA calculations. The relatively favorable estimated binding free energy of 
compound 6g again highlights its promising ability as a potential capsid inhibitor such as 
Pleconaril. 
 
Table 6.2: MM/PBSA-based binding free energy profiles of compound 6g and Pleconaril 
 
ΔEele = electrostatic energy; ΔEvdW = van der Waals energy; ΔGbind = total binding free energy; ΔGsol = 




Systems Energy components 
(kcal/mol) 








-54.50 ± 0.05 
 
 




















3.5 Novel benzothiophene derivative shows strong inhibitory per-residue energy-based 
interactions with HRV-B14 
 
To establish the atomistic basis of the estimated binding free energies with particular focus on the 
energy contributions of residues that make up the “canyon” region, we calculated the per-residue 
energy composition of each active site residue of HRV-B14 towards the binding of compound 6g 
relative Pleconaril. Analyzing per-residue energy contributions towards the binding of compound 
6g was performed in  as performed in comparison with the per-residue energy contributions of 
residues that interacted with Pleconaril , since Pleconaril  has been shown to bind to the “canyon” 
and stabilize the protein, preventing the capsid from opening up as well as inhibiting the entry of 
viruses into the host cell [38]. Exploring the energy contributions of residues that constitute the 





Figure 6.5: Per-residue decomposition analyses revealing individual energy contributions of 
HRV-B14 active site residues to the binding and stability of compound 6g and Pleconaril. Active 





 As shown in figure 6.5, residues that contributed the most to the total binding of Pleconaril 
included; Ile104(-2.07kcal/mol), Tyr152(-3.14kcal/mol), Phe186(-1.30kcal/mol), Val188(-
1.79kcal/mol), Val191(-1.06kcal/mol), Tyr197 (-1.34kcal/mol), Met221(-1.47kcal/mol), and 
Met224(-1.10kcal/mol). Likewise, as shown in figure 5, residues that contributed the most to total 
binding free energy of compound 6g include Pro174(-1.42kcal/mol), Phe186 (-1.83kcal/mol), 
Leu25C(-0.95kcal/mol), Ala24C(-0.81kcal/mol), Tyr152(-2.83kcal/mol), and 
Val191(0.71kcal/mol). Interestingly, it could be observed that there were residues that consistently 
interacted in both pockets, viz; Tyr152, Val191, and Phe186 were notably the most recurrent 
residues that contributed prominently to the total binding energy of both compound 6g and 
Pleconaril. It could, therefore, be inferred that the inhibition of HRV-B14 possibly depends on the 
interaction of the given inhibitor with these three residues. Amongst these three residues, Tyr152, 
which coincidentally was the highest energy contributing residue in both the compound 6g and 
Pleconaril bound systems, further signifies its essentiality in the overall, therapeutic inhibition of 
HRV-B14. Comparatively, residues in the Pleconaril bound complex generally elicited stronger 
energies relative to the compound 6g bound complex, which possibly influenced the overall higher 
binding free energy of Pleconaril as observed. Ultimately, the ability of compound 6g to interact 
with similar residues as Pleconaril with high energies, further reaffirms its ability to inhibit HRV-




By employing advanced computational techniques and MD simulations, this study aimed to 
discover the structural mechanism of inhibition of HRV-B14 upon administration of the novel 
benzothiophene derivative, Isopropyl 3-Methyl-6-{[2-(methylcarbamoyl)pyridin-4-yl]oxy}-
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benzo[b]thiophene-2-carboxylate (compound 6g). The binding landscape at the capsid’s “canyon” 
region was assessed upon binding of compound 6g using Pleconaril, a known capsid inhibitor. An 
initial conformational assessment revealed that the binding of compound 6g conferred stability to 
the conformational structure of HRV-B14 relative to the unbound conformation through a 
calculation of the root mean square deviation of the C-α atoms of each simulated system. An 
estimation of the individual residue fluctuations of the entire HRV-B14 structure upon binding of 
compound 6g relative to Pleconaril further revealed that the binding of compound 6g induced 
increased residue fluctuations, which probably contributed to the inhibition of HRV-B14. A further 
exploration of individual residue behavior over the course of the 130ns MD simulation by 
employing the RIN analysis revealed that binding of an inhibitor into the “canyon” region within 
the active site of HRV-B14 distorts the initially extensively networked residues of the binding site, 
which could, in turn, possibly favored the inhibitory activities of Pleconaril and compound 6g. The 
ability of compound 6g to also perturb the residue interaction network of the HRV-B14 active site 
in a similar fashion as the known capsid inhibitor, Pleconaril, affirms its promising role as a 
potential novel capsid inhibitor. The flexibility between the north and south wall which enclose 
the active site of HRV-B14 was also analysed by calculating the distance between walls over the 
course of the simulation. Distances between the walls in the inhibitor bound systems were shorter 
in the 130ns MD simulation relative to the unbound conformation, with the shortest distance 
average distance 9.94A occurring in the compound 6g bound system. This decreased flexibility as 
result of the binding of compound g could have possibly interfering with the “breathing motion” 
of HRV-B14. Comparative binding free energy analysis using the MM/PBSA-based approached 
also revealed a total binding free energy of -28.87kcal/mol and -45kcal/mol for compound 6g and 
Pleconaril respectively, with the higher binding of Pleconaril attributing to its corresponding high 
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electrostatic and van der Waals interactions. The favorable estimated binding free energy of 
compound 6g enforces its role as a promising capsid inhibitor. Atomistic insights into the energy 
contributions of HRV-B14 active site residues using per-residue energy decomposition approach 
also revealed that the inhibitory activity of both Pleconaril and compound 6g involved engaging 
in interactions with some particular residues within the active site, notably Tyr152. Tyr152 
contributed the most towards the total binding of both Pleconaril and compound 6g, suggesting its 
key role in HRV-B14 inhibition. The structural and atomistic perspectives provided on the 
inhibitory prowess of the benzothiophene derivative, compound 6g towards HRV-B14 further 
reaffirms is promising potential as capsid inhibitor, as could therefore be further explored 
experimentally. 
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Background: The pharmacological inhibition of human N-myristoyltransferase (HsNMT) has 
emerged as an efficient non-cytotoxic strategy to completely thwart the replication process of 
rhinovirus toward common cold treatment. This approach has potentiated the discovery of IMP-
1088, a novel compound that inhibits both HsNMT1 and HsNMT2. 
 Methods/Results: An augmentative computational and nanosecond-based analyses reveal that the 
steady and consistent interactions of IMP-1088 with specific residues; Tyr296, Phe190, Tyr420, 
Leu453, Gln496, Val181, Leu474, Glu182, and Asn246, shared within the binding pockets of both 
HNMT subtypes, in addition to peculiar structural changes account for its dual inhibitory potency. 
Conclusion: Findings unveil atomistic and structural perspectives that could form the basis for the 
design of novel dual-acting inhibitors of N-myristoyltransferase towards common cold therapy. 
  















Respiratory tract infections are among the leading cause of severe illness and death globally, 
associated with high incidence rates and consequential economic implications [1,2]. Common in 
both adults and children, respiratory tract infections categorized into upper respiratory infections 
(URT) and lower respiratory infections [1]. Available reports suggest that 6 to 8 episodes of 
respiratory tract infections occur per child per year, with similar rates occurring in developed and 
developing countries [3,4]. Most respiratory tract infections are moderately mild and usually 
restricted to the URT [4]. Nevertheless, URT infections may spread downwards and cause severe 
in infants and young children,  and in some cases result in life-threatening infections [5].  
Accounting for more that 50% of URT infections [6,7], Human rhinoviruses (HRVs) are 
exclusively responsible for the common cold in humans, together with other life-threatening 
respiratory infections such as cystic fibrosis, chronic obstructive pulmonary disease (COPD)  and 
asthma [8,9]. Common cold constitutes an acute, self-limiting viral infection of the URT involving 
the nose, sinuses, pharynx, and larynx [10].  
Rhinoviruses are members of the picornaviridae family, consisting of viral pathogens such as 
poliovirus, foot-and-mouth disease virus, coxsackievirus, hepatitis A virus, and enterovirus 71  [9]. 
Rhinovirus is spread either directly or indirectly by contact with secretions from an infected person 
or aerosol of the secretions [7]. 
Despite their pathogenic involvements, there have been few therapeutic interventions towards 
HRV. This is widely attributed to the serotype diversity of the virus, which requires a broad-
spectrum of vaccines for thorough efficacy [11,12]. Also, RV has been observed to elicit rapid 
resistance to existing inhibitors due to its high replication and mutation rates [12]. All these have 
compounded the existing challenges of treating or suppressing RV infections.  
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In an infected host cell, the RNA genome of RV usually develops into an infectious virion during 
the viral life cycle by a series of cellular processes  [13]. These processes initiate by a translation 
of the RV RNA genome into a single polyprotein by the ribosomes of the host cell [13]. This 
results in the formation of capsid precursors by viral proteases, which are further processed into 
three capsid proteins, viz.; VP0, VP1, and VP3 [14]. The capsid proteins subsequently trigger a 
cascade of protein self-assembly leading to the development of infectious virions. The cleavage of 
VPO into VP4 and VP2 in the intact viral capsid culminates in the final maturation step [14].  
 
Figure 7.1: Schematic showing of the crucial role of N-myristoyl transferase in the viral life cycle. This 
also highlights how infectious Rhinovirus polyproteins  are generated in the cells of an infected host [9] 
 
In many picornaviruses, VP0 is encoded at the N terminus of the viral polyprotein and is 
subsequently N-myristoylated by the host cell’s N-myristoyltransferase (NMT) [9]. However, in 
humans and other higher eukaryotic organisms, NMT is expressed as NMT1 and NMT2 proteins 
in many tissues [9,15].  
Mutagenesis studies on poliovirus revealed that the N-myristoylation of NMT plays a crucial role 
in viral assembly and infectivity[15–19]. Also, RV replicates inside a host cell by invading host 
NMT and subsequently develops a capsid (shell) that protects its genetic material [20]. Therefore, 
targeting host cell NMT presents an opportunity for inhibiting the infectivity of the virus.  
Recent studies reveal that a newly discovered compound, IMP-1088, exerted potent dual inhibitory 
activities against Human N-myristoyltransferase 1 and 2 (HsNMT 1/2) by halting viral replication, 
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which ultimately results in the prevention of viral infectivity and capsid assembly without causing 
toxicity to the host cell [9]. Using a resolved X-ray crystal structure of HsNMT1/2 in complex 
with  IMP-1088, it was revealed compound IMP-1088 reportedly formed an extensive network of 
interactions at the substrate pocket of its target proteins (HsNMT1/2), which potentiates its 
unprecedented efficacy [20]. However, since these structural insights provided in their report are 
deduced from single snapshots of interactions from the X-ray crystal complexes which may be 
inadequate to provide a thorough and dynamic perspective into the mechanistic binding 
mechanistic activities of compound IMP-1088 towards HsNMT1/2, we employ more rigorous 
computational methods including molecular dynamics (MD) simulations, sequence analysis, and 
cheminformatics to provide additional molecular insights into the structural dynamics of 
HsNMT1/2 upon compound IMP-1088 binding which could account its dual binding activity. MD 
simulation allows for the mimicking of the dynamical events of molecular systems as a function 
of time, with a molecular description of all biological components (inhibitor and protein) in a 
solvent space [21,22]. MD simulations would enable a more detailed elucidation of molecular 
events and inhibitory mechanisms that characterize the dual inhibitory prowess of compound IMP-
1088.  We also employ in silico approaches to assess the physicochemical and pharmacokinetic 
profiles of compound IMP-1088. Findings would augment previous experimental efforts and also 
reveal further important structural perspectives that could advance drug development with respect 







2.0 COMPUTATIONAL METHODOLOGY 
2.1 System preparation 
The X-ray crystal structures of HsNMT1 and HsNMT2 were obtained from RSCB Protein Data 
Bank with code 5MU6 and 4C2X, respectively. 5MU6 is a dimer with two exact chains (A and B) 
complexed with compound IMP-1088 and myristoyl CoA; as such, we deleted chain B and 
prepared our model systems with only chain A to reduce computational cost. The HsNMT2-IMP-
1088 complex, on the other hand, was prepared by docking the 2D structure of compound IMP-
1088 into the substrate-binding pocket of HsNMT2. Prior to molecular dynamics (MD) 
simulations, additional co-crystallized molecules such as crystal water, which were not applicable 
to this study, were removed using the graphical user interface of UCSF Chimera [23]. 
 
2.2 Molecular dynamics (MD) simulations  
This was performed using the GPU version of AMBER 18 with an integrated PMEMD module 
[24], according to standard MD simulation protocols, which have been employed extensively in 
our previous reports[24–28]. IMP-1088 was parameterized using the ANTECHAMBER module 
of AMBER18 in which its atomic partial charges were generated. Parameterization with the 
ANTECHAMBER module was performed using the restrained electrostatic potential (RESP) and 
the General AMBER force field (GAFF) protocol [29].  HsNMT1 and HsNMT2 were 
subsequently parameterized using the FF14SB AMBER force field [30]. Protonation of histidine 
residues was subsequently performed using the pdb4amber files at a constant pH to prepare the 
enzyme structures for the LEAP process that followed. The Leap module integrated with 
AMBER18 was then employed for the purpose of neutralization of the entire system and for the 
addition of hydrogen atoms.  Neutralization was carried out by adding an equivalent number of 
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any of the counter ions, Na+, Cl-. Afterward, the topology and parameter files of IMP-1088, 
HsNMT1, HsNMT2, and complexes of the enzymes with the IMP-1088 were then saved. The 
Leap module also allowed for the addition of water molecules with a TIP3P orthorhombic box size 
of 7Å to explicitly solvate the entire system [31,32]. Prepared systems were then taken through a 
two-phase minimization process in which the initial minimization of 2000 steps was performed at 
500kcal/mol restraint potential. The second minimization referred to as a full minimization 
involved 1000 steps at a steepest descent with no restraint. This was followed by the gradual 
thermalization of the systems with a temperature range of 0-300K for 50ps after which each system 
was equilibrated for 500ps while the temperature and pressure were kept constant at 300K and 
1bar, respectively using the Berendsen barostat [33]. This was followed by MD production runs 
of 100ns for each system during which the SHAKE algorithm [34] was used to constrict all atomic 
hydrogen bonds. The process of MD simulation involved a 1fs time step initiation process while 
at 1ps, coordinates of simulated files were saved.  All trajectories generated over the course of the 
simulation were subsequently analyzed using the PTRJ and CPPTRAJ modules of AMBER18 
[35].  Plots to interpret findings from the generated MD trajectories were also created using 
Microcal Origin [36], while UCSF Chimera was used to visualize and create relevant images. 
 
2.3 Thermodynamics calculations 
 The Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) [37–39] method was 
used to calculate binding free energy. The binding free energy (DGbind) was calculated from the 
following equations: 
DGbind = Gcomplex - Greceptor + Gligand          (1) 
DGbind = DGgas + DGsol -TDS,                   (2) 
230 
 
Where DGbind is considered to be the summation of the gas phase and solvation energy terms less 
the entropy (TDS) term 
DEgas = DEint + D Evdw + D Eelec         (3) 
DEgas is the sum of the AMBER force field internal energy terms DEint (bond, angle, and torsion), 
the covalent van der Waals (DEvdw) and the non-bonded electrostatic energy component (DEelec). 
The solvation energy is calculated from the following equation: 
Gsol = GGB + Gnon-polar                 (4) 
Gnon_polar = gSASA + b               (5) 
The polar solvation contribution is represented as GGB and while Gnon-polar is the non-polar solvation 
contribution. Gnon-polar is calculated from the solvent assessable surface area (SASA), obtained by 
means of a 1.4 A° water probe radius. The surface tension constant (c) was set to 0.0072 kcal/mol 
and b to 0 kcal/mol [40]. Per-residue decomposition analyses were also carried out to estimate 
individual energy contribution of residues of the substrate pocket towards the affinity and 
stabilization of compound IMP-1088. This was aimed at providing atomistic insights in the dual-
targeting ability of compound IMP-1088 towards HsNMT1/2, considering the fact that the 
prominent residual energy contributions could highlight essential residues. In addition to the per-
residue energy contributions of the binding site residues, we also examined the sequence similarity 
of these binding site residues in HsNMT1/2. This was done using the sequence alignment 







3.0 RESULTS AND DISCUSSION 
 
3.1 Sequence profiling of HsNMT1/2 hydrophobic pockets with IMP-1088 
The ability of a small molecule compound to pharmacologically inhibit VPO N-myristoylation by 
targeting HsNMT of host cells can be considered a breakthrough towards common cold therapy. 
Inhibition of N-myristoylation interferes with the assembly of virions and, as a resultant, causes 
suppression of the infectivity and prevents RV replication. Reports of the dual-targeting ability of 
HsNT1/2 by compound IMP-1088 leaves room to explore the molecular and structural bases 
behind its dual inhibitory prowess. As such, we analysed the sequences of amino acid residues that 
constitute the compound IMP-1088 binding pockets in both HsNMT1 and HsNMT2, since these 
residues directly interacted with compound IMP-1088 and could, therefore, influence its function 
and overall binding affinity. A variation or similarity in amino acid sequences of the binding 
pockets of two different enzymes could account for the ability of a particular small molecule 
inhibitor to either bind to both or be selective towards one. With regards to the binding of 
compound IMP-1088, the binding pocket sequence analysis permitted a thorough insight into the 
molecular basis that could account for the ability of compound IMP-1088 to target both HsNMT1 
and HsNMT2. As shown in figure 7.2, binding site residues were almost but the same across both 
enzymes IMP-1088. Some of the common binding site residues across both enzyme binding 
pockets include; Tyr296, Tyr420, Leu453, Gln496, Val181, Leu474, Glu182, Tyr180, Asp183, 
Asp184, Phe188, Arg189, Phe190, Asp191, Tyr192, Asn246, Tyr420, Ser421, Asn452, Ala453 
and Leu454 amongst many others. This suggested a possible similarity in interaction dynamics 
with bound inhibitors. The almost identical binding pocket of both enzymes could also confirm an 
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analogous binding mode of any bound compounds such as IMP-1088 since interaction dynamics 
would be similar. 
 
 
Figure 7.2: Showing the sequence alignment of binding sites residues of HsNMT1 and HsNMT2 and a 
2D structure of compound IMP-1088, highlighting essential moieties. Sequence alignment reveals a 
similarity in binding site residue of both enzyme subtypes.  
 
 
3.2 IMP-1088 binding pocket stability favors dual binding activity   
To understand the conformational dynamics of compound IMP-1088 upon binding to HsNMT1 
and HsNMT2, we monitored the relative stability of compound IMP-1088 within the binding 
pockets throughout the simulation. This was done by a calculation of the root mean square 
deviation of compound IMP-1088 in both pockets. As shown in figure 7.3A, compound IMP-1088 
was relatively more stable in HsNMT1 (1.42Å) than in HsNMT2 (1.94Å). Relative stability within 
HsNMT1 is suggestive of a steady conformation, which could have allowed for favorable and 
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sustained interactions with many residues within the binding pocket. This stable conformation was 
further observed from a superimposition of three representative snapshots (initial, optimized, and 
final) of compound IMP-1088 in both systems over the course of the simulation. As shown in 
figure 7.3B and 7.3C, compound IMP-1088 maintained an almost similar conformation throughout 
the simulation in HsNMT1 relative to varying conformations within HsNMT2. The stable motions 
of compound IMP-1088 within the binding pocket of HsNMT2 could have favored interactions 
with residues within the binding pocket.  
 
Figure 7.3: A) Cα RMSD plot showing comparative stability and motions of IMP-1088 at the binding site 
HsNMT1 (blue) and HsNMT2 (red) over the 100ns simulation B) The differential positioning of IMP-1088 
in the binding site of HsNMT2 and a structural comparison of the initial (yellow), optimized (purple) and 
final snapshot at 100 ns (blue) C) The differential positioning of IMP-1088 in the binding site of HsNMT1 






3.3 Peculiar interactions of Tyr296 with IMP-1088 in both HsNMT1/2 reaffirms role IMP-1088  
 
As reported by Mousnier et al.,[9] interaction of compound IMP-1088  with Tyr296 in HsNMT1 
led to its displacement and subsequent burial of the compound IMP-1088 resulting in increased 
interactions. This was reaffirmed in this report by the observed sustained interactions of compound 
IMP-1088 with Tyr296 throughout the MD simulation period. As shown in figure 7.4, it was 
observed that from the beginning of the MD simulation, at 5ns and 20ns, Tyr296 elicits a p-p 
stacked interaction with the pyrazole ring of compound IMP-1088 in the HsNMT1 complex.  As 
the simulation proceeds, this p-p stacked interaction is shown to change into an alkyl interaction 
at about 60ns, as shown in figure 7.4. The alkyl interaction is subsequently maintained until the 
end of the MD simulations at 100ns. In comparison with its interaction dynamics in the HsNMT2, 
Tyr296 is shown to engage in p-p stacked interactions with the difluorophenyl indazole linker of 
IMP-1088 throughout the simulation. The replication of these crucial interactions withTyr296 in 
both subtypes further enforces the role of Tyr296 in the dual inhibitory activity of compound IMP-
1088. A time-based monitoring of the interactions that IMP-1088 engaged in over the course of 
the simulation revealed a gradual expansion of the interaction network as the simulation continued 
in both enzymes even though there was a larger pool of interactions within HNMT1 relative to 
HNMT2 as shown in figure 7.4. Also, it was also observed that the binding of compound IMP-
1088 in both enzymes involved consistent interactions with particular residues other residues; 
Phe190, Tyr420, Leu453, Gln496, Val181, Leu474, Glu182, and Asn246 across the simulation 
period as shown in figure S1 and S2. These residues consistently reoccurred throughout the 
simulation period in both systems, engaging in various strong interactions with compound IMP-
1088. It could, therefore, be inferred that the inhibitory activity of compound IMP-1088 probably 
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relied on interaction with these particular residues, hence could also possibly underpin the dual 
targeting ability of compound IMP-1088. 
 
Figure 7.4: Comparative time-based analysis of the interactions of IMP-1088 with the binding pocket of 
HsNMT1 and HsNMT2 with particular emphasis on interaction with Tyr296 chain. Shown in the table are 
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individual residues engaged in various intermolecular interactions with IMP-1088. Residues highlighted in 
red are those that consistently interacted with both HsNMT1 and HsNMT2 throughout the simulation 
 
 
3.4 Quantifying energy contribution profiles of binding site residues 
 
After the observed similarity in interacting residues in both HsNMT1 and HsNMT2 upon binding 
of IMP-1088, we proceeded to quantify the specific energy contributions of the individual residues 
towards the overall binding within the pockets. This was performed by calculation of per-residue 
based energy decomposition using the MMGBSA incorporated approach. As shown in figure 7.5, 
prominent energy contributions of active site residues were observed, with most having total 
energy contributions <-1, confirming their cruciality to overall total binding of compound IMP-
1088[41]. Comparatively, residues within the binding pocket of HsNMT1 contributed more 
towards the total binding of compound IMP-1088 relative to the binding site residues of HsNMT2, 
which could largely be attributed to the stronger interaction that’s existed between those residues 
and compound IMP-1088.  It was observed that the residues that consistently interacted with 
compound IMP-1088 in both HsNMT1 and HsNMT2 complex (Tyr296, Phe190, Tyr420, Leu453, 
Gln496, Val181, Leu474, Glu182, and As246) were among the highest energy contributing 
residues with total energies being <-1. Their prominence in total energy contributions establishes 
how essential their roles are in the activity of compound IMP-1088 in dual targeting of HsNMT1 




Figure 7.5: Per-residue energy plot of residues that consistently interacted with both HsNMT1 and 
HsNMT2 over the course of the 100ns MD simulation and their corresponding ligand-residue interaction 
plots highlighting specific interactions involved 
 
3.5 Comparative binding free energy analysis of compound IMP-1088 upon binding to both 
HsNMT1/2 
Having established that compound IMP-1088 exhibits dual-targeting ability on HsNMT1 and 
HsNMT2 due to similarity of interacting residues within the respective binding pockets, we 
proceeded to estimate its total binding free energy towards both enzymes. This was to further 
assess whether the similarity of interacting residues could confer a similarity in binding affinity. 
Using the MM/GBSA approach, binding free energy of compound IMP-1088 in complex with 
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HsNMT1 and HsMNT2 was calculated as presented in Table 7.1. A total binding free energy of -
35.20kcal/mol and -30.42kcal/mol was estimated for compound IMP-1088 in the HsNMT1-IMP-
1088 and HsNMT2 complex, respectively. Although very close, compound IMP-1088 exhibited 
higher total binding free energy towards HsNMT1 relative to HsNMT2. This higher binding free 
energy could be attributed to the expanded network of stronger interactions that compound IMP-
1088 engaged in with HsMNT1 over the simulation period relative to the fewer interactions 
observed in the HsNMT2-IMP-1088 complex. This observed similarity in total binding free energy 
could also be attributed to similarity in prominent energy contributing residues (Tyr296, Phe190, 
Tyr420, Leu453, Gln496, Val181, Leu474, Glu182, and As246) as observed in the per-residue 
energy decomposition.  
Table 7.1: MM/GBSA-based binding free energy profile of compound IMP-1088 
 
ΔEele = electrostatic energy; ΔEvdW = van der Waals energy; ΔGbind = total binding free energy; ΔGsol = 
solvation free energy ΔG = gas phase free energy. 
 
 
3.6 Comparative structural impacts of IMP-1088 binding on HsNMT1 and HsNMT2 
 
The binding of any small molecular compound, in this case, compound IMP-1088, always tends 
imposing structural changes to the respective binding targets. This imposed structural implications 
could lead to a significant change in the structural architecture of the given target, which can 
























consequentially influence the overall function of the given target. Although the potency and drug 
worthiness of compound IMP-1088 have been thoroughly established by earlier experimental 
reports and in silico insights from this report, it was important to further delve into the impact 
IMP-1088 binding on the structural architecture of both HsNMT1 and HsNMT2. This was to 
reveal significant structural perturbations and architectural disorientations that could have 
accounted for inhibitory competence of compound IMP-1088 on both HsNMT1 and HsNMT2 by 
contrasting with their unbound forms.  
To reveal these structural occurrences, we measured parameters such as the C-α root mean square 
deviation (RMSD), root mean square fluctuation (RMSF) and C-α radius of gyration (RoG) and 
solvent accessible surface area (SASA) from the combined trajectories that were generated from 
the 100ns MD simulation. Generated plots from the analysis are presented in figure S3. Insight 
from the C-α RMSD plots provided a perspective on the stability of the simulated models, a crucial 
parameter in the overall functionality of an enzyme, which can largely be influenced by the binding 
of a ligand or a small molecule inhibitor.  
Relatively high C-α atom deviations for a given simulated system is usually consistent with 
structural instability, whereas lower atomic deviation depicts a relatively more stable system. As 
shown in figure S3, the simulated HsNMT1/2 systems both achieved convergence at ~20ns and 
~25ns, respectively. Comparatively, the compound IMP-1088 bound conformations of HsNMT1 
and HsMNT2 both exhibited lower C-α atoms deviations relative to their respective unbound 
conformations, signifying higher structural stability upon compound IMP-1088 binding with 
average C-a RMSD of 3.26Å and 6.09Å, respectively. The unbound HsMNT1 and HsMNT2 
exhibited average C-α RMSD values of 4.02Å and 6.81Å, respectively. Overall it could be deduced 
that the binding of compound IMP-1088 induced a level of stability on both HsNMT1 and 
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HsNMT2, thus impeded the deviation of respective C-α toms. The observed lower C-α RMSD in 
both HsNMT1 and HsNMT2 also suggests a similarity in the mode by which compound IMP-1080 
influences the stability of HsNMT1 and HsNMT2. Nonetheless, there was a relatively higher 
deviation in the HsNMT2 system compared to the HsNMT1 system, suggesting that compound 
IMP-1088 induced higher structural stability on HsNMT2. The flexibility of individual residues 
of a protein could influence the overall function of the protein since residue motions could inform 
how close they are to bound small molecule inhibitors in order to engage in essential interactions 
required to influence the activity of the given target. As such, we monitored the root mean square 
fluctuation of HsNMT1 and HsNMT2 in their bound and unbound conformations. This was 
performed to also deduce if the binding of compound IMP-1088 somewhat had an impact on the 
mobility of individual amino acid residues that make up HsNMT1 and HsNMT2, and as such, 
could be attributed to its inhibitory prowess as experimentally predicted.  
Insights from the comparative RMSF plots shown in figure 7.6 revealed that overall, the binding 
of compound IMP-1088 decreased the flexibility of both HsNMT1 and HsNMT2, signifying a 
similarity in its influence on residue motions. This similarity of influence on residue motions could 
possibly form the structural insight that accompanies the ability of compound IMP-1088 to dual-
target both HsNMT1 and HsNMT2. On average, unbound HsNMT1 and HsNMT2 exhibited 
RMSF values of 9.64Å and 10.36Å, respectively whereas the bound versions had lower average 




Figure 7.6: Characteristic secondary structure fluctuation among the unbound (blue) and IMP-1088-bound 
(red) HsNMT1/2. A) and C) RMSF plot showing regions with notable fluctuation which are indicated 
numerically. B) and D) Superimposed structures of the bound and apo conformation HsNMT1 and 
HsNMT2 showing regions with high fluctuations as indicated in 6A. 
 
To further explore the structural impact of compound IMP-1088 binding on HsNMT1and 
HsNMT2, we also assessed the compactness of the enzymes in the presence and absence of 
compound IMP-1088 throughout the 100ns simulation. This was assessed by a calculation of the 
radius of gyration of the C-α atoms of each enzyme subtype from the generated MD trajectories. 
The comparative RoG plots are presented in figure S1 with the unbound enzymes exhibiting the 
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highest RoG of 21.85Å for HsNMT1 and 22.43Å for HsNMT2. The compound IMP-1088 bound 
system exhibited relatively lower RoG of 21.77Å and 22.41Å for HsNNT1and HsMNT2, 
respectively. The lower RoG in the inhibitor bound systems were consistent with very compact 
enzyme conformation, congruous with the decreased flexibility, as shown in the RMSF 
calculations. This rigid or compact conformation of both enzymes suggested a restricted atomistic 
mobility within the enzymes, which could have inhibited crucial interactions required for the 
function of these enzymes in catalyzing RV myristoylation.  The impact of the binding of 
compound IMP-1088 on the folding and unfolding of the HsNMT1and HsNMT2 was further 
investigated by a calculation of the solvent accessible-surface area (SASA) of the bound 
complexes.  This provided insights on how individual amino acids residues of the enzymes are 
exposed to hydrophilic surface since this could influence the interaction dynamics of each amino 
acid residues to bound ligands. The unbound HsNMT1 and HsNMT2 systems exhibited an average 
SASA of 18333Å2 and 19857Å2, respectively, whereas the compound IMP-1088 bound models 
also exhibited an average SASA of 17501Å2 and 19146Å2, respectively as shown in figureS3. The 
lower average SASA values of the compound IMP-1088 bound N-myristoyltransferases infers that 
IMP-1088 binding induced a burial or folding of the individual amino acid residues of the enzymes 
and thus the residues were less surface-exposed relative to the unbound enzyme conformations. 
The folding of the amino acid residues upon IMP-1088 binding as showcased in the SASA 
calculation is consistent with the compact structure and decreased residue flexibility of the bound 
conformations as observed in the RMSF and RoG calculations. Altogether, it could be inferred 
that compound IMP-1088 inhibited the HsNMT1 and HsNMT2 by impeding atomistic residue 
fluctuation, thus inducing a compact structural conformation which culminated into a burial of 
hydrophobic residues required for the function of the HsNMT1 and HsNMT2. 
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3.7 In silico Physiochemical and ADMET profiling of compound IMP-1088 
Available in silico approaches allow for the prediction of the physicochemical and 
pharmacokinetic properties of chemical compounds prior to rigorous experimental methods. Thus, 
these approaches provide an avenue to assess the drug-likeness of the compound and how its 
physiochemical properties could influence its absorption, distribution, metabolism, and excretion 
of the chemical compound in human systems prior to the application of experimental approaches. 
Following the Lipinski’s rule of five (LRo5) [42] and using  the online platform, SwissADME [43] 
we  predict the physiochemical and pharmacokinetic descriptors of compound IMP-1088 in order 
to validate its drug-likeness as presented in Table 7.2. The descriptors, according to the LRo5 
include molecular weight (MW) [£ 500 Da], octanol-water partition coefficient [log P £ 5], H-
bond donors (HBD) [£ 5] and H-bond acceptors (HBA) [£ 10]. As estimated, compound IMP-
1088 had a molecular weight of 453.53g/mol with 33 heavy atoms, 7 rotatable bonds, 6 hydrogen 
bonds acceptors, and a molar refractivity of 126.59. Accordingly, a small MW of 453.53g/mol [£ 
500 Da] suggests that compound IMP-1088 potentiates low toxicity risk [44,45]. MW also 
determines the bioavailability of molecules because a large-sized compound would be impeded 
during transportation, absorption, and uptake by cells, which could reduce therapeutic potency 
[46,47]. Hence, the small MW of compound IMP-1088 would favor cellular uptake with little or 
no impediment to its transport and delivery at target sites. Effective delivery of the compound to 
the target site could consequently ensure that an adequate concentration of compound IMP-1088 
reaches the surface of intestinal epithelial cells for efficient absorption. The favorable MW of 
compound IMP-1088 also correlated with the moderated number of rotatable bonds (7 rotatable 
bonds) it possessed since a higher molecular weight of a compound is shown to directly correlate 
with a higher number of rotatable bonds. The lower number of rotatable bonds confers some level 
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of molecular rigidity on the structure of compound IMP-1088, which could enhance efficient 
delivery to target sites for further absorption. A highly flexible molecular structure may engage in 
unwanted interactions as it is being delivered to the target site. In all, compound IMP-1080 shows 
no violations of the rule of five, confirming its potential drug likeliness in humans with less 
toxicity.   
Table 7.2: The Summarized ADMET Profile of compound IMP-1088 








































The lipophilicity of compound IMP-1080 as a physiochemical feature has significant effects on 
the solubility, absorption, distribution, metabolism, and excretion properties as well as 
pharmacological activity. Using SwissADME, an octanol-water partition coefficient (log Po/w) of 
4.48 was predicted for compound IMP-1088. A favorable log Po/w usually ranges between -0.4 to 
5.6, with extremely high values suggesting a decrease in aqueous solubility with a consequential 
decrease in absorption rates. In contrast, values below -0.4 depict compounds with lower 
membrane permeability and poor absorption [47,48]. With a favorable predictive lipophilic value 
of 4.48 for compound IMP-1088, it implies that compound IMP-1088 exhibits considerable 
solubility attributes with a tendency of being adequately absorbed in human cells. This could, in 
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turn, improve the compound IMP-1088 bioavailability and permeability across membranes. In all, 
based on the pharmacokinetic features explored, compound IMP-1088 possesses a promising 




The enzyme N-myristoyltransferase is involved in the transfer of myristate from myristoyl Co-
enzyme A to the N terminus of a range of proteins during protein translation. Two variants of this 
protein are expressed in humans, namely HsNMT1 and HsNMT2. The N-myristoylation process 
of VPO in poliovirus from a mutagenesis report proved its essentiality in the assembly of capsids 
and the infectivity of the virus. As such, therapeutic targeting of this process in humans may 
provide a viable therapeutic option in the treatment of viral infections. The ability of compound 
IMP-1088 to double target HsNMT1 and HsNMT2 in host cells has proven to be a very significant 
discovery towards the search of a lasting treatment of common cold. Using molecular dynamics 
simulation and an array of computer-aided tools, the present study, for the first time, sought to 
explore and provide structural and atomistic insight into the dual-targeting ability of compound 
IMP-1088 towards HsNMT1 and HsNMT2.  Exploration of the pattern of the amino acid 
sequences that interacted directly with compound IMP-1088 in both HsNMT1/2 revealed striking 
similarity of interacting amino acid sequences even though HsNMT1 and HsNMT2 only possessed 
an overall sequence similarity of 83.2%. Also, consistent interaction with Tyr296 resulted in the 
displacement of the Tyr296 chain which enhanced the burial of compound IMP-1088 within the 
hydrophobic pocket. The burial within the hydrophobic pocket allowed for the expansion of the 
interaction network in both complexes as simulation persisted. Quantification of the energy 
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contributions of each residue to the binding of compound IMP-1088 showed that these recurring 
residues contributed the highest energies <-1 kcal/mol, further establishing their essentiality in the 
dual acting ability of compound IMP-1088. Estimated total binding free energy of compound IMP-
1088 in HsNMT1and HsNMT2 revealed near-similar ΔGs of -35.20kcal/mol and -30.42kcal/mol, 
respectively whilst the higher binding free energy exhibited in HsNMT1 could be attributed to 
stronger active site interactions. An assessment of the conformational dynamics of HsNMT1 and 
HsNMT2 revealed that compound IMP-1088 exerted a similar pattern of structural inactivation, 
which entails reduced atomistic fluctuation and structural compactness, which culminated into the 
burial of surface-exposed residues. Finally, an assessment of pharmacological and 
pharmacokinetic profiles of compound IMP-1088 revealed a favorable predictive lipophilic value 
of 4.48 and a general agreement with the Lipinski’s rule of five, implying compound IMP-1088 
exhibits a considerable solubility attribute, which can consequentially improve its bioavailability 
and permeability across membranes. Findings from this report unveils essential atomistic insights 
from a structural perspective that support the experimentally reported inhibitory prowess of 
compound IMP-1088 against HsNMT1 and HsNMT2 while providing the basis for the design of 
improved dual-acting inhibitors. 
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Human rhinoviruses (HRVs) account for more than 50% of upper respiratory tract infections. 
These pathogenic organisms are exclusively responsible for common cold in humans together with 
other life-threatening respiratory infections such as asthma, cystic fibrosis and chronic obstructive 
pulmonary disease (COPD).  
N-myristoylation, catalyzed by human N-myristoyltransferase (HNMT) plays a crucial role in viral 
assembly and infectivity, and as such therapeutic targeting the HNMT in a host cell presents an 
opportunity towards inhibiting the infectivity of the rhinovirus.  
IMP-1088 was recently reported to possess potent dual inhibitory activities against HNMT1/2 
thereby halting viral replication and ultimately, elicit the prevention of viral infectivity and capsid 
assembly without causing toxicity to the host cell.  
However, the structural and molecular basis of this dual inhibitory potency remain inconclusive. 
This study therefore attempts to provide essential structural and atomistic insights that explain the 







This study employed in-house pre-molecular dynamics simulation preparation protocols as 
reported in our previous reports. The X-ray crystal structures of Human N-myristoyltransferase 1 
and 2 (HNMT 1/2) were obtained from RSCB Protein Data Bank with code 5MU6 and 4C2X 
respectively. HNMT1 was retrieved co-crystallized with the novel inhibitor IMP-1088 while the 
HNMT2-IMP-1088 complex, on the other hand, was prepared by docking the 2D structure of IMP-
1088 into its substrate binding pocket. 
 A 100ns MD simulation was conducted using the AMBER18 Suite with its CPPTRJ and PTRAJ 
modules employed analyzing generated MD trajectories.  
 
Results/Discussion 
Sequence and nanosecond-based analyses identified Tyr296, Phe190, Tyr420, Leu453, Gln496, 
Val181, Leu474, Glu182, and Asn246 as residues common within the binding pockets of both 
HsNMT1 and HsNMT2 subtypes whose consistent interactions with IMP-1088 could underpin the 
basis for its dual inhibitory potency 
Consistent interaction of IMP-1088 with Tyr296 in both enzymes resulting in the displacement of 
the Tyr296 chain and enhancing the burial of compound IMP-1088 within the hydrophobic pockets 
is also confirmed 
Structural changes upon IMP-1088 binding reveal a characteristic impeding of residue 
fluctuations, structural compactness, and a consequential burial of crucial hydrophobic residues, 
features required for HsNMT1/2 functionality. 
A quantification of the energy contributions of prominent interacting residues to the binding of 
IMP-1088 in both HNMT1/2 showed that these residues contributed the highest energies <-1 
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kcal/mol, further establishing the essentially of these residues in the dual-targeting prowess of 
IMP-1088  
Estimated total binding of IMP-1088 in HNMT1/2 revealed near-similar ΔGs of -35.20kcal/mol 
and -30.42kcal/mol respectively while the higher binding exhibited in HNMT1 could be attributed 
to stronger active site interactions.  
Conclusions 
Dual-targeting activity of IMP-1088 is mediated by its interaction with specific residues (Tyr296, 
Phe190, Tyr420, Leu453, Gln496, Val181, Leu474, Glu182 and As246) accompanied by peculiar 
structural changes.  
Findings unveil interesting atomistic and structural perspectives into dual inhibitory activity of 
IMP-1088 against HNMT1/2 while providing the basis for the design of novel dual-acting 
inhibitors of N-myristoltransferase towards the treatment of common cold.  
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Therapeutic targeting of folate biosynthetic pathway has recently been explored as a viable strategy 
in the treatment of tuberculosis. The metabolite substrate of Para-amino salicyclic acid (PAS-M) 
reportedly dual-targets dihydrofolate reductase (DHFR) and flavin-dependent thymidylate 
synthase (FDTS), two essential enzymes in folate biosynthetic pathway. However, the molecular 
mechanisms and structural dynamics of this dual inhibitory activity of PAS-M remain elusive. 
Molecular dynamics simulations revealed that binding of PAS-M towards DHFR is characterized 
by a recurrence of strong conventional hydrogen bond interactions between a peculiar DHFR 
binding site residue (Asp27) and the 2-amino-decahydropteridin-4-ol group of PAS-M. Similarly, 
the binding of PAS-M towards FDTS also involved consistent strong conventional hydrogen bond 
interactions between some specific residues (Tyr101, Arg172, Thr4, Gln103, Arg87 and Gln106) 
and the 2-amino-decahydropteridin-4-ol group, thus establishing the cruciality of the group. 
Structural dynamics of the bound complexes of both enzymes revealed that, upon binding, PAS-
M is anchored at the entrance of hydrophobic pockets by a strong hydrogen bond interaction whiles 
the rest of the structure gains access to deeper hydrophobic residues to engage in favorable 
interactions. Further analysis of atomistic changes of both enzymes showed increased C-α atom 
deviations as well as an increase C-α atoms radius of gyration consistent with structural 
disorientations. These conformational changes possibly interfered with the biological functions of 
the enzymes and hence their inhibition as experimentally reported. Structural insights provided 
could open up a novel paradigm of structure-based design of multi-targeting inhibitors of 
biological targets in the folate biosynthetic pathway towards tuberculosis therapy. 
Keywords: Mycobacterium tuberculosis, tuberculosis, dihydrofolate reductase, flavin-dependent 










As the leading cause of death from a single infectious disease, Tuberculosis (TB) is caused by  
Mycobacterium Tuberculosis (Mtb) [1].  In 2017, TB caused an estimated range of  1.2–1.4 million 
deaths among HIV-negative people and an additional 266000–335000 deaths from HIV-positive 
co-infected TB patients [1]. In a high TB burden country such as South Africa, the high mortality 
rates associated with TB is compounded by the co-infection with human immunodeficiency virus 
(HIV) [1–3]. In 2017 alone, South Africa contributed about 3% of the total global TB  cases [1,4]. 
In other to curb this global menace, several chemotherapeutic options against the mycobacterium 
have been widely explored over the years with reasonably high success rates towards treatment 
and cure of tuberculosis [5–7]. Nonetheless, these efforts have been challenged by treatment 
failure, poor adherence and the development of drug-resistant strains largely due to the long 
duration of the treatment regimen of a minimum of six months [8–10]. 
Drug resistance in TB  therapy, in particular, has contributed massively to the associated high 
mortality rates of TB such that in 2017 a range of 483000–639000 people developed rifampin 
resistant TB (RR-TB) alone [1,11–13].  With a high incidence of resistance in recent years, there 
have been reports of a subsequent relapse of the disease as well [14,15]. This has therefore led to 
a rise in the search for new therapeutic alternatives possibly targeting new enzymatic biomolecules 
implicated is various essential pathways. One of such high-value drug target therapeutic 
alternatives is the bacterial folate cycle, which is utilized in a wide range of bacterial metabolic 
processes, including DNA replication and repair[16].  
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During the folate biosynthetic pathway, dihydrofolate reductase (DHFR) is utilized as a catalyst 
to convert dihydrofolate to tetrahydrofolate. The tetrahydrofolate is acted on by serine 
hydroxymethyl transferase (SHMT) to form N5, N10 Methylene tetrahydrofolate. The 
tetrahydrofolate is further utilized as a precursor for thymidine synthesis. During this process, 
thymidylate synthase (TSase) enzyme converts N5,N10-methylene-tetrahydrofolate (MTHF) and 
2′-deoxyuridine-5′-monophosphate (dUMP) to 2′-deoxythymidine-5′-monophosphate (dTMP) 
and dihydrofolate (DHF). The dTMP is then utilized in bacterial DNA synthesis. Subsequent to 
dTMP production, the DHF can then be recycled through DHFR in the folate pathway mentioned 
above [17] (Figure 8.1). Interestingly, it was also found that flavin-dependent thymidylate synthase 
(FDTS) also allowed for dTMP production by converting DHF to MTHF. This provided a dual 
role by producing dTMP, as well as reducing DHF to MTHF [17].  
 
 
Figure 8.1: Schematic of the folate biosynthetic pathway 
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Of the plethora of studies directed toward identifying inhibitors against Mtb replication, Para-
amino salicyclic acid (PAS) is the only effective antifolate that is currently in use. The use of PAS 
in combination therapy has been evidenced to potentiate the anti-bacterial properties of isoniazid 
and streptomycin, especially against Mtb [18]. A Recent study by Haijan et al (2019) identified 
PAS as one of the very few drugs that are currently used in drug-resistant tuberculosis and further 
established its use as an alternative substrate in folate biosynthesis. Subsequent to PAS 
metabolism, the substrate is converted to PAS-M, which has shown inhibitory characteristics 
against both DHFR, although it exhibited poor binding affinity [19]. Haijan et al further explored 
the possibility of PAS-M binding to FDTS due to the structural similarities between PAS-M and 
mTHF, since mTHF is able to bind to FDTS. Their report through differential scanning calorimetry 
(DSC) revealed that PAS-M increases in melting temperature (Tm) stability implying a stabilizing 
effect of PAS-M and therefore and hence confirming its binding to Mtb FDTS. This confirmed 
dual-enzymatic binding portrayed by PAS-M may be used to overcome Mtb drug resistance by 
inhibition of more than one rate-limiting enzyme. It may also allow decreased adverse drug 
interactions due to combination therapy against tuberculosis, as well as HIV/tuberculosis co-
infections.   
Although experimental studies have defined PAS-M as an inhibitory lead molecule against DNA 
replication and repair of Mtb, there is missing evidence on the structural mechanism by which 
PAS-M inhibits the above-mentioned enzymes. To further progress through the rational drug 
design process, as well as to allow for the optimization of this lead molecule, the structural 
inhibitory mechanism of the drug is required. In this study, we therefore employ molecular 
dynamics simulations (MD) coupled with binding free energy calculations, to provide additional 
molecular and structural insights associated with the mechanistic binding of PAS-M towards both 
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DHFR and FDTS. We also elucidate the recognition mechanisms that characterize the selective 
binding of PAS-M towards mycobacterial DHFR and FDTS. Molecular dynamics simulations is 
a reliable computational technique extensively explored to mimic the dynamical events of 
molecular systems as a function of time, with a molecular description of all biological components 
(ligand and protein) in a solvent space [20]. Findings from this study will also provide important 
atomistic and structural perspectives that could aid in the design of novel multi-targeting TB 
therapy. 
 
2.0 COMPUTATIONAL METHODOLOGY 
2.1 System preparation and MD simulations 
 
The X-ray crystal structures of DHFR and FDTS were retrieved  from the RSCB Protein Data 
Bank with codes 6DDW and 2DQ7 respectively [21,22].  These structures were then prepared for 
molecular dynamics (MD) simulations using UCSF Chimera [23] and the Molecular Molegro 
Viewer (MMV)[24]. For the purpose of this study all nonstandard molecules co-crystallized with 
the enzyme structures were removed in preparation for the MD simulation to reduce computational 
cost and missing residues were added using Modeller, a structural refinement tool incorporated in 
UCSF Chimera [25]. The 3D structure of PAS-M was retrieved from the PDB structure 6DDW in 
which it was co-crystallized with DHFR and prepared for molecular docking into the binding of 
2DQ7 and subsequently MD simulation. Molecular docking of PAS-M into the FDTS binding 
pocket was performed using AutoDock Vina [26] incorporated in UCSF Chimera with default 
docking parameters. In preparing for the molecular docking, PAS-M was supplemented with 
Gasteiger charges followed by non-polar hydrogen bonds which were merged to the carbon atoms 
prior to docking. The binding site was defined using coordinates obtained from co-crystalized 
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inhibitor with FDTS. A grid box with a spacing of 1 Å and size of 11.27 ×11.08× 8.88 pointing in 
x=-2.03, y=7.21 and z=-11.06 directions). The best-docked pose for each ligand was then subjected 
to 100ns molecular dynamic simulations. Altogether, 4 systems comprising of unbound and PAS-
M bound forms of DHFR and FDTS were subjected to MD simulations using the Amber18 
software package [27]. Protein optimization and explicit solvation were carried out using the 
integrated LEAP module while the AMBER FF14SB forcefield was employed to define protein 
parameters[28]. The systems were partially minimized for 2500 steps with a restraint potential of 
500kcal/mol Å2 followed by full minimization of 10000 steps. The systems were gradually heated 
from 0-300K using a Langevin thermostat in a canonical ensemble (NVT) [29]. Equilibration was 
also carried out without restraints at a temperature of 300k in an NPT ensemble for 1000ps while 
atmospheric pressure was maintained at 1bar using the Berendsen barostat [30]. This was followed 
by MD production runs of 200ns for each system during which the SHAKE algorithm was used to 
constrict all atomic hydrogen bonds [31]. The integrated CPPTRAJ and PTRAJ modules [32] of 
AMBER18 were used to analyze resulting coordinates and trajectories while obtained data were 
plotted using Microcal Origin software [33]. UCSF Chimera was also used to visualize and analyze 
structural events. These are in accordance with our in-house MD simulation protocol that has been 
previously reported [34,35]. 
 
2.2 Binding free energy calculations 
In order to estimate the binding interactions of PAS-M to DHFR and FDTS, binding free energy 
calculations were carried out using the Molecular Mechanics/Poisson-Boltzmann Surface Area 
(MM/PBSA) method [36,37]. This approach has been widely employed in several reports [38–
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41]and has proven to be reliable in measuring binding free energies involved in protein-ligand 
complex formation. Moreover, MM/PBSA is mathematically represented as follows: 
ΔGbind = Gcomplex – Greceptor – Gligand    (1) 
Egas = Eint + Evdw +Eele     (2) 
Gsol = GGB/PB + GSA      (3) 
GSA = γSASA       (4) 
Where van der Waals and electrostatic interactions are represented as Evdw and Eele while Egas 
denote gas-phase energy and Eint as internal energy. The solvation free energy, denoted by Gsol 
represents. Gsol is obtained by a summation of the polar and nonpolar contribution states. To obtain 
the polar solvation contribution, GGB/PB, the GB/PB equation solved. Using a 1.4Å water probe 
radius, the nonpolar solvation contribution, GSA, was  calculated from the solvent accessible 
surface area (SASA. Per-residue decomposition analyses were also carried out to estimate 
individual energy contribution of binding site residues to the stabilization and affinity of masitinib. 
This could provide more insights into the basis of the pan-inhibition exhibited by masitinib since 
high residual energy contributions could depict crucial residues. 
 
 
3.0 RESULTS AND DISCUSSION 
3.1 Assessing structural stability among the simulated models 
It was important to ensure that the unbound and bound systems converged and were structurally 
stable during the 100ns MD production run to avoid disrupted motions and simulation artifacts. 
Therefore, C-α Root Mean Square Deviation (RMSD) was employed to measure structural 
stability across the studied systems. This parameter is used to estimate deviations within the 
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backbone atoms of the respective protein forms. A high RMSD value depicts an increased 
deviation in backbone atoms while on the other hand, a low RMSD value implies reduced motions 
in backbone atoms and could, in turn, explain structural stability[42–44]. The RMSD plots for 
DHFR and FDTS systems showed convergence at the beginning of the MD simulation run until 
~50ns where distinct separation in atomistic motions occurred among PAS-M-bound and unbound 
enzyme forms (Figure S1). As shown in figure S1, the binding of PAS-M to DHFR was 
characterized by  an increase in deviation among the backbone atoms (1.65Å) relative to its 
unbound conformation which exhibited relative structural stability with a lower average RMSD of 
1.29Å. Presumably, disruption of the backbone atoms in DHFR upon inhibitor binding could 
highlight the mechanistic inhibitory activity of PAS-M, since an induced loss of structural integrity 
in a protein correlate with loss of functionality [45–47]. In contrast to its influence of increase C-
a atom deviation on DHFR, the binding of PAS-M on FDTS was characterized by a decrease in c-
a atom deviation with an average RMSD of 1.65Å relative to higher average RMSD of 3.30Å. It 
could therefore be inferred that although the binding of PAS-M generally induced stabilized 
systems with average RMSD values less than 2Å, the was contrasting effect on the stability of both 
DHFR and FDTS which could be attributed to difference in amino acids sequences of the enzymes. 
 
3.2 Exploring the mechanism of PAS-M binding towards DHFR and FDTS 
The ability of a drug molecule to elicit its therapeutic (inhibitory) function is centered on its activity 
at the binding site of its target protein. Moreover, inter-molecular interactions with 
catalytic/allosteric site residues contribute significantly to ligand selectivity, binding affinity and 
stabilization. Therefore, it was essential to investigate the binding of PAS-M to DHFR and FDTS 
in order to understand the molecular basis of its dual inhibition. Firstly, we estimated binding free 
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energies involved in the interaction of PAS-M with the two enzymes using the MM/PBSA-based 
approach. Our results revealed that PAS-M bound favorably with DHFR and FDTS with ΔG 
values of -41.46kcal/mol and -20.72kcal/mol respectively (Table 8.1). The observed prominent 
difference in the estimated ΔG values could indicate dissimilar modes of binding that possibly 
underlie the observed difference in the impact of PAS-M binding on the respective stability of both 
enzymes. This may likewise be attributed to the varying prominent difference in the amino acid 
sequences of both enzymes. In addition, relatively high electrostatic and van der Waals interactions 
were involved in the binding of PAS-M towards DHFR could have accounted for its higher binding 
affinity relative to FDTS (Table 8.1).  
 
Table 8.1: MM/PBSA-based binding free energy profile of PAS-M 
 
ΔEele = electrostatic energy; ΔEvdW = van der Waals energy; ΔGbind = total binding free energy; ΔGsol = 
solvation free energy ΔG = gas phase free energy. 
 
3.3 Probing the interaction dynamics of PAS-M at DHFR and FDTS binding site 
Furthermore, molecular visualization was used to obtain insights into the activity of PAS-M at the 
respective binding pockets of DHFR and FDTS with respect to its affinity, stabilization and dual 
Systems Energy components 
(kcal/mol) 

































inhibitory activity. Also, this was fundamental to the identification of key binding site residues 
and their corresponding interactions with PAS-M. As shown in Figure 8.2 and 8.3, certain residues 
of the hydrophobic deep pocket elicited strong interactions with PAS-M, which accounted for its 
stability and high affinity towards both enzymes. These interactions vary from strong hydrogen 
bond interactions to general hydrophobic interactions.  
To understand the interaction dynamics of PAS-M at the binding pockets of DHFR and FDTS, we 
noted certain residues that interacted consistently, steadily and intermittently across the 100ns MD 
simulation time. These modes of interactions could relatively provide necessary details and 
insights into the molecular basis and mechanisms of PAS-M selectivity and high-affinity binding 
towards the two proteins. As shown in figure 8.2, among all interactions caused by PAS-M-binding 
towards DHFR, there was a recurrence of certain residues that consistently formed strong 
interactions with PAS-M during the simulation. Notable amongst these residues is Asp27 which 
consistently maintained a strong hydrogen bond interaction with the amino group of the 2-amino-
decahydropteridin-4-ol group of PAS-M. Other hydrogen bonded residues observed included; 
Arg60 at 10ns and Arg23 at 100ns. These hydrogen bond interactions in addition to the numerous 
hydrophobic interactions with other binding pockets residues could have collectively contributed 
to the favorable binding free energies calculated. Moreover, PAS-M was anchored at the entrance 
of the hydrophobic pocket by a strong hydrogen bond with Arg60 at 10ns and Arg23 at 100ns.  
This anchorage over the simulation period could allowed for its steady interactions of PAS-M with 
other hydrophobic residues as observed while also permitting its deep access of other hydrophobic 
residues. Access to the deep hydrophobic pocket allowed for favorable interactions with other 
hydrophobic residues which could have contributed to the total binding free energy of PAS-M 
towards DHFR. Altogether, these strong hydrogen bond interaction at the entrance of the 
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hydrophobic pocket and with the deeply embedded residues could suggestively have accounted 
for favorable affinity binding of PAS-M towards DHFR.  
 
Figure 8.2: Structural positioning and orientation of PAS-M at the hydrophobic grooves of DHFR depicting 
residues within the binding pockets at 10 ns [a], 50 ns [b] and 100 ns [c]. Hydrophobic surface 
representations of PAS-M-bound within the DHFR binding pockets (blue), highlighting hydrogen bond 
interacting residues at 10 ns [a1], 50 ns [b1] and 100 ns [c1]. 
 
Similarly, the binding of PAS-M towards FDTS was also characterized consistent strong hydrogen 
bond interactions with some specific residues over the course of the simulation.  Notable amongst 
these residues are Tyr101, Arg172, Thr4, Gln103, Arg87 and Gln106. Tyr101 in particular 
recurred throughout the simulation period. Similarly, PAS-M is anchored at the entrance of 
hydrophobic pocket by strong hydrogen bond interactions whiles the rest of the compound gains 
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access to deeper hydrophobic residues for corresponding favorable interactions. These consistent 
and steady interactions with these residues could have equally accounted for the favorable binding 
free energies towards FDTS as estimated. 
Figure 8.3:  Hydrophobic surface representations of PAS-M-bound within the FDTS binding pockets 
(blue), highlighting hydrogen bond interacting residues at 10 ns [a], 50 ns [b] and 100 ns [c].. Structural 
positioning and orientation of PAS-M at the hydrophobic grooves of FDTS depicting residues within the 
binding pockets at 10 ns [a1], 50 ns [b1] and 100 ns [c1] .  
 
 
Taken together, residues that consistently interacted with PAS-M towards the binding of both 
DHFR (Arg27) and FDTS (Tyr101) over the simulation period were shown to consistently interact 
with the amino moiety on the 2-amino-decahydropteridin-4-ol group of PAS-M. This could imply 
that interactions of this amino group could be crucial for high-affinity binding, and stability of 
PAS-M in the hydrophobic binding pockets of both enzymes and could as well account for the 
dual binding activity of PAS-M towards DHFR and FDTS.  
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The critical roles of the interactions engaged in by the amino moiety on the 2-amino-
decahydropteridin-4-ol group were further revealed via per-residue decomposition analyses, which 
provided a quantitative insight into the energy contributions of individual residues that interacted 
with PAS-M at the DHFR and FDTS binding pockets over the 100ns MD simulation duration, 
particularly Arg27 and Tyr101 respectively. As presented in figure 8.4, residues which formed the 
strongest bonds contributed the highest energies towards the binding PAS-M to either of the 
enzymes as expected. In the PAS-M-DHFR complex as shown figure 3a, residues Asp27, Arg60 
and Arg23 contributed the highest energies towards binding with total energies of -58.07kcal/mol, 
-54.29kcal/mol and -166.07kcal/mol respectively. This reaffirms the prominence of these residues 
in the inhibition of DHFR. Likewise, as shown in figure 3a', residues, Tyr101, Arg172, Gln103, 
Arg87 and Glu3 contributed the most as well towards the binding of FDTS with total energies of 
-170.37kcal/mol, -171.66kcal/mol, -43.20kcal/mol, -164.41kcal/mol and -103.88kcal/mol. 
Also, it was revealed that binding site residues in both DHFR and FDTS also contributed 
significant electrostatic energies towards the total binding of PAS-M which could accounted for 




Figure 8.4 : Per-residue decomposition plots showing individual energy contributions to the binding and 
stabilization of PAS-M at the hydrophobic grooves of DHFR[a]  and FDTS [a1].  This reveals that energy 
contributions were highest in residues that formed hydrogen bond interactions with PAS-M. Corresponding 







3.4 Structural dynamics of hydrophobic deep pockets upon PAS-M binding 
In furtherance to the peculiarities of the dual acting activity of PAS-M towards DHFR and FDTS 
as revealed in the corresponding residue interaction dynamics over the simulation period, we 
proceeded to investigate the dynamics of the hydrophobic deep pockets with respect to the dual 
and favorable binding of PAS-M. In other words, while we first investigated the dynamics of PAS-
M at the respective binding pockets of both enzymes, we further explored the dynamics of their 
hydrophobic deep pocket residues upon the binding of PAS-M across the 100ns MD simulation 
time. This investigative approach necessitated the use of metrics such as C-α root mean square 
deviation (RMSD) and C-α radius of gyration (RoG) to describe the stability and compactness 
among hydrophobic pocket residues. According to previous studies, the stability and compactness 
of these residues could influence their corresponding interactions with bound inhibitors and hence 
can be employed to describe per-residue fluctuations across a protein’s secondary structure while 
C-α RoG can be used to predict structural compactness, perturbations and atomistic mobility 
[35,46,48].  As shown on figure 8.5, the binding of PAS-M towards DHFR increased the deviation 
of C-α atoms of binding site residues within DHFR with an average RMSD of 2.57Å relative to 
the unbound conformation which exhibited a lower average RMSD of 1.29Å.  Similarly, the 
binding of PAS-M towards FDTS also induced an increased deviation of C-α atoms deviation of 
active site residues with an average RMSD of 8.09Å relative to the unbound conformation which 
also exhibited an average RMSD of 3.43Å. It can therefore be implied that the binding of PAS-M 
to both enzymes is characterized by increased instability of the binding site residues which could 
have contributed to its favorable inhibition of both enzymes as experimentally reported [19]. 
Likewise, the instability of the binding site residues due to the inhibitory presence of PAS-M have 
distorted the original conformation of the enzymes required for their biological functions. 
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Presumably, systemic structural C-α atoms deviation of active site could highlight a possible 
mechanism by which PAS-M exhibit its dual-inhibitory activities against these enzymes, that in 
turn result in the disruption of their biological activities.  
 
Figure 8.5: Comparative C-α RMSD plots showing the degree of instability and disruption induced by 
PAS-M at the binding pocket of DHFR and FDTS. Also shown is the binding site superposition of unbound 
(violet) and PAS-M-bound (red) forms of the two enzymes. 
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This presumption was further verified by calculating the C-α radius of gyration, which is able to 
depict the structural compactness of the binding pockets residues in both DHFR and FDTS across 
the MD simulation time of 100ns. As shown in figure 8.6, binding site residues of both enzymes 
exhibited increased radius of gyration of C-α atoms with an average RoG of 9.82Å and 9.65Å for 
DHFR and FDTS respectively. Active site residues of the unbound DHFR and FDTS exhibited 
lower average RoG of 8.24Å and 8.26Å. It could therefore imply that the binding of PAS-M also 
decreased the compactness of these residues, consistent with the increased deviation of C-α atoms 







Figure 8.6: A) Comparative compactness of PAS-M binding site residues of FDTS in the presence and 
absence of PAS-M. Binding site residues in the unbound FDTS were more compact relative to the PAS-M 
bound conformation with averagely lower RoG of 8.26 Å. B) Comparative compactness of PAS-M binding 
274 
 
site residues of DHFR in the presence and absence of PAS-M. Binding site residues in the unbound DHFR 
were more compact relative to the PAS-M bound conformation with averagely lower RoG of 8.24 Å 
 
Taken together, we could suggest that PAS-M selectively targets binding pockets residues of both 
enzymes and disrupts their original conformation by increasing their C-α atom deviations as well 
as their C-α atoms radius of gyration. These conformational changes could in turn have interfered 




Employing advanced computational techniques and MD simulations, this study aims to provide 
molecular perspectives into the dual inhibitory mechanisms of PAS-M towards DHFR and FDTS 
which are crucial in the folate biosynthetic pathway. Differential binding of PAS-M to these 
enzyme targets was measured using the MM/PBSA method, which revealed favorable interactions 
with ΔG values of -41.46kcal/mol and -20.72kcal/mol towards DHFR and FDTS respectively. The 
favorable binding free energies as estimated confirms the possible inhibitory activity of PAS-M 
towards DHFR and FDTS. Investigations into the interaction dynamics of PAS-M at the binding 
pockets of DHFR and FDTS revealed crucial structural insights that could have favored its dual 
binding activity. The interaction of PAS-M with DHFR was characterized by a recurrence of 
certain residues that consistently formed strong interactions with PAS-M during the simulation, 
notably Asp27 which consistently maintained a strong hydrogen bond interaction with the amino 
group of the 2-amino-decahydropteridin-4-ol group of PAS-M. Similarly, the binding of PAS-M 
towards FDTS involved consistent strong hydrogen bond interactions with some specific residues 
over the course of the simulation, notably, Tyr101, Arg172, Thr4, Gln103, Arg87 and Gln106. 
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Interestingly, upon binding to either enzyme, PAS-M is anchored at the entrance of hydrophobic 
pocket by a strong hydrogen bond interaction whiles the rest of the compound gains access to 
deeper hydrophobic residues for corresponding favorable interactions. Quantification of the energy 
contributions through per-residue energy decomposition analysis further revealed that, these same 
residues contributed the most towards total binding of PAS-M, further establishing their cruciality 
to enzyme inhibition. Analysis of the conformational changes of both enzymes upon PAS-M 
binding revealed increased C-α atom deviations as well as an increase in their C-α atoms radius of 
gyration. These conformational changes could in turn have interfered with the biological functions 
of these enzymes and hence their inhibition as experimentally reported. Identification of the 
recurring residues and their crucial roles could open up a novel paradigm of structure-based design 
of highly selective multiple targeting inhibitors of the foliate biosynthetic pathway in the treatment 
of tuberculosis, amidst the rise in TB drug resistance. A further exploration of the 2-amino-
decahydropteridin-4-ol group of PAS-M could serve as a baseline for the design of new therapeutic 
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Therapeutic targeting of the ATP machinery of Mycobacterium tuberculosis (Mtb) has recently 
presented a potent and alternative measure to halt the pathogenesis of tuberculosis. This has been 
potentiated by the development of Bedaquiline (BDQ), a novel small molecule inhibitor that 
selectively inhibit mycobacterial F1Fo-ATP synthase by targeting its rotor c-ring, resulting in the 
disruption of ATP synthesis and a consequential cell death. Although, the structural resolution of 
the mycobacterial C9 ring in complex with BDQ provided a first-hand detail of BDQ interaction at 
the c-ring region of the ATP synthase, there still remains a need to obtain essential and dynamic 
insights into the mechanistic activity of this drug molecule towards a crucial survival machinery 
of Mtb. As such, for the first time, we report an atomistic model to describe the structural dynamics 
that explicate the experimentally reported antagonistic features of BDQ in halting ion shuttling by 
the mycobacterial c-ring, using molecular dynamic (MD) simulation and MM/PBSA methods. 
Results showed that BDQ exhibited a considerably high ΔG while it specifically maintained high-
affinity interactions with Glu65B and Asp32B, blocking their crucial roles in proton binding and 
shuttling which is required for ATP synthesis. Moreover, the bulky nature of BDQ induced a rigid 
and compact conformation of the rotor c-ring which impedes the essential rotatory motion that 
drives ion exchange and shuttling. In addition, the binding affinity of a BDQ molecule was 
considerably increased by the complementary binding of another BDQ molecule, which indicates 
that an increase in BDQ molecule enhances inhibitory potency against Mtb ATP synthase. Taken 
together, findings provide atomistic perspectives into the inhibitory mechanisms of BDQ coupled 
with insights that could enhance the structure-based design of novel ATP synthase inhibitors 
towards the treatment of tuberculosis. 









Tuberculosis (TB), as an infectious disease, has existed for a millennium but still remains a major 
global health concern. TB is caused by the bacillus, Mycobacterium tuberculosis (Mtb) and 
currently ranks above HIV/AIDS as the leading cause of death globally from a single infectious 
agent [1, 2]. The global incidence of TB in 2017 alone was estimated to about 10 million recorded 
cases in which the WHO South Asia region recorded the highest incidence of 44% followed by 
the WHO Africa region with about 25% of total global incidence. South Africa remains prominent 
in its contribution to total global TB burden, contributing about 3% in 2017 alone to the total global 
incidence. Nonetheless, there has been a steady decline in TB in many southern African countries, 
including South Africa between years 2010-2017. The co-infection of TB with HIV has also 
contributed immensely to its current global mortality rate. For instance, in 2017, over 50% of TB 
case were co-infected with HIV in Southern African countries. However, there has also been a 
steady decline death from TB-HIV co-infection as well in the last few years due to an increase 
coverage of antiretroviral therapy in high burden regions. The major impediment to the treatment 
of TB over the years remains the development of resistance of the mycobacterium to current 
therapeutic option. A suitable treatment regimen for TB majorly involves a combinatorial 
therapeutic approach that constitute at least four drugs namely isoniazid, rifampin, pyrazinamide 
and ethambutol [3]. Strains resistant to only one first-line anti-TB agents are categorized and 
mono-resistant TB, of which Rifampin resistance is the most common. On the other hand, 
resistance to both rifampicin and isoniazid is referred as multi-drug resistant TB (MDR-TB) and 
has been categorized as poly-resistant TB. MDR-TB cases are treated with second-line TB drugs 
which are usually more toxic and less effective as compared to the first-line agents [4, 5]. MDR-
TB in which the mycobacterium also develops resistance to any fluoroquinolone and at least one 
of the three second line injectables (capreomycin, kanamycin and amikacin) is further referred to 
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as extensively drug resistant tuberculosis (XDR-TB). In recent years, the most virulent form of 
resistant TB has been classified as totally drug resistant TB (TDR-TB) in strains are resistant to 
all the first second line TB drugs [4, 6, 7]. Hence, there has been a continual surge in the 
identification of potent and highly effective therapeutic molecules that target crucial elements 
(such as protein) involved in the pathogenesis and virulence of Mtb [8, 9]. In this regards, targeting 
the rotor ring of Mtb’s F1Fo-ATP synthase (henceforth F1Fo) has been explored over the years as a 
viable therapeutic option considering the crucial the role it plays in ATP synthesis of the 
mycobacterium [3]. The F1Fo-ATP synthase is a macromolecular, membrane-embedded protein 
complex in MTB that uses the transmembrane electrochemical ion (H+ or Na+) gradient to convert 
adenosine diphosphate (ADP) and inorganic phosphate (Pi) into adenosine triphosphate (ATP) by 
a rotary mechanism [10–13] during respiration. The membrane-embedded Fo domain of the 
complex harbors the rotor ring of the F-type ATP synthase which usually consists of identical 
copies of c-subunits that form an hourglass-shaped cylinder with a central pore (c-ring) in the 
bacteria [14]. F1Fo-ATP synthase shuttles ions across the membrane and thereby powers the 
synthesis of ATP within the three catalytically active sites of the F1 headpiece [10]. A report by 
Andries et al., in 2005, identified bedaquiline (BDQ) , via phenotypic screening, as an 
antitubercular agent which was subsequently approved by the FDA in 2012 as a member of the 
chemical class of diarylquinolines to inhibit F1F0 in mycobacteria [3, 15]. The inhibitory activity 
of BDQ demonstrates that metabolism and energy generation is a promising new target space in 
inhibiting mycobacteria. By acting as an ionophore, BDQ blocks shuttling  H+ and K+ ions across 
membranes [16]. The recently published structure of the c-ring from Mycobacterium phlei with 
bound BDQ suggested the selectivity of BDQ for only mycobacterial species as against other 
prokaryotic and eukaryotic organisms [17].  
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According to Preiss et al., BDQ has a high specificity and affinity towards the mycobacterial c-
ring of M. phlei where it binds in a lock and key fashion, with a virtually complete sequence 
conservation of this region, which suggests an identical surface profile  and binding site geometry 
possibly in all mycobacteria, and most importantly, M. tuberculosis [17]. The binding of BDQ to 
the c-ring rotor of the Fo of  mycobacterial ATP synthase results in an eventual inhibition of ATP 
synthesis leading to mycobacterial death [3, 17–20]. Although the crystal structure of F1F0 in 
complex with BDQ has been resolved experimentally, there has been little or no insights into the 
mechanisms, structural dynamics and conformational changes that accompanies the binding of 
BDQ. Moreover, these insights could be crucial to the development of novel small molecule 
inhibitors of mycobacterial F1F0 ATP synthase, most especially in the treatment of TB. Figure 9.1 
shows a 3D representation of F1F0-ATP synthase subunit c in complex with BDQ. 
The application of computational (in silico) methods in providing structural insights into the 
binding of small molecule inhibitors has gained prominence in the drug discovery process in recent 
years.  Insights from computational reports can aid in the optimization of existing small molecule 
compounds to yield enhanced and improved novel small molecule inhibitors and eventually 
improve the overall efficiency of the drug discovery process [21, 22]. Computational approaches 
have been employed in the study of several conditions and for varying purposes including 
mutational studies and the identification of new inhibitors. In mutations studies computer aided 
techniques have aided in unravelling the structural dynamics of mutant proteins as well as 
revealing the impact of mutations on the activity of bound inhibitors [23–27] while techniques 
have focused on the identification of novel compounds from large pool of existing databases[28]. 
However, in the present report, molecular dynamics simulation coupled with other computational 
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approaches was employed to provide, for the first time, atomistic insights into the reported 
ionophoric features of BDQ relative to the inhibition of ATP synthesis in Mtb.   
 
Figure 9.1: [A] Surface depiction of the mycobacterial c-ring F1F0-ATP synthase (green) bound by BDQ 
(grey). Also, active site and BDQ-interacting residues are depicted in yellow coloration and clearly shown 
in red inset. [B] 2D structure of BDQ showing constituent functional groups. 
 
 
2.0 Computational methodology 
2.1 System preparation 
The X-ray crystal structure of the c-ring rotor (Fo portion) of mycobacterial ATP synthase was 
obtained from RSCB Protein Data Bank with code 4V1F [17], which was already complexed with 
Bedaquiline (ID:5388906). This complex was then prepared for simulation using UCSF Chimera 
[29] and the Molecular Molegro Viewer (MMV) [30], a technical procedure that basically involves 









structure comprised of three chains A, B and C with BDQ bound to all three, however only the 
central region of the three BDQ molecules within the crystal structure was visible whereas parts 
of the other two molecules were partially visible. In this report our focus was restricted to the 
interaction of a single molecule of BDQ with the F1F0 structure. As such the two partially visible 
BDQ molecules were taken off leaving just the full visible molecule in the middle to reduce 
computational cost. Eventually, two systems which comprised of a BDQ-bound F1F0 and an 
unbound (apo) form of the ATP synthase were set up for the molecular dynamic (MD) simulation. 
An additional system was setup comprising two molecules of BDQ bound to F1F0 using UCSF 
Chimera-integrated AutoDock Vina module and the Molecular Molegro Viewer (MMV) to depict 
a dual BDQ-bound F1F0 ATP synthase. This was necessary to investigate the inhibitory prowess 
of dual BDQ molecules on ion-shuttling as compared to single-bound systems, a rationale that was 
aimed at providing important atomistic perspectives based on the report by Preiss et al in which 
they stated that an increased concentration of BDQ could result in the binding of the membrane 
exposed ion binding sites of the c-ring of ATP synthase by one or more molecules of BDQ with 
enhanced inhibitory potency [17]. 
 
 
2.2 Molecular dynamics (MD) simulations  
 
This was performed using the GPU version of AMBER 14 with an integrated PMEMD module 
[31], according to standard simulation protocols, which has been previously adopted in previous 
studies and enumerated as follows [32–36]. Parameterization of the inhibitor was carried out using 
the ANTECHAMBER module wherein atomic partial charges (AM1BCC) gaff, using the bcc 
charge scheme were generated [37]. The FF14SB AMBER force field [38] was then used to 
parameterize the protein. Using the LEAP module, hydrogen atoms were also added, while the 
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entire system was neutralized by the addition of counter ions (Na+, Cl-) followed by a subsequent 
generation of ligand, protein and complex topologies as well as parameter files. The systems were 
explicitly solvated with water using the TIP3P orthorhombic box size of 7Å, which enclosed all 
atoms of the protein [39]. Before running the LEAP module, the pdb4amber script was executed 
to protonate the histidine residues at a constant pH (cpH). This was appointed to automatically 
modify the protein system for use with LEAP.  Both complexes were minimized initially for 2000 
minimization steps applying a restraint potential of 500kcal/mol and then fully minimized for 
another 1000 steps of steepest descent without restrain. These minimization steps were run on 2 
computational nodes with 48 cores on a 48 hours wall-time each. Likewise, at these stages, a fixed 
protein algorithm was used to place restraints on the entire protein and hold it within the TIP3P 
water box. This was followed by the gradual thermalization of the systems with a temperature 
range of 0-300K for 50ps. Similar to initial minimization steps, thermalization was performed 
using 2 nodes, 48 cores and walltime of 48 hours. At this stage, restraints were placed on the 
ligands and proteins altogether to prevent their release from the TIP3P solvent box. Afterwards, 
the equilibration process was initialized using similar MPI run as indicated above and performed 
for 500ps while the temperature and pressure were kept constant at 300K and 1bar respectively 
using the Berendsen barostat [40]. This was followed by MD production runs of 100ns, which 
correlated with an nstlim of 50000 steps for each system during which the SHAKE algorithm [41] 
was used to constrict all atomic hydrogen bonds. Also, the iwrap algorithm was equated to 1 and 
used to hold the simulated systems in place due to thermodynamically induced atomic vibrations 
that characterize the production runs. Also, a cut off distance of 12 Å was set for non-bonded van 
der Waals interactions while the default PME method for summation carried out long-range 
adjustments for occurring electrostatic interactions. The MD simulation was initiated using a time 
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step of 1fs and coordinates saved at 1ps interval followed by subsequent analysis of trajectories 
using the integrated PTRJ and CPPTRAJ module [42]. Visualization of the complexes and data 
plots were carried out using the graphical user interface of UCSF chimera [43], and Microcal 
Origin analytical software [44] respectively. Time-scale dynamics and conformational events were 
visually depicted by retrieving selected trajectories and corresponding snapshots which were 
analyzed graphically on the graphical interface of LIGPLOT to generate ligand interaction plots. 
These were further complimented using graphical tools such as BIOVIA discovery studio to 
properly depict structural and molecular occurrences [45][46]. 
2.3 Binding Energy Calculations 
 The Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) [47–50] method was 
used to calculate binding free energy. The binding free energy (DGbind) was calculated from the 
following equation: 
DGbind = Gcomplex - Greceptor + Gligand          (1) 
DGbind = DGgas + DGsol -TDS,                   (2) 
 
where DGbind is considered to be the summation of the gas phase and solvation energy terms less 
the entropy (TDS) term 
DEgas = DEint + D Evdw + D Eelec         (3) 
 
DEgas is the sum of the AMBER force field internal energy terms DEint (bond, angle and torsion), 
the covalent van der Waals (DEvdw) and the non-bonded electrostatic energy component (DEelec). 
The solvation energy is calculated from the following equation: 
 
Gsol = GGB + Gnon-polar                 (4) 
 




The polar solvation contribution is represented as GGB and Gnon-polar is the non-polar solvation 
contribution and is calculated from the solvent assessable surface area (SASA), obtained by the 
use of a 1.4 A° water probe radius. The surface tension constant (c) was set to 0.0072 kcal/mol and 
b to 0 kcal/mol [51]. Per-residue decomposition analyses were also carried out to estimate 
individual energy contribution of binding site resides towards the affinity and stabilization of 
BDQ. This was aimed at providing atomistic insights in the ionophoric properties of BDQ towards 
the inhibition of ATP synthase considering the fact that prominent residual energy contributions 
could highlight essential residues.  
 
3.0 Results and Discussion  
3.1 Conformational dynamics of Mycobacterium tuberculosis’s F1F0 synthase upon BDQ 
binding 
Up till date, no current experimental data reveals the crystal structure for the rotor ring of Mtb’s 
F1F0 synthase thereby accounting for insufficient insights on the inhibitory activity of BDQ 
towards the inhibition of ATP synthesis in Mtb. As such, it was expedient that we employed the 
non-pathogenic Mycobacterium phlei model so as to give a clear molecular insight on the 
mechanistic activity and efficacy of BDQ. This is feasible because the c-ring of M. phlei shares a 
very high sequence homology and identity (83.7%) with	its M. tuberculosis variant, particularly in 
the transmembrane region, where the drug was proposed to bind [3, 52]. Furthermore, the 
minimum inhibitory concentration (MIC) reported for M. phlei was 0.05 mg/ml which is basically 
identical to that reported for M. tuberculosis (0.06 mg/ml) [52, 53], suggesting the identical mode 
of interaction between the drug and the rotor ring in these two species [17]. MD simulation, as a 
reliable computer aided drug design approach employed in this study, allowed for a time-bound 
analysis of the inhibitory impact of BDQ upon binding to Mtb’s F1F0 synthase in an effort to 
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impede ATP synthesis. To ensure the structural stability of the studied systems and trustworthiness 
of the findings from the resulting trajectories, an initial assessment of system convergence was 
performed, which could depict a reliable simulation run. As observed, the systems converged early 
in the simulation period (~20ns) after which they was a notable separation in motions of the Cα 
atoms among the unbound (Apo) and BDQ-bound systems, further signifying that the assumptions 
drawn from the simulated systems were reliable and depict a near accurate representation of the 
structural events that actually characterize the inhibitory activity of BDQ. From the RMSD plots, 
we also evaluated the impact of the binding of BDQ on the overall stability of F1F0 synthase, 
considering how essential, the stability of a protein is to its function. The effect of BDQ on the 
stability of F1F0 synthase as shown in the plot (Figure 9.2A), was very evident as there was an 
obvious decrease in c-α RMSD after the first 20ns relative to the unbound conformation. The 
markedly lower average RMSD of the bound conformation was suggestive of a reduced atomistic 
deviation and a structurally stable F1F0 synthase, as induced by the binding of BDQ. The relatively 
stable conformation could have ensued due to favorable steady interactions of key active site 
residues with BDQ. A further analysis of the inhibitory impact of BDQ on the structural 
conformation of F1F0 synthase was performed by an estimation of the root mean fluctuation 
(RMSF) of the individual residues. Overall, the unbound F1F0 synthase exhibited the highest 
fluctuation of amino acids with an average RMSF value of 10.9 Å relative to the BDQ-bound F1F0 
synthase. However, there was a notable increase in the flexibility of residues at region “60-75” in 
the bound system relative to the unbound conformation (Figure 9.2B). Interestingly, this region 
encompasses the ion binding site on the rotor-stator region of F1F0 synthase. This could suggest 
that although there was a slight decrease in average fluctuation of all residues of F1F0 synthase in 
the presence of BDQ, there was rather a consequential increase in the flexibility of residues that 
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directly interacted with BDQ with a <5Å radius relative to lower flexibility observed in the 
unbound conformation. We further monitored the compactness or tightness of the c-ring which has 
been experimentally reported to play a crucial role in ion exchange in the bacterial ATP synthase 
[17, 54–56] by calculating the radius of gyration (Rg) of  its Cα atoms [35, 57]. As shown in Figure 
9.2D, it was observed that the Rg of binding site residues in the BDQ-bound F1F0 synthase were 
lowered entirely during the 100ns simulation indicative of a highly compact conformation relative 
to the unbound conformation.  
Consequentially, the lower Rg indicates a relatively tighter conformation [35, 57] which would 
make it impossible for BDQ to bypass the barrier created by the pocket thereby resulting in an 
eventual blockage of the rotation of the c-ring followed by a consequential blockage of the ion 
exchange. Moreover, a disruption in the ion exchange mechanisms could consequently halt ATP 
synthesis posing a significant impact on the general bio-energetic metabolism in Mtb, which is 
ultimately fatal to the survival of mycobacteria [20, 58]. Taken together, the binding of BDQ 
lowered the structural activity in the F1F0 synthase model, which could impede or interfere with 







Figure 9.2: Conformational dynamics of F1F0 ATP synthase upon binding of BDQ. A) Plot of the RMSD 
showing a gradual increase in RMSD and subsequent steadying of the systems after about 20ns. B) RMSF 
showing the comparative fluctuations of Glu65B in the bound (BDQ) and the unbound (Apo) systems. Note: 
The scale used is from tleap numbering of residues, F1F0 of M. phlei has three chains of repeated residues 
as such the RMSF plot shows these chains in brackets and the position of the Glu65B in the two systems. 
C) Scatter plots showing fluctuations of the binding site residues among the bound and unbound systems. 
Indicated in green (unbound) and red (BDQ-bound) circles are the main residues (Glu65B) responsible for 
ion exchange in both systems D) Radius of gyration (Rg) of the binding site residues showing a low Rg due 
to the binding of BDQ resulting in a highly compact F1F0 structure. 
 
 
3.2 Dual-molecule BDQ binding increases binding affinity  
The concentration-dependent increase in the inhibitory activities of BDQ towards F1F0 synthase, 
as reported by Preiss et al., necessitated the use of the MM/PBSA approach to study the 
mechanistic single-mode and dual-mode binding and inhibitory potencies of BDQ to the target 
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protein [17]. This was to provide atomistic perspectives on the findings by Preiss et al., in which 
it was revealed that one or more BDQ molecules could approach and bind to the c-ring of ATP 
synthase depending on the concentration [17] and that the more the BDQ molecules bound the 
stronger the inhibitory potency. To this effect a third system was examined, which comprised of 
two molecules of BDQ bound to the c-ring of the ATP synthase to depict an increase in 
concentration of BDQ. Moreover, free binding energies of the BDQ singly- and dual-bound F1F0 
ATP synthase was evaluated using the MM/PBSA method to obtain a quantitative perspective into 
the mechanistic high-affinity binding and stability of the compounds at the target site of F1F0 
synthase. Differential ΔGbind free binding energies for BDQ when bound to F1F0 ATP synthase as 
a single molecule as well as double molecules were estimated and presented in Table 9.1. As 
estimated, ΔG was higher in the dual bound system as compared to the singly bound F1F0 system. 
The singly bound system had a ΔG value of -29.41kcal/mol while it was considerably higher in 
the dual system with a value of -38.13kcal/mol. Therefore, we can presume that binding affinity 
would possibly be higher when there is an increase in the number of BDQ molecules bound to 
F1F0 ATP synthase in agreement with earlier findings that reported improved BDQ potency when 
the concentration is increased [17]. Furthermore, high-affinity binding in both BDQ-bound 
systems was evidenced by the estimated high ΔE electrostatic energies as presented in Table 9.1, 
indicative of the formation of strong interactions that mediated the binding and stability of BDQ 
in both single and dual states. 
Table 9.1: MM/GBSA-based energy profiles of BDQ-singly and double-bound F1F0 ATP synthase. 
Systems Energy components 
(kcal/mol) 
          




















ΔEele = electrostatic energy; ΔEvdW = van der Waals energy; ΔGbind = total binding free energy; ΔGsol = 
solvation free energy ΔG = gas phase free energy. 
 
3.3 Time-bound analysis of the interaction of BDQ at the c-ring F1F0 synthase 
To further corroborate the mechanistic binding of BDQ molecules, we performed a thorough 
elucidation of complementary interactions that occurred at the F1F0 active site when singly- or 
dually bound. This entailed a thorough molecular visualization of these interactions over the 
simulation period followed by the estimations of the residual energy contributions of residues at 
the c-ring of F1F0 synthase towards the high-affinity binding and stabilization of BDQ molecules. 
This was also important so as to be able to identify key residues that play crucial roles in the BDQ 
binding. As observed in the singly bound system, certain residues of the hydrophobic groove, 
which constitutes chains A and B, showed strong interactions with BDQ, and could underlie the 
basis for its stability and high affinity. Firstly, we investigated key residues and their roles 
involvement in the binding and stabilization of BDQ over the simulation period. This provided a 
closer look into the interaction dynamics between certain c-ring residues of F1F0 synthase and 
BDQ where it was revealed that some residues interacted in a consistent, steady and a recurrent 
manner across the 100ns of simulation period. These residues include; Glu65B, Tyr68B and Ile70A. 
Notably, these residues formed strong high affinity interactions with constituent BDQ moieties 
from the beginning of the simulation as shown at 5ns until the end of the simulation at 100ns 
(Figure 9.3).  Interestingly, among these recurrent residues was Glu65B, which has been shown to 
play a critical role in the binding of BDQ as evidenced by the systematic occurrence of strong 
hydrogen, ionic and salt bridge interactions at different periods during the simulation. According 
to previous reports, Glu65B is a conserved carboxylate harbored at the ion binding site and plays 
critical roles that majorly involve the binding and shuttling of protons [14, 17, 54, 59]. Therefore, 
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the steady engagement of BDQ with Glu65B could depict a situation whereby the primary role of 
Glu65B in ion transport is persistently blocked by BDQ, indicative of its mechanistic activity in 
disrupting the microbial (Mtb) process of ATP synthesis. Likewise, the persistence of Tyr68B and 
Ile70A in forming strong hydrophobic interaction with BDQ over the simulation period could 
suggest an augmentative role in enhancing the high-affinity binding and inhibitory activity of 
BDQ. These modes of interactions could relatively provide essential details and atomistic 
perspectives into the ionophoric inhibitory property of BDQ. 
 
 
Figure 9.3: Structural positioning and orientation of BDQ at the hydrophilic c rotor-stator region of F1F0 
synthase BLK depicting steady, consistent and recurrent interaction of BDQ with the c-ring residues.  
Surface representations of BDQ-bound c-ring in the F1F0 synthase are shown in [. The degree of H-bonds 




To further delve into the nature of the binding site residue interactions, we quantified the energetics 
of the individual residues to the total binding affinity of BDQ with particular emphasis on the 
electrostatic and van der Waal energy contributions. In doing so, we estimated the individual 
energy contributions of each active site residue using the MM/GBSA-integrated per-residue 
decomposition method. Generally, residues with interaction energies lower than -0.8 kcal/mol are 
regarded as crucial in the molecular recognition, high-affinity binding and stability of small 
molecule compounds [60]. As estimated, Phe69B (-2.65 kcal/mol), Tyr68B (-2.34 kcal/mol), 
Ala66A (-1.11 kcal/mol), Glu65B (-1.04 kcal/mol) and Leu72B (-0.98 kcal/mol) exhibited the high 
energy contributions which, could suggest their high importance to the inhibitory activity of BDQ. 
However, among these residues, Phe69B showed the highest total binding energy contribution of -
2.65kcal/mol. This could have been due to the reported conformational change it exhibits in order 
to avoid steric clashes with the bulky BDQ, which could contribute to the optimal and favorable 
positioning of BDQ, and in turn account for the relatively high total energy involved. This crucial 
involvement of Phe69B could be substantiated by its intermittent interactions with BDQ over the 
simulation time, which could be vital for active site stability and optimal positioning. Interestingly, 
two of the prominent residues that contributed to the binding of BDQ were the conserved 
carboxylates; Glu65B and Asp32B, which exhibited the highest electrostatic contributions of -
47.37kcal/mol and -19.42kcal/mol respectively as shown in Figure 9.4. Earlier reports have 
indicated that the electrostatic interactions of these two residues with the DMA group of BDQ 
could account for the measured salt effects in ATP synthesis in M. smegmatis IMVs  in the 
presence of BDQ [19, 61]. As such, the prominent involvements of these two residues via 
electrostatic interactions, over the course of the simulation, as earlier estimated corroborates earlier 
experimental reports, which further emphasizes the antagonistic mechanisms the essential roles of 
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these conserved carboxylates in the binding of BDQ. Prominent van der Waals energies were also 
contributed towards the binding of BDQ by certain binding site residues which could as well favor 
the overall inhibitory activity of BDQ. Notable residues with van der Waals contributions included 
Gly62B, Glu65B, Ala66A, Ala67A, Tyr68B, Phe69B, Phe74A and Leu72B, which are consistent with 
previous experimental reports [17].  
Using the averaged structure of the BDQ-F1F0 ATP synthase complex, a closer look at the specific 
nature of interaction of the binding site residues revealed that Glu65B exhibited important 
hydrogen, ionic, salt-bridge and amide-Pi stacked interactions with BDQ, which could account for 
its high-affinity binding and stabilization (Figure 9.4). In addition, interactions elicited by BDQ 
with other active site residues included Pi-Pi T-shaped interaction with Phe69B, two Pi-alkyl 
interactions with Ile70A and a Pi-alkyl interaction with Ala66A. Overall, this blockade mechanism 
elicited by BDQ towards key residues of F1F0 ATP synthase c-ring such as Glu65B could interrupt 
the processes of ion exchange and shuttling which are crucial to the synthesis of ATP as mediated 












Figure 9.4: Per-residue decomposition plots showing individual energy contributions to the binding and 
stabilization of BDQ at the c-ring of F1F0 synthase. Energy contributions were highest in conserved 
carboxylates (Glu65B, Asp32B) and Phe69B. Corresponding inter-molecular interactions between BDQ and 
the hydrophilic c rotor-stator region residues in F1F0 synthase is shown as well. 
 
4.0 Conclusion 
The uninterrupted synthesis of ATP is crucial for the survival of organisms, which is mediated by 
the enzyme ATP synthase. This is as well a crucial machinery that has been recently identified as 
an attractive drug target against Mtb largely due to a significant variation in the regulatory 
mechanisms amongst bacterial and eukaryotic organisms [3, 18, 62]. Among the notable 
therapeutic agents that target F-type ATP synthase is BDQ, a diarylquinoline that has been 
experimentally reported to inhibit mycobacterial ATP synthesis by binding to its hydrophilic c 
rotor-stator region. The main aim of this study was to provide atomistic insights into the inhibitory 
mechanisms of the ionophore; BDQ, when bound to F1F0 ATP synthase using MD simulations and 
MM/PBSA methods. 
Differential assessment of the single and dual binding affinities of BDQ toward F1F0 ATP synthase 
using the MMGBSA free energy calculations revealed that a higher and a more favorable binding 
of -38.13kcal/mol occurred in the dual molecule bound system relative to the single molecule 
bound system with a binding free energy of -29.41kcal/mol. This could agree with earlier reports 
which revealed that increased concentrations of BDQ enhances inhibitory potency against the ATP 
synthetic machinery of Mtb. A time-scale and nanosecond based visualization of the interaction 
dynamics between BDQ and the c-ring residues of F1F0 ATP synthase revealed a consistent and 
steady high-affinity involvement of Glu65B, a conserved carboxylate residues involved in ion 
transfer, an interaction that could explain the mechanistic inhibitory activity of BDQ since this act 
could block ion shuttling at the c-ring, which could in turn stall the operation of ATP synthase. 
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Further investigations of the involvement of individual residues at the c-ring region further 
implicated Asp32B and Phe69B, indicative of their essentiality to the binding and stability of BDQ. 
Decomposition of the ΔG revealed that Glu65B and Asp32B had high energy contributions which 
further conformed their importance as stipulated in a previous study which revealed that the 
electrostatic interactions mediated by these residues account for measured salt effect in the 
synthesis of ATP in M. smegmatis. 
Conformational dynamics of the entire F1F0 ATP synthase and the c-ring BDQ binding site 
residues were also investigated over the course of the simulation by calculating the RMSF and Rg 
of their Cα atoms. It was observed that although there was a slightly decreased average fluctuation 
of all residues of F1F0 synthase in the presence of BDQ, there was rather an increased flexibility 
of the residues that directly interacted with BDQ with a <5Å radius relative to lower flexibility in 
the unbound conformation which could have been induced by BDQ. A lower Rg of the c-ring 
suggested a tighter conformation which could have led to a blockage of c-ring rotation with a 
subsequent halt in the ion exchange required for ATP synthesis. Findings from this report provide 
atomistic perspectives into the inhibitory properties of BDQ towards ATP synthesis when bound 
to the c-ring of F1F0 synthase. These useful insights could serve as the basis for the structure-based 
design of novel and next generation of small molecule inhibitors of ATP synthase in the treatment 
of TB. Findings from this study also presents a pathway for further investigations into possible 
resistance to BDQ by mutation of the F1F0 ATP synthase due to the numerous resistant strains in 
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Bedaquiline (BDQ) has demonstrated formidable bactericidal activity towards Mycobacterium 
tuberculosis (Mtb) in the treatment of multi-drug resistant (MDR) and extensively drug resistant 
(XDR) tuberculosis (TB). BDQ elicits its therapeutic function by halting the ionic shuttle of Mtb 
via mycobacterial F1F0 ATP-synthase blockade. However, triple mutations (L59V, E61D and 
I66M) at the ligand-binding cavity characterize emerging BDQ-resistant strains thereby restraining 
the potentials embedded in this anti-microbial compound, particularly in MDR/XDR-TB therapy. 
In this report, the effects of these triple mutations on BDQ-Mtb F1F0 ATP-synthase binding were 
investigated using molecular dynamics, free energy binding and residue interaction network (RIN) 
analyses. 
The highlight of our findings is the drastic reduction in BDQ binding affinity (ΔG) in the triple 
mutant protein, which was caused by a systemic loss in high-affinity interactions primarily 
mediated by L59, E61 and I66. While wildtype L59 and I66 formed pi-alkyl interactions with BDQ 
at the F1F0 ATP-synthase binding site, E61 elicited conventional (O--HO) bond. Upon transition, 
V59 and I66 were devoid of interactions with BDQ while D61 existed in a weaker non-
conventional (C--HO) bond. Likewise, these mutations distorted the binding site and overall 
structural architecture of F1F0 ATP-synthase in the presence of BDQ as revealed by the RIN and 
conformational analyses. 
Insights from this study could serve as a starting point for the structure-based design of novel 
inhibitors that could overcome mutational setbacks posed by BDQ-resistant strains in MDR/XDR-
TB treatment. 
Keywords: Mycobacterium tuberculosis, Multi-Drug resistant TB, Bedaquiline, F1F0-ATP 





Tuberculosis (TB) is currently the leading cause of death from an infectious disease worldwide, 
killing more people than Human immunodeficiency virus/ Acquired immunodeficiency syndrome 
(HIV/AIDS)  [1]. Eradication of TB still remains a challenge despite the availability of vaccines 
as well as drug treatments. In 2017, 10 million people fell ill with TB, among which 1.6 million 
died from the disease (including 0.3 million among people with HIV) [1]. The continual emergence 
of resistant Mycobacterium tuberculosis (Mtb) strains further complicates existing treatment 
options and consequently poses a serious global threat toward curtailing TB epidemic.  
Resistance over the years exists in different forms, ranging from Multidrug-Resistant TB (MDR-
TB) to Extensive Drug Resistance TB (XDR-TB). While the former is mediated by an Mtb strain 
resistant to isoniazid and rifampin; the two most potent first-line anti-TB drugs [2], the latter 
describes resistance to the fluoroquinolones or injectable second-line anti-TB drugs such as 
capreomycin, viomycin and ciprofloxacin (CIP) [3]. Moreover, the most virulent form of 
resistance is described as the Totally Drug Resistant TB (TDR-TB) which categorizes strains that 
are resistant to both first-line and second-line anti-TB therapy [4]. 
The 2018 WHO Global TB report on MDR-TB revealed an estimated 588,000 cases globally with 
South Africa alone accounting for about 14,000 cases. MDR-TB strains are historically difficult 
to treat compared to drug susceptible TB, which poses a global threat towards disease eradication. 
As such there is the need to explore new therapeutic options in this field of research. Emerging 
reports have revealed that Bedaquiline (BDQ), a recently approved anti-TB drug, is potent in the 
treatment of MDR-TB and XDR-TB. 
Bedaquiline, an antibiotic drug belonging to the chemical class of diarylquinolines, was recently 
granted approval by the Food and Drugs Administration (FDA)[2]. As an anti-TB agent, BDQ has 
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shown that targeting energy metabolism is a new and efficient approach for inhibiting Mtb activity 
[5, 6]. Moreover, structural and inhibitory mechanisms that underlie BDQ mode of action at 
atomistic level have been recently elucidated in report from our research group, supportive of its 
potency. BDQ functions by targeting F1F0 ATP synthase, an essential enzyme in ATP synthesis 
[7]. Further to this, BDQ has been known to cause mycobacterial cell death through a phenomenon 
known as uncoupling in which it functions as a H+/K+ ionophore, causing transmembrane pH and 
potassium gradients to be equilibrated [8]. 
The F1F0 ATP synthase is a macromolecular membrane embedded protein complex which employs 
electrochemical ion gradient for the conversion of adenosine diphosphate (ADP) and inorganic 
phosphate into adenosine triphosphate (ATP) by a rotary mechanism [9–12]. Moreover, the Fo 
domain of the F1F0 harbors the rotor ring where BDQ is known to bind. In bacteria, it consists of 
identical copies of c-subunits forming an hourglass-shaped cylinder with a central pore known as 
the c-ring  [13]. 
In a recent study, the crystal structure of the c-ring from Mycobacterium phlei (M. phlei) in 
complex with BDQ was resolved, indicating that BDQ cannot bind to the ATP synthase of non-
mycobacterial species [14]. Also BDQ reportedly forms a large number of hydrophobic, 
hydrophilic and electrostatic interactions, which explains the high affinity binding demonstrated 
by BDQ towards the M. phlei c-ring [14]. 
Despite the widely reported potency of BDQ in the treatment of MDR-TB via F1F0 ATP synthase 
inhibition, the emergence of mutations has been related to BDQ-resistant Mtb [6, 15, 16]. The 
occurrence of a triple mutation; L59V, E61D and I66M, reportedly interferes with the direct 




This necessitates the development of novel therapeutic options that could help surmount BDQ 
resistance in the treatment of XDR/MDR-TB. Moreover, detailed understanding into the 
mechanisms by which triple mutation impedes BDQ activity is highly crucial, hence the design of 
this study. We employed molecular dynamics and binding analyses to obtain structural and 
molecular insights into the triple L59V, E61D and I66M mutational effects of BDQ on F1F0 ATP 
synthase. Findings would form an important basis for the design and development of novel non-
resistant Mtb F1F0 ATP synthase inhibitors. 
 
2.0 Computational Methodology 
2.1 Homology modelling of F1F0 ATP synthase of Mycobacterial tuberculosis 
The unavailability of an X-ray crystal structure for Mtb F1F0 ATP synthase necessitated the use of 
homology modeling (HM) technique to obtain its 3-D structure from a template M. phlei structure 
with PDB entry 4V1G. The FASTA sequence of the target protein used for HM was retrieved from 
Uniprot database with entry C1AMU9, having ~90% sequence similarity with M. phlei F1F0 ATP 
synthase. The HM of the Mtb  F1F0 ATP synthase was based on established in-house protocols as 
employed in our previous reports [17].  
Structural validation of the obtained model was done using MolProbity webserver [18] with a 
Ramachandran plot that provided visual representations of energetically allowed or stable regions. 
Further validation of the modelled structure was done via PROSA[19] and PROCHECK[20] 
analysis. The F1F0 structure modelled comprised of three identical chains A, B, and C, with each 






2.2 Molecular Docking 
Molecular docking was performed on the modelled Mtb F1F0 ATP synthase subunit C structure to 
predict the binding conformation and affinity of the BDQ within the active site region. The active 
site was determined by using the match maker functionality on UCSF Chimera [21] to superimpose 
the built homology model with the X-ray crystal structure of the template M. phlei. Molecular 
docking was then carried out using the AutoDock Vina software [23]. The grid box that defines 
the binding site region of the F1F0 was generated using the AutoDock Vina functionality on UCSF 
Chimera. BDQ was then docked to the active site region which constituted chains A and B. The 
grid box for the docking of BDQ had size and center coordinates of x = (14, -168.70), y = (11, 
58.11) and z = (10, 29.70) respectively. 
 
2.3 System Preparation  
The modelled structure of Mtb was then prepared for molecular dynamic simulation (MD) using 
UCSF chimera [24] and Molecular Molegro Viewer (MMV) [25], to eliminate molecules that are 
irrelevant to the current study. Three-point mutations 59(Leu → Val), 61(Glu → Asp) and 66(Ile 
→ Met) were carried on the protein structure (Figure 10.1) using the integrated Dunbrack rotamer 
method of UCSF Chimera [26]. Altogether, BDQ-bound non-mutated (wildtype, wt) and mutant 
(mt) systems were obtained and set up for 150ns simulation time in order to clearly distinguish 




Figure 10.1: 3-D structure of Mtb F1F0 ATP synthase (light blue) bound by BDQ (grey) at the 




Molecular dynamics (MD) simulations  
 
MD simulation was performed using the GPU version of AMBER18 with an integrated PMEMD 
module [27], according to in-house standard simulation protocols, as employed in several of our 
previous studies [28–32]. The MD simulation was initiated using a time step of 1fs and coordinates 
saved at 1ps interval followed by subsequent analysis of trajectories using the integrated PTRJ and 
CPPTRAJ module [33]. Visualization of the complexes and data plots were carried out using the 




2.5 Thermodynamic calculations 
The Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) [35–38] method was used 
to calculate binding free energy of the BDQ in the wild and mutant Mtb F1F0 ATP- synthase.  
 
 
The binding free energy (DGbind) was calculated from the following equation: 
DGbind = Gcomplex - Greceptor - Gligand          (1) 
DGbind = DGgas + DGsol -TDS,                   (2) 
 
Where DGbind is considered to be the summation of the gas phase and solvation energy terms less 
the entropy (TDS) term 
DEgas = DEint + DEvdw + D Eelec         (3) 
 
DEgas is the sum of the AMBER force field internal energy terms DEint (bond, angle and torsion), 
the covalent van der Waals (DEvdw) and the non-bonded electrostatic energy component (DEelec). 
The solvation energy is calculated from the following equation: 
 
Gsol = GGB + Gnon-polar                 (4) 
 
Gnon_polar = gSASA + b               (5) 
The polar solvation contribution is represented as GGB and Gnon-polar is the non-polar solvation 
contribution and is calculated from the solvent assessable surface area (SASA), obtained by the 
use of a 1.4 A° water probe radius. The surface tension constant (c) was set to 0.0072 kcal/mol and 
b to 0 kcal/mol [39]. Per-residue decomposition analyses were also carried out to estimate 
differential energy contributions of binding site resides towards BDQ affinity and stabilization in 
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both systems. This was important to further monitor triple mutational effects on BDQ binding 
complementarity. 
 
3.0 Results and Discussion 
3.1 Structural validation of the 3D Homology model of Mtb F1F0 ATP-synthase 
 
The Molprobity web server was employed in validating the homology model built in this study 
and the resulted presented in a Ramachandran plot as shown in figure S1.  From the plot 95.2% of 
all residues were in favored region while 98.3% were in the allowed region leaving 4 residues as 
outliers. Interestingly these four outliers did not include residues of the active site region when the 
homology model was assessed for its active site residues by superimposing with the template M. 
phlei structure (4V1G) on Chimera Multi-align viewer [21].The results show a level of  precision 
of the dihedral angles and backbone in three dimensional space. In addition to this, the PROSA 
web server was used to measure the total model quality, as it affirms if built model was within the 
acceptable X-ray and NMR studies. The Z-score for the modelled ATP synthase was -1.88, as 
shown in Figure S2, which implies a good quality model for use. Further validation was also 
carried out using PROCHECK which identified 92.6% of the residues to be in the favored region, 
5.7% of the residues in the additionally allowed regions whiles 1.1% in the generously allowed 
region and 0.6% of the residues in the disallowed region (figure S3). Taken together, these 







3.2 Triple mutation induces loss of crucial interactions and consequential energy contributions 
 
The binding affinity of inhibitors to their respective targets is largely influenced by complementary 
interactions occurring within the binding sites, particularly with certain site residues. As such 
point-mutational changes or disorders among these residues could alter the binding mechanisms 
of high-affinity inhibitors and in turn affect their therapeutic functionalities [40, 41]. 
At first, we measured the involvement of those residues (wtLeu59A, wtIle66A and wtGlu61B) in the 
binding of BDQ prior to mutations. This was done by evaluating differential energy contributions 
of BDQ-interactive site residues across wt and mt F1F0 ATP synthase. Overall energies were 
decomposed into van der Waals and electrostatic energy including their overall contributions to 
total energy. This was performed using MM/GBSA-based per-residue energy decomposition 
method. As estimated, Leu59A, Ile66A and Glu61B contributed total energies of -2.60kcal/mol, -
1.21kcal/mol and -1.38kcal/mol respectively to BDQ binding in the wt form (Figure 5.2).  
Interestingly, we observed that the mutational change in residues (wtLeu59A→ mtVal59A; wtIle66A 
→ mtMet66A; and wtGlu61B → mtAsp61B) accounted for a reduction in total energies where 
mtVal59A, mtMet66A and mtAsp61B had energies of -1.69kcal/mol, -0.82kcal/mol and -
0.69kcal/mol respectively. These energy differences could account for weaker BDQ interactions 
given that wtLeu59A, wtIle66A and wtGlu61B played critical roles in the binding and stabilization 
of BDQ consistent with its high-affinity inhibitory activities. In a similar fashion, vdW and 
electrostatic energies were lower in the mutated residues compared to their wt forms as presented 
in Table 10.1. Relatively, an increase in positive value for the vdW energy contributions in 
mtMet66 could be more unfavorable towards BDQ binding. 
Additional insights were provided by elucidating the nature and types of bonds that occur at the 
Mtb F1F0 ATP synthase binding site relative to the BDQ activities in both wt and mt variants. 
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Leu59A → Val59A Ile66A   →   Met66A Glu61B → Asp61B 
vdW -2.77 -1.99 -1.40 -0.62 -2.12 -0.74 
ELE -1.97 -1.68 0.86 0.96 -7.52 -5.20 
TOTAL -2.60 -1.69 -1.21 -0.82 -1.38 -0.69 
 
As shown in Figure 10.2, wtLeu59 and wtIle66 mediated a pi-alkyl interaction with BDQ; 
interactions that could be crucial for its stabilization at the binding site. However, these interactions 
were lost when mutated to Val59A and Met66A, events that could possibly affect BDQ stability 
and binding affinity. Similarly, there was the occurrence of a high-affinity hydrogen bond between 





Figure 10.2: Per-residue decomposition plots showing individual energy contributions to the 
binding of BDQwith much emphasis on the residues in the wild ATP synthase-BDQ system and 
the corresponding mutants in the mutant ATP synthase-BDQ system. Corresponding inter-
molecular interactions between the wild and mutant systems is shown as well. 
 
Moreover, while this was an OH--O H-bond type (conventional), mtAsp61B mediated an 
unconventional CH--O bond with BDQ which is less strong compared to the conventional types. 
This correlates with a reduction in ELE energy among both residues as shown in Table 10.1. 
Common to both is the attractive charge interaction mediated by Asp28B in both wt and mt variants 
as shown in the per-residue plot in Figure 10.2. 
Mutational-induced alterations in the primary or wildtype interactions mediated by BDQ could 
also correlate with the reduction in total energies observed in the mutant system. Hence, we can 
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infer that the triple mutation of wtLeu59A, wtIle66A and wtGlu61B destabilizes their critical 
involvement in BDQ binding, which could in turn account for a loss in therapeutic activity. 
3.3 Triple mutation impacts BDQ binding by disorienting residue interaction network profile of 
Mtb F1F0 ATP synthase   
 
The structural integrity of any enzyme largely depends on the inter-residue interactions existing 
between the individual residues that form the basic unit of that particular enzyme. As such any 
perturbation or disorientation of the residue interaction profile of  the enzyme, Mtb F1F0 ATP 
synthase  could possibly influence its biological activity and hence curtail its involvement in ATP 
synthesis [42, 43]. An exploration of residue-residue interaction network within Mtb F1F0 ATP 
synthase as performed in this report could also provide essential structural insights into the impact 
of BDQ binding on its structural integrity as well as reveal crucial atomistic insights into the impact 
of the induced triple mutation. Individual residues of Mtb F1F0 ATP synthase are represented by 
nodes while specific inter-residue interactions are described by edges shown in figure 10.3 and 
figure 10.4. Predominant interactions that exist between residues included hydrogen bonds, van 
der Waals interactions and ionic interactions [44]. To explore the structural impact of the induced 
triple mutation on BDQ binding, specific parameters described as centrality measures were taken 
into consideration to provide insights on the residue network profile of Mtb F1F0 ATP in its wild 
and mutant conformation. The assessed parameters included diameter density, betweenness, short 
path length, node degree and closeness centrality. The number of connections between nodes is 
described as node degree whereas the compactness of the enzyme network is described by the 
diameter (D) [43, 44]. Likewise, the sparsity of the network profile measured between 0 and 1 is 
described by the density parameter whereas the betweenness and closeness centrality revealed 
essential residues within the residue interaction network of Mtb F1F0 ATP synthase [43, 44]. The 
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short path length parameter provides insights on the residue flexibility and takes into consideration 
the interconnective edges between respective nodes[43, 44].  Results as shown in figure 10.3 for 
the wild conformation suggests the essentiality of (Leu59, Ile66 and Glu61) in the overall integrity 
of Mtb F1F0 ATP synthase considering the extensive interactions each of these residues engaged 
in with neighboring residues. These residues exhibit centrality and coordination by forming 
various interactions, notably, hydrogen bonds, van der Waals and ionic interactions with 
neighboring residues as shown in figure 10.3. As observed, there was also a high node degree as 
well as prominent betweenness and closeness centrality in the wild conformation. The observed 
shortness of length of the connective edges confers with a compact and relatively stable residue 
conformation of the BDQ bound wild conformation. The roles of these residues in imposing 
stability and compactness further highlights their cruciality in Mtb F1F0 ATP for which their 






Figure 10.3: Residue Interaction network analysis of wild Mtb F1F0 ATP synthase in complex 
with BDQ. (A) Circled insert shows hotspot residues (Lue59A, Glu61B and Ile66A) which are 
subsequently mutated. (B) Network and topology representation highlighting both hotspot residues 
with the corresponding interacting neighboring residues. (C) Closer network view showing the 
residual interaction network and centrality of the hotspot residues. 
 
 
In contrast to wild conformation, the mutant bound conformation exhibited varying residue 
interaction network profile as shown figure 10.4. Which could largely be attributed to the induced 
triple mutation. Although the mutated residues-maintained interactions with neighboring residues 
there was an apparent reduction in node degree, much longer path lengths between nodes and a 
corresponding reduction connectivity of nodes relative to the wild conformation. These 
corresponds with a relatively loose and less compact residue interaction network profile of the 
mutant conformation. The occurrence of these observed residue network distortions even in the 
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binding of BDQ suggests that, regardless of the BDQ binding, the structural integrity of ATP 
synthase is stilled disoriented. This could eventually influence BDQ binding affinity and its 
consequential inhibitory potency.  
 
Figure 10.4: Residue Interaction network analysis of mutant Mtb F1F0 ATP synthase in complex 
with BDQ. (A) Circled insert shows hotspot mutant residues (Val59A, Asp61B and Met66A). (B) 
Network and topology representation highlighting both hotspot residues with the corresponding 
interacting neighboring residues. (C) Closer network view showing the residual interaction 
network and centrality of the hotspot residues. 
 
 
To further explore the impact of the triple mutation residues interaction profile of Mtb F1F0 ATP, 
the hydrogen bond patterns of active site residues of the wild and mutant bound conformation of 
Mtb F1F0 ATP was estimated from the generated 150ns MD trajectory. The formation of hydrogen 
bonds between residues in a protein is very essential in the conformational dynamics of the protein 
structure [45].  As shown in the comparative hydrogen bonds plot in figure 10.5A, the wild bound 
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conformation of Mtb F1F0 ATP exhibited the highest average hydrogen bonds of 94 H-bond 
interactions whiles the mutant showcased an estimated average hydrogen bonds of 92 interactions. 
The decrease in hydrogen bond interaction in the mutant bound conformation was consistent with 
the distorted residue interaction network of the mutant complex as shown in figure 10.4. The 
distorted residue network profile could have impeded the formation of hydrogen bonds, hence 
lower average hydrogen bonds as estimated. Upon mutation, Glutamate 61(Glu), the main residue 
involved in ion exchange in mycobacteria [46], was replaced with Aspartate (Asp). Even though 
both Glu and Asp are polar and negatively charge hydrophilic amino acids that are essential in the 
formation of hydrogen bonds the shorter side chain of Asp could have informed its varying 
structural impact on Mtb F1F0 ATP. Similarly in the Leu59Val mutation, although  both Leucine 
and Valine are aliphatic hydrophobic amino acids, buried in the core of the enzyme structure, the 
non-reactive side chain on Valine [46] which rarely involves in protein function could have 
accounted for the lower hydrogen bond formation. More so, unlike most amino acids which 
possess only one non-hydrogen substituent attached to the c-β carbon, Valine contains two non-
hydrogen substituents. This property of Valine could have also influenced its formation of 
hydrogen interactions with neighboring residues and a consequential decrease in hydrogen bond 
formation within the active site of the mutant Mtb ATP synthase. Mutation of Ile66 with 
methionine (Met) could have also influenced the decreased hydrogen bond formation in the mutant 
bound complex. Even though both are favorable to be substituted by each other due to their 
hydrophobic nature, the sulphur atom on methionine possibly impeded its connection with 
hydrogen atoms but rather favored its interaction with methyl groups and consequently limiting its 
reactivity within Mtb F1F0 ATP synthase.   Taken together, the triple mutation structurally distorted 
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the conformation integrity of Mtb F1F0 ATP synthase and consequential reduced its overall 
hydrogen bonding and probably the binding affinity of BDQ. 
 
Figure 10.5: (A) Comparative hydrogen bond plots of within active site region of the wild and 
mutant bound Mtb ATP synthase. (B) 3D representation of the degree of hydrogen bond donors 
(magenta) and acceptors (light green) within the active of site of the wild bound Mtb ATP synthase. 
(C) 3D representation of the degree of hydrogen bond donors (magenta) and acceptors (light green) 
within the active of site of the mutant bound Mtb ATP synthase. 
 
 
3.4 Triple mutation interferes with BDQ binding affinity on Mtb F1F0 ATP synthase 
Binding free energy, calculated using the Molecular Mechanics/Generalized Born Surface Area 
(MM/GBSA) [35–38] method was estimated to assess any differences in the binding of BDQ to 
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Mtb F1F0 ATP synthase, in the presence and absence of the induced triple mutation.  This provided 
insights on whether the mutation could probably influence BDQ binding and its overall inhibitory 
potency. Results obtained from the calculation reveals that the total binding energy of BDQ was 
higher in the wild Mtb F1F0 ATP conformation, with a total binding free energy of -30.10kcal/mol 
relative to a lower energy of -18.47kcal/mol in the mutant conformation as shown in Table 10.2. 
The lower binding of BDQ in the mutant structure could be attributed to the observed distortion in 
the residue interaction network of the mutant Mtb F1F0 ATP, characterized by increased residue 
flexibility, which could have impeded the favorable interaction crucial residues with BDQ.  
Table 10.2: Estimated Binding free energy profiles of BDQ to mutant and wild Mtb F1F0 ATP 
synthase 
 
ΔEele = electrostatic energy; ΔEvdW = van der Waals energy; ΔGbind = total binding free 
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3.5 Exploration of the structural and conformational dynamics of wild and mutant Mtb F1F0 
ATP synthase upon binding of BDQ 
 
As reported experimentally, mutations on Mtb F1F0 ATP synthase causes direct structural 
interference and subsequently affects the binding of BDQ [14]. In light of this we assessed the 
stability and structural dynamics of the wild and mutant Mtb F1F0 ATP synthase to establish the 
effects of the triple mutations. To ascertain the impact of the triple mutation on structural stability 
of Mtb F1F0 ATP synthase, the root mean square deviation (RMSD) of its C-α atoms were 
calculated over the simulation period. As shown in figure 10.6A all simulated models were well 
stabilized and model was observed to have achieved convergence after about 20ns. The average 
deviations computed for C-α atoms of the mutant BDQ bound Mtb F1F0 ATP synthase was 2.83Å 
whiles the wild bound conformation exhibited an average RMSD value of 1.80Å. This suggested 
a more stable conformation in the wild conformation compared with the mutant which was 
relatively unstable.  It could therefore be inferred that the residue network disorientation and 
residue flexibility in the mutant complex as observed in the RIN analysis possibly conferred the 
observed conformational instability on Mtb F1F0 ATP synthase relative to the wild bound complex. 
This could have in turn influenced the overall binding of BDQ considering the fact that the 
increased deviation of the C-α atoms in the mutant conformation could have equally impeded the 
interaction of crucial residues required for the binding of BDQ. To further assess the 
conformational dynamics of bound Mtb F1F0 ATP synthase in the wild and mutant forms, 
fluctuations of individual residues were assessed by calculating the root mean square fluctuation 
of corresponding C-α atoms as shown in figure 10.6B. The RMSF calculations also gave insights 
on the flexibility of each residues as was observed in the RIN analysis. Comparatively, the bound 
mutant complex exhibited a slightly higher average RMSF of 12.5Å whiles the bound wild 
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conformation exhibited a exhibited a lower RMSF of 11.0Å. This higher flexibility of residues is 
also consistent with the increase in short path length of residues as observed in the RIN analysis 
further highlighting the impact of the mutation on residue flexibility as well as a consequential 
effecting on BDQ binding. In all, although the difference in average flexibility was minimal 
between the two models, the slightly higher flexibility in bound wild conformation, it confers with 
earlier assertion that mutation perturbed the conformation dynamics of Mtb F1F0 ATP synthase 
and hence influence BDQ binding. With the observed increased flexibility in the mutant complex, 
we further assessed the compactness of Mtb F1F0 ATP synthase by calculating the radius of 
gyration (RoG) of its C-α atoms over the simulation period. A compact or rigid enzyme structure 
is consistent with reduced residue flexibility of the enzyme [47]. As shown in figure 10.6C the 
mutant complex exhibited a slightly higher average RoG 20.4Å relative to the wild complex which 
exhibited an average RoG of 20.3Å. Though minimal, the slight less compact conformation of the 
mutant Mtb F1F0 ATP synthase complex due to its relatively higher RoG conferred with its slightly 
higher overall enzyme flexibility as observed in the RMSF and RIN analysis. In summary the 
effect of the induced triple mutations on F1F0 ATP synthase was definitive in causing structural 
alterations characterized by the high C-α deviations, increased residue flexibility and less compact 
enzyme structure. These structural alterations could in turn have interfered with BDQ binding, 






Figure 10.6: A) Comparative C-α RMSD plots wild and mutant BDQ bound Mtb ATP synthase. 
B) RMSF plots showing the degree of residue fluctuations that occurred on both wild and mutant 
Mtb ATP synthase over the simulation period. Inset shows 3D representation of some prominent 
residue fluctuation regions (region 37-67 and 160-175). C) C-α Rg plot showing distinct structural 
compactness and rigidity of wild and mutant bound Mtb ATP synthase. 
 
4.0 Conclusion 
Multi-Drug resistance TB remain a public health concern and the continuous search for various 
therapeutic approaches that will counter this menace is on the rise. The recent approval of BDQ 
for the treatment of MDR-TB has shown great advancement toward attenuating the disease. By 
inhibiting ATP production in Mtb, BDQ deprives the microorganism of energy to carry out 
metabolic activities leading to cell death. However emerging reports suggests resistance to BDQ 
in Mtb to be attributed to some notable mutations {59(Leu → Val), 61(Glu → Asp) and 66(Ile → 
Met)} in the amino acid sequence of the mycobacterium. In this study we employed computational 
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methods to provide insights into the effect of mutations on the inhibitory prowess of BDQ by 
ascertaining any mutation induced structural perturbations as well as the residue interaction 
network of Mtb F1F0 ATP synthase. Per-residue energy decomposition analysis revealed that, upon 
mutation, there was reduction in the total energies contributed by the residues of interest towards 
the binding of BDQ with a corresponding loss of crucial interactions such as hydrogen and pi-
alkyl interactions that were formed with BDQ in the wild complex. A further exploration of the 
impact of the mutation revealed, the triple mutations induced, altered BDQ binding by distorting 
the structural integrity of Mtb F1F0 ATP synthase. This was characterized by an increase in short 
path lengths of edges between nodes as observed in the RIN analysis and a corresponding increase 
in individual residue flexibility as shown with increased C-α atom fluctuation and deviation of the 
mutant complex relative to the wild complex. The disorganization of the structurally compact wild 
Mtb F1F0 ATP synthase complex into a more flexible conformation upon mutation was further 
exhibited by a decrease in hydrogen bond formation in the mutant complex relative to the wild 
complex. These findings provide structural and atomistic insights into the experimental reports 
that indicate that these triple mutations could interfere with BDQ binding and consequently prevent 
its ionophoric role of halting ion transfer as an anti-TB agent. Conclusions from this report could 
also aid in the design of new Mtb F1F0 inhibitors that could overcome resistance in MDR-TB. 
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The mobility of loops around the catalytic site of a protein remains crucial to its activity. Dynamics 
of the WPD-loop is an essential determinant of the catalytic activity of tyrosine-protein 
phosphatase zeta, an implicated protein in glioblastoma cells. The WPD-loop assumes a closed 
conformation upon substrate binding in order to position its catalytic aspartate to participate in 
catalysis. Herein, we explore the impact of NAZ2329, a recently identified allosteric inhibitor of 
tyrosine-protein phosphatase zeta, on the atomic flexibility of the WPD-loop. The druglikness of 
NAZ2329 was assessed using the SwissADME online tool. The enzymatic complex was then 
subjected to conformational simulations using the AMBER molecular dynamics software. 
Structural analysis revealed that NAZ2329 induced an open conformation of the crucial WPD-
loop, consequently impeding enzyme activity even upon substrate binding. Based on the molecular 
interactions between of NAZ2329 and tyrosine-protein phosphatase zeta, a pharmacophore model 
was generated to exhibit the important functional moieties of NAZ2329. These findings provide 
an insightful molecular and structural mechanism in targeting tyrosine-protein phosphatase zeta as 
a therapeutic intervention for glioblastoma.  We believe that this optimized pharmacophoric model 
will aid in the design of improved anti-tyrosine phosphatase agents, thus allowing for increased 
patient adherence. 
Keywords: Glioblastoma therapy, pharmacophore, molecular simulations, WPD-loop, 






Glioblastoma is classified as the most aggressive and frequently diagnosed central nervous system 
malignancy, with an annual incidence of 100,000 new cases, globally 1.  Adding to the complexity 
of the disease, glioblastoma is associated with poor prognosis and low survival rates. 
Glioblastomas are tumors that arise from astrocytes in the cerebral cortex, but may be found 
anywhere in the brain or spinal cord 2. The tumors are highly vascularized to allow oxygen and 
nutrients to pass through, thus increasing its growth 3. Currently, there are no preventative therapies 
or cure for the disease, with only surgical resection and adjuvant chemotherapy being available 4.  
There have been numerous studies elucidating the development of new therapeutic approaches, 
including an article that investigated the receptor type tyrosine-protein phosphatase zeta (PTPRZ) 
as a target in glioblastoma cells 5. The PTPRZ enzyme plays a crucial role in regulating protein 
tyrosine phosphorylation, thereby leading to the survival of the glioblastoma cells and promoting 
the growth of tumors 6. Due to this mechanism of action, the PTPRZ enzyme is a crucial target in 
the design of efficient inhibitors of against glioblastoma 3. Structurally, active site architecture of 
PTPRZ is made up the Phosphate binding P-loop, the catalytic acid/base aspartate containing 
WPD-loop, the conserved glutamine containing Q-loop, the pTyr-recognition pTyr-loop and the 
multiple conserved residues containing E-loop 7. As a vital component of the catalytic process of 
PTPRZ, the WPD-loop serves as a flexible gate to catalytic site which is shown to assume a closed 





Figure 11.1: Graphical representation of the WPD-loop (yellow) of PTPRZ. The active form of 
the protein is associated with a closed WPD-loop upon binding of the natural substrate, whereas, 
an open conformation of results in an inactive protein.  
 
Upon binding of a substrate to the active site the, the WPD-loop assumes a close conformation to 
position its catalytic aspartate to participate in catalysis 7. Therefore a compromised WPD-loop 
mobility can substantially decrease the catalytic activity of the overall PTPRZ protein as was 
reported by studies with mutated tryptophan hinge residue 9,10. 
There have been multiple phosphotyrosine competitive inhibitors that have been designed to 
inhibit the PTPRZ enzyme. These compounds, however, have failed to successfully attenuate 
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cancer due to the drugs inability to permeate the cell wall 11. Another challenge when designing 
effective inhibitors of the enzyme is its highly conserved, positively charged active site. Due to 
these reasons, the enzyme was long known as an “undruggable target” 5.   
Over recent years, targeting the allosteric site of the PTP family of enzymes has proven to be 
successful 12. In 2017, a cell-permeable small molecule, NAZ2329, was identified to allosterically 
inhibit both the PTPRZ and PTPRG, thus mitigating the tumorigenicity in glioblastoma cells 13. 
This allosteric inhibition strategy has since then shown to be extremely promising in glioblastoma 
drug design. 
Here we assess, through the use of in silico tools, the structural mechanism of inhibition of 
NAZ2329 at the allosteric site of PTPRZ, with particular emphasis on the dynamics of the WPD-
loop. Also, a pharmacophore model was design based on the binding profile and structure activity 
relationship of NAZ2329 with PTPRZ. This pharmacophore model approach will facilitate the 
design of small molecule inhibitors that will not only target PTPRZ and PTPRG but will be 
applicable to other tyrosine phosphatases as well. 
2. COMPUTATIONAL METHODS 
2.1 Exploring the Drug Likeliness of NAZ2329 
SwissADME 14, an online software, was used to assess the physicochemical descriptors, the 
pharmacokinetic features and the drug-worthy nature of NAZ2329. In computing the lipophilicity 
and polarity of NAZ2329, the “Brain Or Intestinal Estimated permeation, (BOILED-Egg)” method 





2.2 Preparation of PTPRZ System 
To identify the most suitable crystal structure for molecular dynamic simulations, all PTPRZ 
structures available on RSCB Protein Data Bank 15 were assessed. Of the eight structures, only 
four were of human origin. As our study focused on the NAZ2329 molecule bound to the allosteric 
site of PTPRZ, the PDB code 5AWX was chosen as the most suitable crystal structure. Based on 
the literature accompanying the crystal structure, it was noted that the free enzyme demonstrated 
a closed WPD-loop, whilst an open WPD-loop was depicted in the NAZ2329-bound complex. 
This justified the use of both the bound crystal structure as well as the free enzyme (PDB codes: 
5AWX and 5H08, respectively) 16.  
To validate the binding site of PTPRZ, the NAZ2329 molecule was extracted from the complex 
using the UCSF Chimera software package 17. Molecular docking was then carried out using the 
Autodock Vina plugin on the Chimera software, where default settings were used. The grid box 
was defined around the following key residues Glu1981, Arg1939, Gly1938, Pro1905, Glu1898, 
Trp1899, Val1911 and Glu1977, which covered the allosteric region of PTPRZ. The X, Y and Z 
centre values of the grid box were defined as 30.58, -2.11 and 43.21, respectively, whereas, the X, 
Y and Z size dimensions were defined as 10.8, 14.3 and 11.4, respectively. Docking results, of 
binding affinity -9.7 kcal/mol, indicated significantly similar binding poses of the original crystal 
structure to the docked NAZ2329 (Figure S1). This validated the docking pose, thus allowing 
further analysis to be carried out. The structures of PTPRZ and NAZ2329 were then prepared and 






2.3 Molecular Dynamic (MD) Simulations 
Molecular dynamic (MD) simulations present a vigorous tool to explore the physical movements 
of atoms and molecules, and in so doing, unveiling dynamical evolution of biological systems. 
Using the GPU version of the PMEMD engine provided with the AMBER package, MD 
simulation was carried out in which the FF14SB variant of the AMBER force field 18.  
Atomic charges for NAZ2329 were created by employing the Restrained Electrostatic Potential 
(RESP) and the General amber Force Field (GAFF) in ANTECHAMBER.  Neutralization of all 
systems and addition of all hydrogen atoms was performed by using the Leap module incorporated 
in the AMBER 14 package. Na+ and Cl
- served as counter ions for the neutralization process. As 
per Leap’s default settings, the amino acids were renumbered in a sequential order, so that residue 
“G1696” was renamed as “G1”. Results were thus displayed as per renamed residues. Using TIP3P 
water molecules of 8Å box size, all systems were implicitly solvated. 
Minimizations of the systems were carried out in two separate stages. The first stage involved a 
2000 steps minimization with an incorporated restraint potential of 500kcal/mol Å2. The second 
stage involved a 1000 steps full minimization process incorporating a conjugate gradient with no 
restrain. 
All systems were then steadily heating from 0K to 300K over 50ps, in a manner that ensured that 
all systems such that the systems conserved a fixed atom number and volume. Solutes in the 
systems were given a potential harmonic restraint. A potential harmonic restraint of 10kcal/mol 
with a collision frequency of 1.0ps was imposed on solutes in all systems.  Equilibrations of all 
systems were then performed after heating over a 500ps period at a constant operating temperature 
of 300K. Constant pressure and atom numbers were also ensured by mirroring an isobaric-
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isothermal ensemble (NPT).   A 1 bar pressure was maintained for all systems using the Berendsen 
barostat.  
A 100ns MD simulation was carried out on all systems in which the SHAKE algorithm was 
incorporated to constrict bonds of hydrogen atoms.  A 2fs simulation step coupled with a SPFP 
precision model was used. The simulations coincided with isobaric-isothermal ensemble (NPT), 
with randomized seeding, constant pressure of 1 bar maintained by the Berendsen barostat, a 
pressure-coupling constant of 2ps, a temperature of 300K and Langevin thermostat with collision 
frequency of 1.0ps.  
2.4 Post-Dynamic Analysis 
The PTRAJ module of AMBER14 suit was used to analyze all trajectories generated from 
coordinates at every 1ps from all simulated systems. Also, the CPPTRAJ module of AMBER14 
package was used to analysis of RMSD, RMSF and Radius of Gyration. 
2.4.1 Binding Free Energy Calculations 
The binding free energy generated in the simulated systems was estimated using the Molecular 
Mechanics/GB Surface Area approach as has been employed  in some of our previous reports19–
21.  The estimated binding free energies may expound the binding mechanism between NAZ2329 
and PTPRZ.  From the 100ns simulation trajectory, 10000 snapshots were obtained and 
subsequently used to estimate the binding free energy.   By the MMGBSA approach, the binding 
free energy is estimated for the complex, ligand and receptor as follows; 
∆G[U\] = G^_`abcd − GTc^cae_T − GbUfg\]																																									(1) 
∆G[U\] = Efgh + Gh_b − TS																																																																		(2) 
Efgh = EU\e + Ei]j + Ecbc																																																																			(3) 
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Gh_b = Gkl + Gmn																																																																																			(4) 
Gmn = γSASA																																																																																											(5) 
Egas represents gas-phase energy and is made up of the sum total of the internal energy Eint; 
Coulomb energy Eele and the van der Waals energies Evdw. Gsol represents the solvation energy 
which is estimated by the sum total of polar state energy contributions, GGB and non-polar energy 
contributions, GSA . Using a water probe radius of 1.4 Å, GSA is estimated from the solvent 
accessible surface area (SASA). GGB is determined from the GB equation. Total entropy of solute 
and temperature is represented as S and T respectively. The accuracy of the estimated relative 
binding free energies reported here might be enhanced if the terms in the equation (2) are averaged 
over multiple conformations or MD snapshots 22, but this usually dependent on the research interest 
under consideration. Conducting MD simulations for NAZ2329, PTPRZ and the complex will 
yield more accurate results in the calculating the binding free energies; it requires greater 
computational resources, which were not readily available for this study.  
3.4.2 Dynamic Cross-correlation Analysis (DCC) 
The correlation coefficient of motions between the atoms in PTPRZ over the simulation period 
were quantified by calculating the dynamic cross correlation matrix 23. DCC was performed using 
CPPTRAJ module of the AMBER 14 suite. The formula used to describe dynamic cross 
correlation is given below: 
 
𝐶𝑖𝑗 = 	
< Δri. Δrj >







Where, i and j represents the ith and jth residue respectively. The displacement vectors that 
correspond to the ith and jth residue respectively is represented as Δri or Δrj .The Origin software 24 
was then used to plot the DCC matrix.  
2.4.3 Principal Component Analysis (PCA) 
Principal component analysis (PCA), is a covariance-matrix-based approach that is used to show 
the displacement of atoms and the dynamics of loops of a protein 25.   Using the PTRAJ module 
of the AMBER14 package, solvent water molecules and neutralizing ions added by the Leap 
module are stripped prior to MD trajectory generation. There is then an alignment of the stripped 
trajectories against their respective fully minimized structures. PCA was performed for C-α atoms 
on 1000 snapshots each.  The first two principal components and covariance matrices were 
calculated using scripts developed with our research group. PCA calculations were conducted over 
1000 snapshots each for C-α atoms. PC1 and PC2, which represent the first two principal 
components, are created from the trajectories averaged from the unbound PTPRZ and the bound 
system.  Using Cartesian coordinates of C-α atoms a 2X2 covariance matrix is created. The first 
two eigen vectors of covariant matrices correspond with the created PC1 and PC2. The Origin 
software24 was then employed to create PCA plots. 
 
2.5 Pharmacophore Model Creation  
Following the simulation of NAZ2329 at the active site of PTPRZ, per-residue energy 
decomposition analysis was used to determine the amino acids that contribute the most towards 
the binding of NAZ2329. In constructing the pharmacophore in this study, the pharmacophoric 
moieties that exhibited prominent interaction with highest energy contributing amino acids were 
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used. In validating and generating our model, it was uploaded on the  ZincPharmer 26 and 
LigandScout 27.   
 
 
3 RESULTS AND DISCUSSION 
3.1 Sequence analysis and structural stability of PTPRZ  
To understand the structural mechanism of inhibition of PTPRZ, it is important to identify the 
fundamental structural characteristics of the protein. Based on previous studies, it has been 
established that the active and allosteric sites may be found adjacent to each other. The WPD-loop, 
a vital catalytic site regulator, forms an outer cover to part of the allosteric site, indicating that the 
ligand that binds to this allosteric pocket would govern the dynamics of this loop. Figure 11.2 
graphically represents these unique structural features, including the corresponding amino acids 




Figure 11.2: Structural and corresponding sequence representation of the unique regions of the 
PTPRZ protein; active site-red, allosteric site- green and WPD-loop- yellow (PDB Code: 5H08) 
16.  
PTPRZ as a protein expressed in the central nervous system is localized in the glial cell where it 
reportedly mediates cell adhesion signaling events during neurogenesis. The strong expression of 
PTPRZ glioblastoma 28 renders them as viable anti-cancer therapeutic targets treatment. The 
inhibitory activity of NAZ2329 as experimentally reported, could potentially influence the 




As such, the stability of 3-D backbone atoms of the simulated APO and complexed PTPRZ was 
ascertained by calculating the root mean standard deviation (RMSD) of the generated trajectories 
over the 100ns simulation period.  Calculated RMSD also assessed the convergence of the 
respective systems as depicted in Figure S1, with each system assuming an energetic plateau after 
about 22ns. An initial increase in RMSD to 3.4Å in the APO system between 0 to 20ns was 
observed, illustrating the dynamic conformational changes associated with the expansion of 
PTPRZ over that period. The expansion allowed infiltration of solvent molecules in hydrophobic 
pockets. However, after about 20ns, all systems rendered energetically stable. The average RMSD 
for both APO and complexed PTPRZ was 2.0Å and 1.6Å respectively. With the average RMSD 
less than 2.0Å, it was deduced that the systems attained conformational stability 29–31. The lower 
RMSD of the NAZ2329-complex relative to the APO system suggest that the inhibitory activity 
of NAZ2329 possibly induced conformational dynamics that contributed to the system achieving 
stability at a lower RMSD. 
 
3.2 Investigation of the dynamic structural features of PTPRZ WPD-Loop 
 
Considering the essential role of the WPD-loop in the catalytic activity of PTPRZ, we explored 
the atomic flexibility of the residues this loop and the entire protein upon binding NAZ2329. The 
use of the crystal structures chosen for this particular study was of utmost importance as the 
binding of NAZ2329 to the allosteric site demonstrated a modification in the crystallized WPD-
loop of the protein. To the best of our knowledge, this is the only available crystal structure that 
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demonstrates binding to the allosteric site of the PTPRZ enzyme, thus validating its use for further 
analysis.    
 
The conformational dynamics of a protein is usually largely dependent on its basic building blocks, 
thus amino acids 32, hence understanding the flexibility of amino acids that make up WPD-loop 
and PTPRZ could reveal important structural insights on the inhibitory activity of NAZ2329. The 
ligand induced motions that occur upon the binding and interaction of NAZ2329 to binding site 
residues, thus triggering a significant conformational change that influence the function of the 
protein 32. As a result of this, we calculated the root mean square fluctuation (RMSF) of the 




Figure 11.3: (A) Shows the comparative RMSF plot of the unbound (APO-red) and bound PTPRZ 






Interestingly, residues 198-204 displayed increased fluctuation in the bound system when 
compared to that of the APO PTPRZ. This particular region of interest encompasses the WPD-
loop, a loop that serves as a flexible gate to the catalytic site of PTPRZ. A “closed” conformation 
of the WPD-loop denotes an active protein, whilst an “open” conformation indicates inactivity of 
the protein 8. It could therefore be inferred that the allosteric inhibition of NAZ2329 induced an 
open conformation of WPD-loop, resulting in an inactive protein conformation of PTPRZ. As 
shown in Figure 11.3, the was a consistent higher flexibility of the WPD-loop in the presence of 
NAZ2329 as the simulation proceeded, suggesting that the allosteric inhibitory activity of 
NAZ2329 could have induced the increased fluctuation of the WPD-loop in order to ensure its 
continuous “open” conformation and hence a consequent inactivity of PTPRZ. Overall, the 
unbound APO and complexed protein appeared to be rigid with the exceptions of select regions, 
being “175-185”, “71-76” and “34-37”. 
 
To further reveal the conformational dynamics that occur on PTPRZ due to the inhibitory action 
of NAZ2329, DCCM matrix analysis was conducted to determine the occurrence of correlated 
motions over the simulation period based on the positions of Ca atoms of the PTPRZ 33. High 
correlated motion, also referred to as positive correlation, ranges from the colour yellow to deep 
red (+1), while anti-correlated motions, also referred to as negative correlation, ranges from cyan 
to black (-1). DCCM analysis revealed that binding of NAZ2329 alters the structure conformation 
of PTPRZ as shown by the changes in the correlated motions and dynamics. There was an overall 
anti-correlated motion of residues within the WPD-loop (residues 198-204) in the bound system 
relative to more correlated motion in the APO system. Since anticorrelated motions of a protein 
may arise from a significant structural external perturbation such as ligand binding34,35, the 
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observed anticorrelated motion in the bound WPD-loop could be attributed to the allosteric 
inhibitory prowess of NAZ232936. This was also consistent with the increased residue fluctuation 
of the loop in the bound conformation as revealed in RMSF in Figure 11.3 as the simulation 
proceeded. It is also evident from the correlation matrix that a more widely correlated motion is 
observed in the APO protein, thus confirming conformational shifts after ligand binding (Figure 
11.4).  The residues within regions “71-76” and “175-185” of PTPRZ exhibited anti-correlated 
motions in both the unbound and bound system which conferred with the observed residue 
fluctuation results.  
 
 
Figure 11.4: Cross-correlation matrices of the fluctuations of C-a atoms in (A) APO and (B) 
NAZ2329-complex. 
 
Considering the fact that the biological function of a protein is influenced by its conformational 
dynamics 37,  we also employed Principal Component Analysis (PCA),  an advanced computational 
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tool to explore the conformational transitions of the APO and complexed PTPRZ over the 100ns 
simulation as illustrated in Figure 11.5. The clustering method of PCA was employed in this study 
due to its proven capability of describing varying conformational states generated during an MD 
simulation. Variations in the conformational states were described by categorizing molecular 
structures into clusters according to conformational similarities 38. Figure 11.5 highlights the 
overall motional shifts across two principle components in the case of APO and the NAZ2329-
complex.   
 
 
Figure 11.5: PCA projection of the motion of Ca atoms constructed by plotting the first two 
principal components (PC1 and PC2) in the conformational space with APO (red) and NAZ2329-
complex (black) respectively. PC1 and PC2, respectively, represent a covariance matrix after 
elimination of eigenvectors (rotational movements). Each point between the single-directional 
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motions represents a unique conformation during the simulation, whereby, similar structural 
conformations overlap in the graph. 
 
The simulated systems were projected along the directions of first two principal components (PC1 
vs. PC2) or eigenvector. The PCA scatterplot generated for the APO and complexed PTPRZ 
systems shows a significant difference between the two systems along the direction of PC1 and 
PC2. Overall, the less correlated motion of the APO system confers with the observed higher 
residue flexibility in the Figure 11.3. This implied that the inhibitory activity of NAZ2329 on 
PTPRZ triggered conformational dynamics as conferred by the conformational flexibility and 
dynamic cross-correlation analysis. The variation in structural dynamics prompted us to assess the 
binding mechanism of NAZ2329 to the allosteric site of PTPRZ. 
 
3.3 Exploring the drug likeness of NAZ2329 
Having been experimental reported to exhibit inhibitory activity against PTPRZ in mouse models, 
we used online software SwissADME 14 to determine the physicochemical descriptors, 
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The lipophilicity and polarity of NAZ2329 was computed using SwissADME, based on the  “Brain 
Or Intestinal Estimated permeation, (BOILED-Egg)” method 39. A suitable balance of the 
pharmacokinetic properties, safety, potency and selectivity is usually paramount in the design of 
therapeutic chemical agent. Chemical properties such as lipophilicity (LogP), which are assessed 
by SwissADME, are very essential features to be considered in the interaction between a chemical 
compound and its biological target. Usually lipophilicity of a chemical agent influences its 
permeability, hepatic clearance or solubility. A chemical compound with a LogP value that ranges 
from 2 to 3 exhibits a highly favorable potential of achieving permeability and first pass clearance 
40. However, NAZ2329 showed a LogP value of 3.06, an indication that NAZ2329 exhibits a less 
favorable potential of achieving permeability and first pass clearance. Although NAZ2329 
exhibited drug-likeness according to Lipinski rules of five 41, it has poor water solubility, low 
gastrointestinal absorption, and cannot permeate through the blood-brain-barrier (BBB). A low 
gastrointestinal absorption may result in a large amount of the drug being excreted resulting in a 
possible decrease inhibitory activity. The inability of NAZ2329 to pass the BBB as observed 
suggests the need for its improvement in its design as a therapeutic agent glioblastoma, a 
malignancy of the central nervous system. 
 
3.4 Estimating the binding mode of NAZ2329 to PTPRZ through Free Energy Calculations 
Using the MM/GBSA based approach; the binding free energy of the NAZ2329-complex was 
estimated over the 100ns MD simulation. This revealed the various energy contributions at the 
catalytic site. To estimate the energies contributed by individual residues located in the catalytic 
site, per residue decomposition analysis was performed. A depiction of the individual energy 
contributions and a map of the interactions between the NAZ2329 and active site residues are 
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illustrated in Figure 11.6. The estimated relative binding free energy for NAZ2329 is displayed in 
Table 11.2.  
Table 11.2: MM/GBSA-based binding free energy profile of the simulated NAZ2329 complex 
 
Figure 11.6: Energy contributions of the interacting residues at the NAZ2329 active site.  
The residue ligand interaction network illustrates stabilizing hydrophobic interactions pocketing NAZ2329 
at the active site. The highest energy contribution was two hydrogen bond interactions shared between ARG 
237 with two separate oxygen moieties of NAZ2329. 
 
Energy Components (kcal/mol) 




-60. 72± 0.15 -114.60± 0.16 61.98±0.14 -52.63±0.09 
∆Eele = electrostatic energy; ∆EvdW = van der Waals energy; ∆Gbind = calculated total 
binding free energy; ∆Gsol = solvation free energy. 
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NAZ2329 showed a relative binding free energy of -52.63 kcal/mol, implying a favorable 
thermodynamic stability, which conferred with the compact bound protein upon calculation of 
radius of gyration as shown in Figure S2. Residues that contributed the most to the binding of 
NAZ2329 include; ARG 237 (-7.201 kcal/mol), PRO 203 (-2.584 kcal/mol) and GLN 279 (-2.064 
kcal/mol). From the residue-ligand interaction plot, it could be observed that, ARG 237 formed 
the most hydrogen bond interactions hence its high-energy contribution to the total binding energy 
estimated.  
 
3.5 Pharmacophore Model Creation 
An informative structural ensemble of steric and electronic features that were necessary to ensure 
supramolecular interaction of NAZ2329 with PTPRZ was generated (Figure 11.7). This chemical 
structural scaffold was developed based on the observed NAZ2329-PTPRZ interaction shown in 
Figure 11.6, while taking into consideration the residues that contributed the most to total binding 
energy as well. The generated pharmacophore model unveils useful chemical insights that could 




Figure 11.7. (A) Common pharmacophoric features from alignment of the PTPRZ ligand/residue 
interaction plots, 3-D pharmacophore model generated on ZINCPharmer (Green- 
Hydrophobic/Aromatic moiety, gold - hydrogen bond donor/acceptor). (B) 2-D representation of 




The comprehensive bio-computational analysis employed in this study establishes the structural 
modifications in PTPRZ subsequent to binding of allosteric inhibitor, NAZ2329. Molecular 
dynamic simulations divulged profound motional shifts the WPD-loop of the PTPRZ. This 
flexibility was reported in the RMSF analysis and verified by the graphical investigation of the 
loop at different time intervals during the simulation. Investigation of the DCC matrix and PCA 
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led to the deduction that the activity of NAZ2329 on PTPRZ triggered conformational dynamics 
that may be used to explain the mechanism of inhibition of the protein. Based on previous 
experimental evidence supporting the inhibitory activity of NAZ2329 and the structural dynamics 
leading to the design of the pharmacophore in this study, we believe that our conclusions could 
facilitate the design of small molecules that will not only inhibit PTPRZ and PTPRG, but will be 
applicable to other tyrosine phosphatases as well.  This optimized pharmacophoric approach may 
also lead to a decline in cross-resistance and may increase patient adherence.  
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Background: The last few decades have witnessed groundbreaking research geared towards 
immune surveillance mechanisms and have yielded significant improvements in the field of cancer 
immunotherapy. This approach narrows down on the development of therapeutic agents that either 
activate or enhance the recognitive function of the immune system to facilitate the destruction of 
malignant cells. The α-galactosylceramide derivative, KRN7000, is an immunotherapeutic agent 
that has gained attention due to its pharmacological ability to activate CD1d-restricted invariant 
natural killer T(iNKT) cells with notable potency against cancer cells in mouse models; a 
therapeutic success was not well replicated in human models. Dual structural modification of 
KRN7000 entailing the incorporation of hydrocinnamoyl ester on C6’’ and C4-OH truncation of 
the sphingoid base led to the development of AH10-7 which, interestingly, exhibited high potency 
in human cells. 
Objective/Methods: Therefore, to gain molecular insights into the structural dynamics and 
selective mechanisms of AH10-7 for human variants, we employed integrative molecular 
dynamics simulations and thermodynamic calculations to investigate the inhibitory activities of 
KRN7000 andAH10-7 on hTCR-CD1d towards activating iNKT.  
Results: Interestingly, our findings revealed that AH10-7 exhibited higher affinity binding and 
structural effects on hTCR-CD1d, as mediated by the incorporated hydrocinnamoyl ester moiety 
which accounted for stronger intermolecular interactions with ‘non-common’ binding site 
residues. 
Conclusions: Findings extracted from this study further reveal important molecular and structural 











Immune surveillance mechanisms are physiologically employed in cancer to ameliorate the 
debilitating effects of the disease [1]. However, there is usually an eventual failure of the immune 
response due to changes that occur in the microenvironment, which in turn permit tumor growth 
with a concurrent sabotage of the anti-cancer immune responses [1]. Nonetheless, some immune 
cells exhibit prominent roles in regulating immune response to cancer, notably, the invariant 
natural killer T cells iNKT, distinguished by their semi-variant T cell receptor (TCR) in humans 
and mice (Vα24Jα18 in humans and Vα14Jα18 in mice) [2–5]. As a unique class of lymphocyte 
involved in both innate and adaptive immune response [6–9], iNKT are characterized by their 
ability to identify lipid-based antigens presented by the MHC class I-like CD1d protein [3,10–13].  
Unlike other natural killer cells, iNKT are selected by CD1d-expressing thymocytes instead of 
interacting with class 2 MHC molecules [6,14]. As a sub-type of NKT, iNKT are the only CD1d-
restricted cells that harbor the invariant TCR and is able to identify the prototype alpha-
galactosylceramide inhibitors [5]. Though low in frequency in the peripheral blood, iNKTs are 
dominant in the adipose tissues of both humans and mice. By secreting IL-4, iNKT assume an anti-
inflammatory role that has been shown to prevent resistance to insulin as well as inflammatory 
responses in the adipose tissue [15–20]. When activated, iNKT cells can also increase the 
expression of NKTs and consequently increase the stimulation of conventional T cells via their 
cytokine and mature dendritic cells secretion [21,22].Upon antigenic triggering, iNKT cells 
usually respond in few hours by releasing of Th1, Th2, and Th17 cytokines [23]. The involvement 
of iNKT in the rapid secretion of cytokines as well as in CD40L expression potentiates their 
prominent roles in immune response [5]. In antitumor immune response, iNKTs are directly 
involved in the killing of tumor cells via the induction and release of cytotoxic lymphocytes 
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(CTLS) coupled with the activation of NK cells and modulation of immunosuppressive tumor 
microenvironment [24,25]. Hence, considering their crucial roles in antitumor immune response, 
iNKTs have been extensively explored as immunotherapeutic targets [5,26,27].Current therapeutic 
approaches that entail iNKT cell targeting have focused on stimulating iNKT activation with the 
aid of exogenous agents, an approach referred to as active immunotherapy [24,27]. Alpha-
galactosylceramide (α-GalCer), a potent marine sponge sphingolipid antigen was identified in the 
early 1990s as an exogenous molecule that can activate iNKT towards cancer treatment [28–30]. 
Over the years, α-GalCers have been widely investigated and developed as immunotherapeutic 
agents and vaccines [26,31]. This feature has resulted in the discovery of KRN7000, the first 
synthetic α-GalCer by Kobayashi et al., in 1995[32,33] (Figure 12.1). Although KRN7000 showed 
potent anticancer properties as well as some interesting efficacy against autoimmune and 
infectious diseases in mouse models [26], its successful translation and advancement into clinical 
use has been relatively limited [34,35]. A recent phase 1 trial by Nair and Dhodapka in 2017, 
reported that KRN7000 had limited clinical benefit to humans [35,36]. However, the foremost 
challenge associated with KRN7000 is its propensity of inducing high levels of helper T cells: T 
helper 1 (Th1) and T helper 2 (Th2), a phenomenon that accounts for their contradictory function, 




Figure 12.1: 2D structures of AH10-7 (above) and KRN7000 (below) coupled with the 3D X-ray crystal 
structure of human iNKT-TCR (middle). Red inset showcases constituent hydrophobic pocket residues. 
 
Due to the limited success recorded for KRN7000, efforts have been made over the past years to 
twig the moieties of KRN7000 so as to obtain new α-GalCer derivatives with improved potencies 
and activities in humans while propagating  the release of  either Th1 or  Th2,  but  not a concurrent 
release of both [22,37,38]. The latest of such attempts was reported by Chennamadhavuni et al., 
where a new α-GalCer derivative, AH10-7 was synthesized by incorporating a C6’’ hydro 
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cinnamoyl ester while removing the C4-OH of the sphingoid base [34] (Figure 1). This unique 
dual modification resulted in demonstratable AH10-7 potency towards the activation of iNKT in 
both mouse and human models while highly biased towards Th1 secretion. Chennamadhavuni et 
al., further explored the mechanistic basis of the dual modification of iNKT activation via X-ray 
crystallography and molecular modelling. Molecular docking and QM/MM studies showed that 
the simulated binding pose of AH10-7 reproduced well the 2C12 TCR-mCD1d-AH10-7 ternary 
complex structure obtained by X-ray crystallography with better binding affinity. However, since 
molecular docking is inadequate in providing a thorough and dynamic perspective into the 
mechanistic binding  and recognition of the dually modified α-GalCer derivative, AH10-7, this 
current study employs molecular dynamics simulation techniques to provide additional molecular 
insights into the structural dynamics and mechanistic binding of the novel α-GalCer derivative to 
human iNKT-TCR [39]. Molecular dynamics (MD) simulation mimics the dynamical events of 
molecular systems as a function of time, with a molecular description of all biological components 
(ligand and protein) in a solvent space [40]. Hence this approach would enable a detailed 
elucidation of molecular events and recognition mechanisms that characterize selective binding of 
AH10-7 [34]. Findings will also reveal important atomistic perspectives that could aid in the design 
of novel α-GalCer derivatives for cancer immunotherapeutics. 
 
2.0 Computational Methods 
2.1 System Preparation 
The X-ray crystal structures of 2C12 TCR-CD1d in complex with AH10-7 (PDB:6BNL) and 
KRN7000 ((PDB code:6BNK) [34] were retrieved respectively from RCSB Protein Data Bank 
[41] and were used as the starting structures. The retrieved structures exist as a homomultimers 
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with eight chains, however, only chains (A, C) which contained the ligand binding pockets were 
used in this study to reduce the computational cost. All non-standard residue molecules and ligands 
were deleted during the preparation of the receptor structure. Hydrogen atoms were added to the 
isolated ligands using the UCSF Chimera software package during structure preparation. Software 
was developed by the Resource for Biocomputing, Visualization, and Informatics (RBVI), 
University of California, San Francisco, USA [42]. 
 
2.2 MD simulations 
MD simulations for 2C12 TCR-CD1d complexed distinctly with AH10-7 and KRN7000 were 
performed. Altogether, three systems comprising of unbound and bound forms of 2C12 TCR-
mCD1d were subjected to MD simulations using the AMBER14 software package. Software was 
developed by Case et al., University of California, San Francisco, USA [43]. Protein optimization 
and explicit solvation were carried out using the integrated LEAP module while the AMBER 
FF14SB force field was employed to define protein parameters. The systems were partially 
minimized for 2500 steps with a restraint potential of 500 kcal/mol Å2 followed by full 
minimization of 10000 steps. The systems were gradually heated from 0-300K using a Langevin 
thermostat in a canonical ensemble (NVT) [44]. Equilibration was also carried out without 
restraints at a temperature of 300K in an NPT ensemble for 1000 ps while atmospheric pressure 
was maintained at 1 bar using the Berendsen barostat [45]. This procedure was followed by MD 
production runs of 100 ns for each system during which the SHAKE algorithm was used to 
constrict all atomic hydrogen bonds [46].The integrated CPPTRAJ and PTRAJ modules [47] of 
AMBER14 were used to analyze resulting coordinates and trajectories while obtained data were 
plotted using Microcal Origin software, developed by OriginLab Corporation, United States [48]. 
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2.3 Binding free energy calculations 
In this study, the Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) method  
was used to estimate the differential binding of AH10-7 and KRN7000 to 2C12 TCR-mCD1d [49] 
as employed in many of our previous reports [50–54]. This technique could help predict the 
differential binding strengths and affinities of both ligands to 2C12 TCR-mCD1d. Mathematically, 
the binding free energy (ΔG) for each complex is represented as: 
ΔGbind = Gcomplex - Greceptor - Gligand            (1) 
Egas = Eint + Evdw + Eele                 (2) 
Gsol=GPB + GSA       (3) 
GSA = γSASA      (4) 
 
Van der Waals and electrostatic interactions are represented as Evdw and Eele while Egas denotes 
gas-phase energy and Eint internal energy. The solvation free energy, denoted by Gsol represents 
the solvation free energy and can be decomposed into polar and nonpolar contribution states. The 
polar solvation contribution, GPB, is determined by solving the PB equation, whereas, GSA, the 
nonpolar solvation contribution is estimated from the solvent accessible surface area (SASA) 
determined using a water probe radius of 1.4 Å. Per-residue energy contributions of active sites 
residues towards the stabilization of AH10-7 and KRN7000were estimated using data obtained 
from the MM/PBSA calculations [49]. Energy contributions of these residues give a clue into the 
essentiality of these residues towards the stabilization of the ligands in the binding pocket and their 




3.0 Results and Discussion 
AH10-7 successfully demonstrated its potency in human cells which earned it a significant 
advantage over earlier derivatives such as KRN7000 [34]. Investigated model systems in this 
report depict unbound human TCR-CD1d, a KRN7000-bound TCR-CD1d and a AH10-7 bound 
TCR-CD1d taken through 100 ns MD simulation to explore impact of the dual modification which 
characterize AH10-7 relative to its enhanced potency over earlier derivative, KRN7000 in human 
models. An initial sequence analysis as shown in Figure 12.2 showcased a large similarity in 
sequence of residues that interacted directly with both AH10-7 and KRN7000 due to similarity in 
structure. Nonetheless there were notable variations in the interaction with distinct residues 
observed particularly in the AH10-7 complex, which could partly be attributed to the additional 
interactions mediated by the incorporated hydrocinnamoyl ester moiety. The similarity in sequence 
of the interacting residues also suggests similar binding modes of the both AH10-7 and KRN7000. 
Figure 12.2: Comparative sequence analysis of AH10-7 and KRN7000-2C12 TCR-mCD1d complexes 
with corresponding highlights of interacting residues at the hydrophobic pockets. Green inserts indicate 




3.1 Enhanced binding affinity and mechanistic electivity mediated by the incorporated 
hydrocinnamoyl ester on the C6” of the sugar 
 
The ability of α-GalCer to potentially activate in human iNKT cells is largely dependent on their 
respective interactions at the hydrophobic pocket on TCR-CD1d in which they bind, and the 
corresponding binding energies elicited. The respective interactions between the α-GalCer 
derivatives and amino acids at the binding pocket of TCR-CD1d are crucial to the overall stability, 
selectivity and total binding affinity. With a highly favorable binding energy of AH10-7 over 
KRN7000 from QM/MM calculations as estimated in earlier reports, we again calculated their 
total binding free energy (ΔG) over the course of the MD simulation period, in an attempt to 
corroborate earlier reports using the extensively explored MM/PBSA approach [49,51,52,55]. This 
procedure was performed to also understand the molecular basis of the reported favorable binding 
of AH10-7 over KRN7000 from experimental reports. The calculated binding free energy also 
provided a deeper quantitative understanding of the binding of both KRN7000 and AH10-7 while 
also providing a direct insight into driving forces that support their binding. As shown in Table 
12.1, AH10-7 exhibited a total binding free energy of -30.12 kcal/mol while KRN7000 exhibited 
a total binding free energy of -28.2 kcal/mol. As estimated, AH10-7 exhibited a higher binding 
affinity (ΔG) relative to KRN7000 which corroborates earlier reports in which AH10-7 exhibited 
superiority in binding over KRN7000 [34]. As presented in Table 12.1, the intermolecular van der 
Waals and electrostatic interactions provide the major contribution for the binding of both 
KRN7000 and AH10-7 even though the van der Waals forces were more prominent towards the 
binding of AH10-7 than KRN7000. The van der Waals and electrostatic energies in the TCR-
CD1d-AH10-7 were estimated as -28.11 kcal/mol and -11.81 kcal/mol, respectively as shown in 
Table 12.1. Also, a positive polar solvation energy estimation indicates the binding interactions 
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were more favorable in the hydrophobic (non-polar) regions of the ligand-protein complex. 
Likewise, we observe that van der Waals interactions further contributed to complex formation in 
both ligands. These interactions altogether, could account for the binding affinities exhibited by 
both ligands when bound to hCD1D as previously reported [34]. 
 
Table 12.1: MM/PBSA-based binding free energy profile of KRN7000 and AH10-7 
ΔEele = electrostatic energy; ΔEvdW = van der Waals energy; ΔGbind = total binding free energy; ΔGsol = solvation 
free energy ΔG = gas phase free energy. 
 
3.2 Energy-based decomposition of binding site residues and corresponding contributions 
towards ligand binding 
 
To further understand the favorable and preferential binding mechanisms of AH10-7 over 
KRN7000, we performed the decomposition of total ΔG involved with respect to the contributions 
of individual ligand binding site residues. This operation was carried out using the MM/PBSA-
incorporated per-residue energy decomposition method. Estimated per-residue energies allowed a 
more thorough quantitative insight into the differential binding mechanisms of both KRN7000 and 
AH10-7 while showcasing the superiority of AH10-7 based on the energy contribution of each 
binding site residue. An interesting observation was the obvious variation in major energy 
contributing residues when comparing both the AH10-7- and KRN7000-bound systems. Basically, 































the involvement of certain residues that interacted with the hydrocinnamoyl ester group on C6’’ 
of AH10-7 could account for enhanced binding when compared to KRN7000. Figure 12.3 
showcases the energy contributions of residues unique to the binding of both AH10-7 and 
KRN7000. The introduction of the hydrocinnamoyl ester in AH10-7 visibly increased the number 
of interactions as compared to KRN7000 with relatively fewer interactions. As shown, many of 
the residues with higher energy contributions interacted are those involved in complimentary 
interactions with the hydrocinnamoyl ester moiety. Cumulatively, these unique interactions with 
the hydrocinnamoyl ester group in AH10-7 could have contributed to a higher affinity binding 




Figure 12.3: Per-residue energy decomposition plot of uncommon binding site residues and their 
differential interactions with AH10-7 and KRN7000, with corresponding ligand interaction plots of average 
structures. 
 
As shown in Figure 12.4A, the modification in AH10-7 accounted for a higher number of 
conventional hydrogen bonds with shorter distances relative to those elicited by KRN7000 as 
presented in Figure 12.4B using average structures obtained from the MD trajectories. The higher 
number of conventional hydrogen interactions amidst other notable interactions such as van der 
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Waals and alkyl interactions with surrounding hydrophobic residues could have equally 






Figure 12.4: Complementary binding site-surface interactions of [A] C6” modified hydrocinnamoyl ester 
in AH10-7 and [B] “non-modified” KRN7000 galactosyl moiety. Conventional (OH--O) and non-
conventional/carbon-hydrogen (CH--O) bonds are also indicated. 
 
A broader analysis of the differential activities of AH10-7 and KRN7000 focused on binding 
pocket residues within 5Å radius from them, which revealed striking insights that could further 
support the binding superiority of AH10-7 to 2C12 TCR-mCD1d over KRN7000 as previously 
established. Overall, residues with energy contributions less than -1.0 kcal/mol were considered 
very crucial to the interaction of the α-GalCers within the hydrophobic pocket and could 
consequently influence their overall activity [56]. From the calculations, residues within 5Å radius 
which contributed prominently to KRN7000  binding included Cys12, Val30, Ile47, Phe70, Tyr73, 
Ser76, Phe77, Asp80, Ile81, Leu84, Leu100, Leu116, Val118, Leu151, Asp153, Thr156 and 
Pro28, all located on chain C. Amongst these, residues Thr156, Asp80 and Tyr73 exhibited the 
highest energies of -4.11kcal/mol, -4.31kcal/mol and -3.88kcal/mol, respectively as shown in 
TableS1. On the other hand, residues that notably contributed to the binding of AH10-7 included 
Cys12, Val30, Lue66, Met69, Phe70, Val72, Tyr73, Ser76. Phe77, Leu79, Leu100, Leu116, 
Val118, Leu150, Asp153, Thr156, Thr159, Val160, Leu163, and Ile76, Pro28, Asn30, Asp94, and 
Arg95 on chain C. Moreover, residues Asp153, Thr156 and Tyr73 contributed the highest energies 
towards the binding and stabilization of AH10-7 with estimated total energies of -3.72 kcal/mol, -
3.52 kcal/mol and -4.56 kcal/mol, respectively (Table S2). As observed, many of the high energy 
contributing residues in both AH10-7 and KRN7000 complexes were both similar suggesting an 





Figure 12.5: Structural superposition of AH10-7 and KRN7000 at the binding pocket of human iNKT-





3.3 Dual sphinganine base and hydrocinnamoyl ester modification of αGalCer enhanced 
residue interactions with TCR-CD1d. 
 
To get a further molecular grasp of the effects of hydrocinnamoyl ester incorporation on the 
therapeutic potential of AH10-7 towards iNKT cellular activation in humans, we performed 
a time-scale molecular visualization of resulting snapshots (10 ns, 40 ns, 70 ns and 100 ns) 
taken across the MD simulation period as shown Figure 12.6A and 12.6B. This procedure 
permitted a thorough and dynamical exploration of the nature of interactions that the 
incorporated moieties elicited during at the hydrophobic pocket region which could have 
accounted for its favorable interaction relative to KRN7000 as evidenced by the differential 
ΔGs earlier estimated. As shown in Figure 12.6A and 12.6B, certain residues maintained 
steady “strong intermolecular” interactions with the incorporated moiety of AH10-7 at the 
hydrophobic pocket across the 100 ns simulation time. At the beginning of the simulation at 
around 10 ns, the residues: Ser30, Asp153, Thr156 and Asp80 on chain A and Gly96 on chain 
C formed strong hydrogen interactions with the modified moieties as shown in Figure 12.6A. 
At about 40 ns, these same interactions were preserved as shown in Figure 12.6A. Towards 
the end of the simulation at about 70 ns as shown in Figure 12.6B, two new hydrogen bond 
interactions were formed between the hydrocinnamoyl ester group, Asp29 and Asn30 on 
chain C in addition to Asp153 and Thr156. At the end of the simulation at 100 ns as shown 
in Figure 12.6B, strong hydrogen bonds were formed between the modified moieties and 
Asp80, Arg153 on chain A and Gly96 and Arg95 on chain C. It was observed, that although 
the interacting residues varied over the course of the simulation, most of the interactions were 
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steadily maintained with Thr153. These same set of residues were amongst the highest energy 
contributing residues in the per-residue energy decomposition calculations shown in Table 
S1. These strong interactions could have contributed to the stronger binding of AH10-7 over 
KRN7000 as estimated. These could also contribute to the enhanced therapeutic activity in 
human cells. 
 
Likewise, we monitored the interactions of KRN7000  at the hydrophobic pocket at the same 
time-scales of 10 ns, 40 ns, 70 ns and 100 ns, with keen interest on the “non-modified” region, 
allowing for comparative analysis with AH10-7 so as to properly comprehend the impact of 
the dual modification. As shown in Figure 12.6A, at 10 ns, although KRN7000 almost 
engaged in similar number of hydrogen bond interactions as AH10-7, KRN7000 had fewer 
hydrophobic contacts. Also, KRN7000 did not interact with Ser30 which was shown to form 
a strong hydrogen bond with AH10-7 at 10 ns. Similarly, at 40 ns, as shown in Figure 12.6A, 
whilst AH10-7 formed an even stronger hydrogen bond with Ser30, KRN7000 did not still 
engage in any interaction with Ser30 with few hydrophobic contacts as well. Towards the 
end of the simulation at 70 ns as shown in Figure 12.6B, although AH10-7 formed two strong 
hydrogen bond interactions with Asp153, there was no interaction of KRN7000 with Asp153. 
At the end of our simulation at 100 ns, AH10-7 again formed strong hydrogen bond 
interaction with Arg153, an interaction that did not occur again with KRN7000. Therefore, 
taken together, the strong hydrogen bond interactions engaged between AH10-7 and Ser30 
at 10 ns and 40 ns as well as the two hydrogen bond interactions with Asp153 at 70 ns and 
the single hydrogen bond with Arg95 on chain C, coupled with other hydrophobic contacts, 
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could have accounted for the more favorable activity of AH10-7 towards human TCR-CD1d 
variant; hence, the stronger binding free energy estimated compared to KRN7000. 
Previous studies have revealed that the modified sphinganine base together with the 
stabilized surface binding mediated by the C6” substitution synergistically play crucial roles 
in hCD1d binding affinity and Th1 biasing. From our findings (Figure 12.4A and B), we 
observed that the modified sphinganine base was positioned in the deep hydrophobic pockets 
of the receptor. However, the substituted hydrocinnamoyl ester group was protruded and 
made stabilizing contacts with surface residues which was essential for stabilizing the polar 
galactosyl head group for TCR recognition, affinity and potency (Figure 12.5). Additional 
interactions elicited by the C6” substituents presumably compensated for the sphinganine 
base modification. Hence, strong affinity and interaction compensation synergistically 
mediated by the C6” substituent and sphinganine base (4’OH) modification could suggest 
the Th1 biasing activity and high hCD1d binding affinity/potency of AH10-7. These are in 




Figure 12.6: [A] Comparative time-based monitoring of complimentary interactions of “modified” 
and “non-modified” regions of AH10-7 and KRN7000, respectively at 10 ns and 40 ns. [B] 
Comparative time-based monitoring of complimentary interactions of “modified” and “non-
modified” regions of AH10-7 and KRN7000, respectively at 70 ns and 100 ns.  
 
3.4 Conformational effects of AH10-7 and KRN7000 and differential binding on hTCR-
CD1d  
 
Since proteins are basically made up of different amino acids [57], structural changes and 
alterations among these components, particularly those involved in ligand binding and 
stabilization could greatly influence overall protein function [58,59]. Moreover, the binding 
of small molecule inhibitors greatly influences the integrity of the protein active site and 
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overall conformation with regards to structure-functional inactivation or activation [59]. We, 
therefore, performed a conformational analysis of hTCR-CD1d binding site residues over the 
course of simulation comparing their dynamics in the unbound state and when distinctly 
bound by both AH10-7 and KRN7000. This procedure also enabled a thorough insight into 
the impact of the incorporated groups on AH10-7 relative to its superior therapeutic efficacy. 
Prior to the analysis of the structural dynamics, we monitored the validity of our simulated 
models which was ascertained by calculating the root mean square deviations (RMSD) of the 
Cα atoms of hTCR-CD1d across the 100 ns  simulation as presented in Figure S1 [60–62]. It 
was observed from the plot that all systems achieved convergence after about 20 ns following 
an initial gradual rise in structural deviation due to motions of constituent Cα atomsfrom the 
beginning of the simulation. Overall unbound hTCR-CD1d exhibited the highest deviation 
of Cα atoms with an average RMSD of 8.84Å while the KRN7000 bound system showcased 
the lowest deviation with an average RMSD of 6.70Å while the AH10-7-bound hTCR-CD1d 
exhibited an average RMSD of 7.14Å. Taken together, the bound systems were characterized 
by comparatively lower deviations of Cα atoms relative to the unbound hTCR-CD1d, 
suggesting that the binding of AH10-7 and KRN7000 stabilized hTCR-CD1d structure. With 
all studied systems having achieved convergence and subsequent stability after about 20 ns, 
it is suggestive that subsequent deductions and assumptions drawn from the generated MD 
trajectories are trustworthy [63]. Moreover, the binding of AH10-7 and KRN7000 to hTCR-
CD1d induced a consistent pattern of structural alteration, which was characterized by a 
decrease in deviation among the Cα backbone atoms in contrast to the unbound hTCR-CD1d 
conformation that relatively exhibited higher structural instability. Suggestively, the minimal 
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disruption of the backbone atoms in hTCR-CD1d upon binding of AH10-7 and KRN7000 
could highlight the mechanistic therapeutic potencies of these α-GalCer derivatives. 
We then proceeded to calculate the root mean square fluctuation (RMSF) of the Cα atoms as 
well as the solvent accessible surface area (SASA) of each of the residues on both chains 
over the course of the 100 ns simulation as shown in Figure 12.7. With RMSF calculations 
as shown in Figures 12.7C and 12.7D, we were able to access the flexibility of each of the 
residues while SASA (Figures 12.7A and 12.7B) calculations showcased the exposure and 
unfolding mechanism of buried residues within the hydrophobic pocket which could have 
engaged in essential interactions with bound ligands. From the RMSF plots it was observed 
that the ligand bound conformations of the hydrophobic pocket residues were less flexible 
relative to the unbound conformation, possibly implying that the binding of both AH10-7 
and KRN7000 restricted the movement of these residues and subsequently imposed some 
level of rigidity. However, relative to KRN7000, hydrophobic residues in the AH10-7-bound 
system were more flexible with an average RMSF of 7.53Å while KRN7000 exhibited an 
average RMSF of 5.8Å. The higher flexibility could be attributed to the structural 
destabilization and distortion induced by the structural modification incorporated in AH10-
7. The SASA plots also revealed that the binding of both AH10-7 and KRN7000 induced 
lower average SASA values relative to the unbound hTCR-CD1d which was consistent with 
protein folding and an expulsion of the hydrophobic residues toward the protein core. 
However, among AH10-7 and KRN7000, AH10-7 showcased higher average SASA which 
further implied that the hydrophobic residues were more exposed to the aqueous environment 
hereby exposing buried surfaces, which justifies an increase in SASA value. The exposure 
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of the buried surfaces could have potentially favored the suitable intermolecular interactions 
that contributed to the enhanced binding free energy estimated.    
Figure 12.7: A) Comparative SASA plots of residues that make up the binding pocket of both AH10-
7 and KRN7000 as well as the unbound conformation. B) 3D surface representation of the higher 
SASA of the AH10-7 complex with hydrocinnamoyl ester region showcasing the highest SAS (deep 
blue). C) Comparative RMSF plots of binding site residues with the unbound iNKT-TCR showing 
the highest residue flexibility. D) 3D representation of superimposed X-ray crystal structures of 






The plethora of scientific reports that have been conducted over the years towards enhancing 
the therapeutic competence of earlier α-GalCer derivatives towards the design of improved 
molecules such as AH10-7. The recent discovery of AH10-7, which exhibited impressive 
therapeutic efficacy in human iNKT-TCR variant typified a significant breakthrough in the 
search for an alternative approach to physiological immune surveillance. The uniqueness of 
AH10-7 over previous α-GalCer derivatives is attributed to its sphingoid base and 
hydrocinnamoyl ester on its C6”. However, regardless of the exciting experimental studies, 
there is little to no reports on the structural dynamics, molecular mechanisms and binding 
profile of AH10-7 in support of its therapeutic prowess. As such, this study sought to provide 
essential and augmentative details using MD simulation techniques coupled with post-MD 
analytical methods such as RMSD, RMSF, SASA and MM/PBSA. Dual modifications of 
AH10-7 enhanced its binding superiority over the earlier α-GalCer KRN7000 by forming 
stronger intermolecular and hydrophobic interactions with some specific binding site 
residues of TCR-CD1d. Unique hydrogen bonds interactions of AH10-7 with Ser30, Asp153 
on chain A and Arg95 on the chain C could have equally accounted for its outstanding 
binding superiority as estimated in the binding free energy analysis. Although there exists 
similarity in ligand-interacting residues due to structural similarities between AH10-7 and 
KRN7000, the introduced hydrocinnamoyl ester in AH10-7 potentiated favorable 
intermolecular interactions which probably contributed to enhanced binding. Also, the dual 
modification on AH10-7 induced a higher structural flexibility and increased the exposure of 
buried hydrophobic residues which could have favored their respective interactions when 
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compared with KRN7000. Findings unveiled atomistic insights into the binding profile of 
AH10-7 and could serve as a basis for further research into sphinganine derivatives towards 
the design of novel immunotherapeutic agents that could augment current cancer therapies.  
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13.0 Conclusion and Future Perspectives 
 
13.1 Conclusions 
Studies in this thesis employed CADD approaches in unraveling the mechanism of inhibition 
of some known therapeutic targets in treating viral infections, cancer, and tuberculosis. Drug-
target interactions and mechanisms of actions elucidated in this thesis are relevant since the 
interaction dynamics of drugs at binding sites play a vital role in the drug discovery process 
by influencing new drugs' overall therapeutic success. These interactions dynamics also 
provide essential insights that could inform the identification of new drug compounds for 
biological targets or improving the therapeutic activity of existing compounds. Therapeutic 
targets investigated included; SARS-CoV-2 RNA dependent RNA polymerase (SARS-CoV-
2 RdRp), Human Rhinovirus B14 (HRV-B14) and human N-myristoyltransferases in viral 
infections, Dihydrofolate reductase (DHFR) and Flavin-dependent thymidylate synthase 
(FDTS) in tuberculosis, human variants of TCR-CD1d and Protein Tyrosine Phosphatase 
Receptor Zeta (PTPRZ). As such, the focus of this research was divided into three domains. 
The research that culminated in this thesis began with a thorough review of the concept of 
druggability and drug-likeness since the crux of the following research objectives revolved 
around therapeutics and their inhibitions by small molecule inhibitors. The review 
highlighted druggability and drug-likeness principles and their recent advancements in the 
drug discovery field. Subsequently, the different computational tools, their predictive 




In the first domain of the research, studies presented sought to unravel some small molecule 
inhibitors' mechanism against some therapeutic targets in viral infections by explicitly 
focusing on the therapeutic targets; SARS-CoV-2 RdRp, HRV-B14, and N-
myristoyltransferase.  
Studies in the first domain of the research began with an exploration of the binding 
mechanism of Remdesivir by unraveling the structural and conformational implications on 
SARS-CoV-2 RdRp towards identifying crucial pharmacophoric moieties of Remdesivir. 
Our analysis showed that the modulatory activity of Remdesivir is characterized by an 
extensive array of high-affinity and consistent molecular interactions with specific active site 
residues that anchor Remdesivir within the binding pocket for efficient binding. Results also 
showed that Remdesivir binding induces minimal individual amino acid perturbations, subtly 
interferes with deviations of C-α atoms, and restricts the systematic transition of SARS-CoV-
2 RdRp from the “buried” hydrophobic region to the “surface-exposed” hydrophilic region. 
We also mapped a pharmacophore model based on observed high-affinity interactions with 
SARS-CoV-2 RdRp, which showcased the crucial functional moieties of Remdesivir and 
was subsequently employed for virtual screening. The structural insights and the optimized 
pharmacophoric model provided would augment the design of improved analogs of 
Remdesivir that could expand treatment options for COVID-19 the molecular mechanism of 
action of a novel benzothiophene derivative against HRV-B14 was investigated. Residue 
interaction network analysis revealed that the binding of the benzothiophene derivative upon 
binding into the “canyon” region of the active site of HRV-B14 distorts its initially 
extensively networked and compact residue profile with conformational changes 
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characterized by fewer inter-residue hydrogen bonds, reduced van der Waals interactions, 
and increased residue flexibility. Also, the binding of this benzothiophene derivative 
decreased the north-south wall's flexibility around the canyon region, possibly impeding the 
“breathing motion” of HRV-B14.  
In addition, the structural and molecular mechanism of action associated with the dual 
inhibitory activity of IMP-1088, a novel compound that reportedly inhibits both HsNMT1 
and HsNMT2 towards common cold therapy was also investigated. An augmentative 
computational and nanosecond-based analyses reveal that the steady and consistent 
interactions of IMP-1088 with specific residues; Tyr296, Phe190, Tyr420, Leu453, Gln496, 
Val181, Leu474, Glu182, and Asn246, shared within the binding pockets of both HNMT 
subtypes, in addition to peculiar structural changes account for its dual inhibitory potency. 
Findings unveil atomistic and structural perspectives that could form the basis for the design 
of novel dual-acting inhibitors of N-myristoyltransferase towards common cold therapy. 
 
In the second domain of the research, studies presented attempted to unravel the mechanism 
of actions of some small molecule inhibitors against some therapeutic targets in tuberculosis 
therapy by unraveling the molecular mechanisms and structural dynamics associated with 
dual inhibitory activity of PAS-M against both DHFR and FDTS towards tuberculosis 
therapy. MD simulations revealed that PAS-M binding towards DHFR and FDTS is 
characterized by a recurrence of strong conventional hydrogen bond interactions between a 
peculiar site residue the 2-amino-decahydropteridin-4-ol group of PAS-M. 
Using an atomistic model of mycobacterial c-ring the structural dynamics that explicate the 
experimentally reported antagonistic features of BDQ in halting ion shuttling by the 
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mycobacterial c-ring towards the treatment of TB was also described. Results showed that 
BDQ exhibited a considerably high ΔG while it specifically maintained high-affinity 
interactions with Glu65B -and Asp32B, blocking their crucial roles in proton binding and 
shuttling required for ATP synthesis. Moreover, the bulky nature of BDQ induced a rigid and 
compact conformation of the rotor c-ring, which impedes the essential rotatory motion that 
drives ion exchange and shuttling. The binding affinity of a BDQ molecule was considerably 
increased by the complementary binding of another BDQ molecule, which indicates that an 
increase in BDQ molecule enhances inhibitory potency against Mtb ATP synthase. 
Furthermore, the effects of triple mutations (L59V, E61D, and I66M) on BDQ-Mtb F1F0 
ATP-synthase binding were also investigated. Findings revealed a drastic reduction in BDQ 
binding affinity (ΔG) in the triple mutant protein, which was caused by a systemic loss in 
high-affinity interactions primarily mediated by L59, E61, and I66. Likewise, these 
mutations distorted the binding site and overall structural architecture of F1F0 ATP-synthase 
in the presence of BDQ, as revealed by the RIN and conformational analyses. 
 
The last domain of the research in this thesis unraveled some small molecule inhibitors' 
mechanism against some therapeutic targets in cancer, specifically PTPRZ and hTCR-CD1d. 
In studying the possible therapeutic inhibition of PTPRZ towards cancer treatment, we 
explored the impact of NAZ2329, a recently identified allosteric inhibitor of PTPRZ, on the 
atomic flexibility of the WPD-loop. Structural analysis revealed that NAZ2329 induced an 
open conformation of the crucial WPD-loop, consequently impeding enzyme activity even 
upon substrate binding. Based on the molecular interactions between of NAZ2329 and 
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tyrosine-protein phosphatase zeta, a pharmacophore model was generated to exhibit the 
essential functional moieties of NAZ2329.  
Lastly, the mechanism behind the selective inhibition hTCR-CD1d by AH10-7 towards the 
activation of iNKT cells was also investigated. Findings revealed that AH10-7 exhibited 
higher-affinity binding and structural effects on hTCR-CD1d, mediated by the incorporated 
hydrocinnamoyl ester moiety, which accounted for stronger intermolecular interactions with 
‘non-common’ binding site residues. 
Overall, this study has provided essential conformational and structural molecular insights 
into the design and development of new therapeutic approaches to treat cancer, viral 






13.2 Future Scope and beyond 
 
As evidenced in this research, CADD is vital in drug design research and has gained 
prominence in the pharmaceutical industry and academic research, particularly towards 
scouting and identifying potential drug candidates. The atomistic insights and molecular 
mechanisms unraveled in the research conducted in this thesis could inform future drug 
design processes, including but not limited to improving the potency of the studied inhibitors, 
repurposing the inhibitors' activity, and redesigning the compounds towards dual-targeting 
propensities. Also, the structural dynamics and conformational changes showcased upon 
inhibitor binding towards the studied inhibitors could also form the basis for the design of 
novel inhibitors to overcome resistance and increased selectivity. However, as technology 
advances, there is a need to continuously improve CADD methods towards enhancing their 
computational efficiency. Also, as the challenges of drug resistance and adverse side effects 
of drugs persist, there is a need to continue drug discovery efforts considering different 
perspectives. The concept of multi-targeting drugs should be extensively explored, 
considering its advantages in minimizing the amounts of drugs consumed for therapy and 
reducing the risk of side effects. Finally, the in silico insights provided in the reports could 
be augmented by experimental investigations while essential scaffolds highlighted could be 
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Figure S1: Comparative sequence alignment of the constructed homology model of SARS-CoV-2 
RNA-dependent polymerase and the experimentally resolved X-ray crystal structure of SARS-CoV-




























Table S1: Hits compounds identified from the ZINC database using the developed pharmacophore 
model 
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Figure S2: The RG plot illustrating the difference in compactness and surface area of all four relative 










Figure S3: Superimposed representation of the Pleconaril bound complex (PDB:1NCQ) (blue) and 
the docked compound 6g bound complex (red). The validates that compound 6g was successfully 
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Figure S1: Showing nanosecond-based variation in residue-ligand interaction between 
compound IMP-1088 and binding pocket residues of HsNMT1 
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Figure S2: Showing nanosecond-based variation in residue-ligand interaction between 





Figure S3: Showing the comparative RMSD plots (A,B), SASA plots (C,D) and radius of gyration 
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Figure S1: Comparative RMSD plot of unbound DHFR and FDTS(magenta) and when they are 
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Figure S1: Comparative RMSD of PTPRZ when bound to the allosteric inhibitor 


















Figure S2: Comparative compactness of PTPRZ when bound to NAZ2329 (COMPLEX) 
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Figure S1: Comparative RMSD plot of unbound human TCR-CD1d (black) and complexed with 





Table S1: Hydrophobic site residues and corresponding per-residue energies in the presence 
of KRN7000. Residues with energies < -1kcal/mol were considered prominent. 
Residue vdW (kcal/mol) ELE (kcal/mol) TOTAL (kcal/mol) 
CYS   12 -1.683 -0.022 -1.43 
VAL  30 -0.903 -0.003 -1.124 
ILE  47 -0.92 0.005 -1.066 
PHE  70 -3.079 0.171 -2.08 
TYR  73 -4.265 -0.749 -3.879 
SER  76 -1.375 -1.264 -1.551 
PHE  77 -1.843 -0.245 -1.553 
ASP  80 1.121 -15.883 -4.315 
ILE  81 -1.163 -0.042 -1.2 
LEU  84 -1.218 0.071 -1.305 
VAL  85 -0.368 0.022 -0.332 
LEU  100 -1.416 0.041 -1.581 
LEU 116 -0.869 0.002 -1.04 
VAL 118 -0.915 -0.005 -1.074 
LEU 143 -1.525 -0.21 -1.669 
ASP 153 0.333 -16.588 -3.463 
THR 156 -3.466 -0.81 -4.114 
PRO 28c -1.384 -0.382 -1.535 








Table S2: Hydrophobic site residues and corresponding per-residue energies in the presence 



























Residue VDW (kcal/mol) ELE (kcal/mol) TOTAL (kcal/mol) 
CYS   12 -1.902 -0.043 -1.629 
VAL  30 -0.908 -0.003 -1.129 
LEU  66 -0.999 0.149 -1.109 
MET  69 -2.247 -0.435 -2.65 
PHE  70 -3.597 0.161 -2.374 
VAL  72 -1.296 0.248 -1.565 
TYR  73 -4.895 -0.459 -4.56 
SER  76 -1.437 -1.451 -2.169 
PHE  77 -1.891 -0.126 -1.543 
ILE  76 -1.26 -0.094 -1.292 
LEU  79 -1.346 0.046 -1.415 
LEU  100 -1.773 0.049 -1.846 
LEU 116 -0.908 -0.002 -1.07 
VAL 118 -0.893 -0.005 -1.052 
LEU 150 -1.397 -0.27 -1.524 
ASP 153 0.625 -16.595 -3.716 
THR 156 -3.391 0.014 -3.521 
THR 159 -2.06 0.628 -1.816 
VAL 160 -1.276 0.229 -1.394 
LEU 163 -2.144 0.073 -2.277 
PRO 28c -1.892 -0.512 -2.09 
ASN 30c -1.099 -2.189 -1.495 
ASP 94c -0.688 0.683 -1.15 
ARG 95c -2.454 -1.559 -2.763 
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